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TNBC Triple negative breast cancer  
TR Repetition time 
TRA Trastuzumab (chemotherapy agent) 
TSE Turbo spin echo 
US Ultrasound 
WAV Wavelet features 
∆z slice thickness 
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SUMMARY 
Breast cancer is the most common cancer in the UK, accounting for a third of 
cancers diagnosed annually.  To better manage patients it is essential to 
diagnose early, with high accuracy, the type and grade of cancer to ensure 
correct and rapid treatment. 
 
Breast magnetic resonance imaging (MRI) provides excellent soft tissue contrast 
and is unaffected by fibroglandular tissue density.  By dynamically imaging 
during the injection of a contrast agent, a sensitivity approaching 100% is 
realised and lesion vascularity is portrayed.  This makes the examination not 
only useful in detection and staging of breast cancer, but also for monitoring 
response to neoadjuvant chemotherapy (NAC) treatment. 
 
This work used an image processing technique known as texture analysis (TA), 
which analyses pixel intensity distributions on a pixel-by-pixel scale to identify 
patterns that may not be visually interpretable, to probe MRI images of women 
with proven breast cancer.  Whilst previous works have demonstrated 
differentiation between normal, benign and malignant tissue, this work sought 
to extend this and look at classification of breast cancer subtypes, the utility in a 
clinical environment and to assess whether the technique could identify early 
response in patients undergoing NAC.  
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TA cannot only be applied using standard MRI set-ups, but the studies 
demonstrated preliminary promise in the classification of different cancer 
subtypes- both in terms of histological subtype and grading, as well as state-of-
the-art molecular subtyping.  While larger patient data sets are required to 
demonstrate this definitively, initial results show encouraging findings. 
 
It has also been shown that TA can be used in patients undergoing NAC to 
indicate whether the patient will respond well or not, and of particular interest 
is that these results appear to correlate well with the final pathological 
outcome. 
 
The research within this thesis has clearly demonstrated that TA is a useful 
research tool within the area of breast MRI and further investigation in this area 
is essential. 
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CHAPTER ONE: INTRODUCTION 
 
1.1 THE HEALTHY BREAST 
1.1.1 Anatomy of the Breast 
The function of the female breast is for milk production in order to suckle and 
nourish the young. Figure 1.1 shows a schematic diagram of the structure of the 
breast [1].  The breast develops during puberty, under the influence of 
hormones such as oestrogen and progesterone [2].  The breast tissue (often 
referred to as fibroglandular tissue or parenchyma) consists of 15-20 glandular 
lobes which form a conical mass with the nipple at the apex, and each lobe has 
a lactiferous duct through which milk drains and collects in lactiferous sinuses, 
just below the surface of the nipple.  The lactiferous ducts are formed from 
  
Figure 1.1- Schematic labelled view of the healthy breast [1] 
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epithelial cells, Figure 1.1.  Each lobe is formed from 20-40 lobules [3] consisting 
of branching ducts leading back to the milk producing glands known as alveoli, 
or acini.  The glandular tissue and ducts are supported by connective tissue 
(Cooper’s ligaments) which extend over the pectoralis muscle and the skin, and 
are surrounded by fat which gives the breast its form. 
 
1.1.2 Normal Changes 
In pre-menopausal women, the breast is responsive to cyclical changes in 
oestrogen and progesterone as controlled by the menstrual cycle as shown in 
Figure 1.2 [4].  During the second half of the cycle, the high levels of oestrogen 
and progesterone result in increased proliferative activity within the luminal 
epithelial cells [5-7].  This, coupled with vascular and lymphatic changes  results 
in an increased breast volume of up to 100 ml [8] which is attributed to not only 
the increase in parenchymal volume, but an accompanying increase in water 
Figure 1.2- Hormonal fluctuations throughout the menstrual cycle 
Oestrogen 
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content [9] due to stromal oedema [5].  At the end of the cycle, apoptosis 
occurs whereby the epithelium atrophies and the lumina of the alveoli close [5, 
6] resulting in ducts with little or no lumen [6]. 
 
In post menopausal women, there is no longer the cyclical influence of 
oestrogen and progesterone on breast tissue and therefore the glandular tissue 
shrinks and is replaced by fatty tissue.  The epithelial cells atrophy and the 
connective ligaments generally lose strength and stretch. 
 
1.1.3 Benign Breast Disease 
Benign breast disease is that which poses no threat to life, despite often 
presenting with symptoms that may be concerning, such as lumpiness, pain or 
mass.  Benign disease is split into two categories- that which poses no increased 
risk of breast cancer development and that which can result in an increased risk 
of subsequent breast cancer development. 
 
The most common type of benign change with no increased threat of breast 
cancer development is benign ‘fibrocystic disease’.  This change shows no 
increased proliferation of epithelial cells and is believed to be caused by a 
hormone imbalance and the most common findings are mammary cysts, 
stromal fibrosis and lobule expansion [1].  
 
Some benign conditions that can result in an increased risk of developing breast 
cancer are atypical ductal hyperplasia, radial scar and papilloma.  
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1.1.4 In Situ Carcinoma 
Non-invasive cancers do not invade into normal surrounding breast tissues and 
are characterised by hyperplasia either in ducts (Ductal Carcinoma in situ, DCIS) 
or lobules (Lobular Carcinoma in situ, LCIS) with a disordered proliferative 
appearance [10].  DCIS increases the risk of developing breast cancer later in life 
and is termed pre-cancerous disease, whereas LCIS is a misleading term as there 
is no direct link with pre-malignancy. 
 
 
1.2 BREAST CANCER 
Breast cancer is the most common cancer in the United Kingdom with more 
than 120 new women diagnosed per day.  Cases have increased by 14% over the 
past ten years and it is estimated that by 2024 the number of women 
presenting annually with breast cancer will have reached 55, 700 [11]. 
 
Mortality has fallen over the past 30 years, partly due to improved treatment 
options as well as the introduction of the National Health Service (NHS) Breast 
Screening programme, which often detects early onset of malignancy before 
tumours are able to be detected by physical examination.  As survival is closely 
related to the stage of diagnosis, earlier detection is crucial in managing the 
treatment of the disease. 
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1.2.1 Pathophysiology of Breast Cancer 
While it is still unclear exactly what initiates the onset of breast cancer, certain 
risk factors have been identified that result in increased risk of breast cancer 
development, such as dense parenchymal breast tissue, early menarche, late 
menopause, age of first full-term pregnancy, exposure to ionising radiation, 
obesity, use of hormone replacement therapy, alcohol consumption, smoking 
and certain benign conditions as discussed in Section 1.1.3.  There has also been 
a link with family history of breast cancer and the inheritance of the BRCA1 or 
BRCA2 gene mutation increases a woman’s lifetime risk of breast cancer to 
between 40 and 85% [12].  Both of these hereditary genes result in a high 
prevalence of breast cancer in women of a younger age. 
 
The progression from healthy breast to invasive, metastatic breast cancer is 
shown in Figure 1.3 as modified from [13].  Early stage breast cancer begins with 
the hyperplasia of epithelial (or luminal) cells, or the basal/myoepithelial layer 
in either the lactiferous duct or milk-producing lobule which has been 
hypothesised to be due to a hormonal imbalance over-stimulating these cells.  
Whilst the basal cell layer (as shown in Figure 1.1 and Figure 1.3) remains intact, 
this disease is classified as in situ cancer (either ductal carcinoma in situ [DCIS] 
or lobular carcinoma in situ [LCIS]) as there is no ability for invasive spread 
through lymphatics or the blood vessels.  However both in situ cancers can 
spread along the ductal system.  Not all in situ carcinoma will progress to 
invasive cancer- particularly low grade DCIS.  It has been estimated, however, 
-33- 
that around 40% of DCIS cases will progress to invasive breast cancer within 30-
years [14].   
 
Once the basal layer is disrupted, the tumour cells are able to grow more freely, 
outwith the confines of the duct or lobule and the disease is then classified as 
invasive breast cancer (Figure 1.3(b)).  The subsequent reactive proliferation of 
connective tissue results in dense layers of fibroblasts around the tumour and a 
hardening of the breast tissue- the ‘lumps’ that are usually felt on palpation.  
The tumour cells are free to proliferate rapidly and release an angiogenic 
stimulator, known as vascular endothelial growth factor (VEGF), that disrupts 
Normal Breast 
DCIS 
Invasive Ductal Carcinoma 
Advanced Metastatic Cancer 
Epithelial Cells 
Myoepithelial Cells 
Basement Membrane 
Fibroblasts 
Blood Vessel 
(a) 
(b) 
(c) 
Figure 1.3- Progression of breast cancer through from the normal healthy breast to invasive, metastatic breast 
cancer 
(a) progression to in situ cancer   (b) progression to invasive cancer   (c) progression to metastatic cancer 
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the basement membrane of blood vessels, causing them to sprout capilliaries 
that infiltrate the tumour to supply oxygen and nutrients to fuel free growth 
[15].  Once the tumour has acquired its own vascular system, it becomes 
capable of unrestricted growth and has the potential for metastasising through 
the lymph glands or the blood stream [16].  
 
1.2.2 Histological Classifications of Breast Cancer 
More than 95% of breast tumours arise in the milk-producing glands or ducts 
[17].  Breast cancer is a very heterogeneous disease and there are a wide range 
of histopathological types of breast cancer defined by the World Health 
Organization [18].  Each type of tumour has a characteristic growth pattern, and 
can be classified based on the appearance of cells under a microscope.   This 
thesis will only deal with the most common histopathological types of breast 
cancer- invasive ductal, invasive lobular and ductal carcinoma in situ (DCIS), 
which are briefly discussed and a typical histology pattern for each shown in 
Figure 1.4. 
(a) (c) (b) 
Figure 1.4- Histology for  (a) Grade 2 ductal cancer   (b) Grade 3 lobular cancer    (c) Intermediate DCIS 
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Ductal cancer is the most common type of breast cancer, accounting for an 
estimated 80% of invasive breast cancers diagnosed in the US [19].  Ductal 
cancer cells typically invade stroma forming variable patterns or grow as solid 
sheets or nests [18].  
Lobular cancers which account for around 10% of invasive cancers [19] are 
generally composed from small, non-cohesive cells which are dispersed through 
connective tissue or arranged in single-file linear patterns [18].  The majority of 
lobular cancers demonstrate a complete loss of the adhesion molecular e-
cadherin which is attributed to the histological diffuse growth pattern [20]. 
 
DCIS, while not an invasive disease, is associated with an increased risk of 
subsequently developing invasive cancer.  This manifests as increased epithelial 
proliferation within the terminal duct lobular unit.  It remains bounded by the 
basement membrane and grading is associated with the degree of cellular 
atypia.  
 
1.2.3 Grading of Breast Cancer 
The grading of a cancer refers specifically to the characteristics of the cancerous 
cells.  Grading of a lesion is standardised according to the World Health 
Organization classification as described in Table 1.1.  
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               Grading 
 1 2 3 
Degree of tubule/ 
glandular structure 
formation 
Majority of tumour  
(>75%) 
Moderate degree  
(10-75%) 
Little or none 
(<10%) 
Nuclear 
pleomorphism 
Small, regular 
uniform cells 
Increase in size 
and variability 
Marked 
variation 
Mitotic count Low Moderate High 
Table 1.1- World Health Organization classification for breast cancer grading [18] 
 
In general Grade 1 cancers are low grade and tend to grow more slowly while 
Grade 3 tumours are very different from normal cells and grow much more 
quickly. 
 
1.2.4 Molecular Subtypes of Breast Cancer 
Recently there has been an increasing drive towards patient targeted 
treatments as it is recognised that the receptor status of a breast cancer can 
result in more successful treatment outcomes for specific cancer types.  The 
most commonly considered receptor statuses are oestrogen (ER), progesterone 
(PR) and human epidermal growth factor 2 (HER2) receptors and this leads to a 
new classification regime.  Therefore breast cancer is now more commonly 
becoming described by the molecular subtype [21] in terms of luminal cancers 
(ER positive, HER2 negative), HER2 cancers (HER2 positive) and triple negative 
cancers (ER negative, HER2 negative), which each exhibit distinct growth 
patterns [22, 23] and require different therapeutic regimens. 
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1.2.5 Staging of Cancer 
Staging of a cancer refers to how advanced a cancer is when detected, and is 
often used for planning radical treatment or surgery.  Breast cancer is staged 
using a four point scale (Table 1.2) according to how advanced the tumour is, 
and how far it has spread.   
Physiology 
Stage 
Tumour 
Axillary Lymph 
Nodes? 
Clumping of 
nodes?
* Spread 
I  <2cm    
A 
<2cm 
<5cm 
 
 
 
 
 
 
II 
B 
<5cm 
>5cm 
 
 
 
 
 
 
A 
<5cm 
>5cm 
 
 
 
 
 
 
B 
Fixed to skin or 
chest wall 
   
III 
C Any size   
To either the 
breast bone or 
collarbone lymph 
nodes 
IV  Any size   
Other parts of 
body 
Table 1.2- Summary of the four different stages of breast cancer, according to how advanced 
the tumour is (
*
clumping of axillary nodes or sticking to other structures)  
 
 
The earlier that breast cancer is detected, the better the prognosis for disease 
free survival.  It has been reported that the 5-year survival rate decreases from 
92% to 13% for Stage IV cancer compared to Stage I disease [11] and therefore 
imaging plays a crucial role in increasing survival times by detecting cancers at 
an earlier stage. 
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1.3 THE ‘TRIPLE ASSESSMENT’- DIAGNOSTIC TECHNIQUES 
Whilst breast cancer is the most common form of cancer in women, it is often 
treatable which requires identification of malignancy as well as accurate 
grading, staging and classification.  In general, imaging, followed by a targeted 
biopsy, is the most reliable method of performing this task.  
 
The usefulness of a diagnostic test is described in terms of its sensitivity, 
specificity and predictive values.  Sensitivity refers to how well a test identifies 
disease in patients who truly have a disease, while specificity is concerned with 
how well the test identifies those without disease [24].  Predictive values are 
concerned with the probability of the test giving a correct diagnosis- i.e. positive 
predictive value (PPV) is the proportion of patients who have a positive 
examination who truly who have the disease, while negative predictive value 
(NPV) is the proportion of patients with a negative test who do not have the 
disease [25]. 
 
An ideal imaging examination therefore would have a high sensitivity, 
specificity, positive and negative predictive value such that every patient with 
disease was correctly diagnosed, and every patient without disease was 
correctly identified.   
 
Women with suspected breast cancer will usually undergo ‘triple assessment’ 
whereby a clinical history and physical examination, ultrasound and 
mammography examination, subsequently followed by biopsy, will be 
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performed.  The reported diagnostic characteristics for each of these 
procedures are reported in Table 1.3, and each is discussed in further detail 
below. 
Table 1.3- Comparison of sensitivity, specificity and positive predictive value (PPV) for each 
breast examination as reported in the literature [26, 27] 
 
1.3.1 Physical Examination 
Based on a clinical history, including questions about the risk factors outlined 
previously, clinicians feel for signs of malignancy- typically cancer is a palpable 
breast mass with indistinct borders that may be attached to skin or deep fascia 
[28-30].  This is very much dependent on the experience of the clinician and 
often cysts cannot be conclusively distinguished from solid masses [28, 29].  The 
sensitivity of physical examination is dependent on the size of the lump and no 
mortality benefit has been demonstrated for this technique alone [26, 30].  
 
1.3.2 Mammography 
Mammography is one of the most common methods of imaging the breasts and 
is currently the primary imaging modality utilised in the NHS breast screening 
program.  It uses low doses of x-ray radiation and breast compression to 
produce an image that shows the x-ray attenuation properties of the breast.  
Areas of attenuation different to that of normal tissue, such as architectural 
distortion, masses and abnormal calcification, may be indicative of malignancy 
(see Figure 1.5).  Whilst mammography was traditionally carried out using x-ray 
 Sensitivity Specificity PPV 
Mammography 67.8 - 77.6 % 75.0 – 98.8 % 35.8 – 85.7 % 
Ultrasound 75.3 – 83.0 % 34.0 – 96.8 % 20.5 – 73.5 % 
Physical Examination 27.6 – 50.3 % 92.0 – 99.4 % 28.9 – 94.0% 
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film; recent trends have been towards digital full-field mammography (FFDM) 
which utilises a digital detector allowing manipulation of brightness and 
contrast on a computer monitor.  A study comparing the two techniques in just 
under 43,000 women demonstrated that diagnostic accuracy was similar for the 
two techniques in the screening environment, but that FFDM was more 
accurate in women with radiologically dense breasts, including those under 50 
and pre- or peri- menopausal women [31]. 
 
 
 
Figure 1.5- Left hand image shows mammography of a grade 3 infiltrating lobular cancer in the left breast.  The 
enlarged insert view on the left hand side shows calcification within the lesion.  The right hand image is a 
contrast enhanced magnetic resonance imaging view demonstrating the same cancerous lesion 
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As the detection of malignancy using mammography is reliant upon 
identification of regions with differing x-ray attenuation properties, cancers 
with similar densities to normal parenchymal tissue, and many of the BRCA 
gene mutation cancers, will appear mammographically benign [32, 33].  
However, the major advantage of mammography is that it is a relatively cheap 
and quick screening tool and can identify microcalcifications within the breast.  
Whilst this is not directly indicative of cancer, specific distributions can be 
suggestive of malignancy [34, 35] as calcium appears to be linked with necrosis 
associated with breast cancer [36]. 
 
One of the main limiting factors associated with mammography is that the 
sensitivity of the modality is inversely proportional to the density of the 
parenchymal tissue.  Reports suggest that the sensitivity drops from 87% for 
fatty breast tissue to around 45-63% in dense fibroglandular tissue [26, 27, 37].  
As dense breast tissue is known to be a risk factor in breast cancer 
development, this results in a confounding problem that women with higher 
risk of developing breast cancer could have the lowest  mammographic 
sensitivity [38]. 
 
Mammography uses low doses of ionising radiation, which is a known risk factor 
in cancer induction [15].  One group have suggested that to prevent inducing 
more cancers than it leads to treatment for, mammographic screening should 
only be performed in women over the age of 40 [38]. 
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Recent advances in x-ray based mammography have been towards breast 
tomosynthesis, or DBT, which acquires a number of projection images at various 
angles around the breast.  By moving the x-ray source in an arc around the 
breast, these projection images can be reconstructed in order to produce high 
(a) (b) 
(c) 
Figure 1.6- (a) conventional digital mammography image from a large ductal grade 3 cancer 
extending into the left axilla (b) shows DBT image, with cancer clearly demonstrated as indicated 
(c) corresponding contrast enhanced magnetic resonance imaging showing extent of lesion 
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resolution slices (Figure 1.6).  Doses are reported to be similar, while providing 
an improvement in contrast detail and a significant improvement in diagnostic 
accuracy over conventional  2D mammography [39].   
 
1.3.3 Ultrasound  
Ultrasonography (US) uses a transducer to transmit high frequency sound waves 
through tissue and forms the final image using information extracted from the 
reflected waves from muscle, fluid and solid masses.  Lesions are identified by 
comparing normal breast parenchyma with those of suspicious regions [33] and 
US is particularly useful in differentiating between solid masses and fluid filled 
cysts [40].  The blood flow to areas of suspicion can be mapped using Doppler 
imaging (a technique measuring frequency shifts of sound waves to determine 
speed and direction of moving structures, such as blood) and this can also 
provide further information as to whether a lesion is benign or malignant [40].  
 
Ultrasound is relatively independent of breast density and therefore is useful in 
younger women and those with dense fibroglandular tissue, however it can be 
very operator dependent [32] and is a time-consuming examination.  It can be 
problematic to identify deep abnormalities and microcalcification cannot always 
be reliably identified due to the inherent ‘speckle’ of US imaging [40, 41].  
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1.4 BREAST MAGNETIC RESONANCE IMAGING 
Breast Magnetic Resonance Imaging (MRI) is a specific application of MRI 
utilising a dedicated breast radiofrequency coil (Figure 1.7) that encompasses 
both breasts to provide high resolution anatomical imaging that is not degraded 
by dense fibroglandular tissue, scar tissue, radiotherapy changes or breast 
implants [42].  It has become more routinely used in recent years in the context 
of problem solving, monitoring treatment response, implant assessment and in 
the screening of women classified at high risk of developing breast cancer. 
 
In a study comparing the accuracy of the conventional triple assessment to MRI, 
it was found that the 
sensitivity of 
mammography, 
ultrasound and 
physical examination 
combined was still 
lower than that of a 
Breast MRI 
examination (93.2% vs 94.4%) [27].  One of the main advantages of the MRI 
examination is the high negative predictive value, and therefore a negative 
study can almost always be considered conclusive proof of no malignancy (Table 
1.4). 
Figure 1.7- Image of the Siemens dedicated 2-channel breast matrix 
coil 
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 Sensitivity Specificity PPV NPV Accuracy 
MRI 91.0-94.4 % 26.0-88.0 % 66.0-73.6% 91.7-100.0% 72.9-92.2% 
Table 1.4- Reported sensitivity, specificity, positive and negative predictive values and accuracy 
of breast MRI examinations as reported in the literature [27, 43-46] 
 
The breast MRI examination utilises different techniques in order to provide 
information on anatomy and physiology of the tumour, which is why one 
examination provides so much information.  The theory of MRI is discussed in 
detail in Chapter 2, however a brief outline of the key features of the MRI 
examination is provided below. 
 
1.4.1 Morphological Imaging 
MRI images hydrogen nuclei, which are found in the water of which the body is 
mainly comprised.  By imaging this water, excellent soft tissue contrast is 
realised and the technique is relatively unaffected by fibroglandular density, 
making it particularly suited for screening and imaging younger women where 
exposure to ionising radiation is less favourable and breast tissue density is 
generally higher. 
 
High resolution morphological imaging generally provides an in-plane pixel size 
around 1×1mm or less and thus tumour morphology can be classified. 
Sequences that highlight water content (known as ‘T2 sequences’) can be useful 
in identification of intramammary cysts, classification of lymph nodes as benign 
or malignant by clear visualisation of the intracapsular fat, and finally as a useful 
-46- 
adjunct to other sequences in the differentiation between benign and malignant 
lesions.  Kuhl et al. reported that these sequences can be a useful tool in 
interpretation of whether a mass may be malignant or not as many benign 
tumours demonstrate a rich extracellular oedematous matrix which appears as 
increased signal on such T2 sequences [47].  The majority of malignant lesions 
behave similar to normal breast parenchyma, with a dense cellularity and 
therefore will appear as low signal on such imaging sequences [47]. 
 
1.4.2 Kinetics 
The advantage of Breast MRI is that physiological information regarding tumour 
vascularity can be obtained.  An imaging sequence that is sensitive to the 
presence of contrast agent is used (known as a ‘T1 sequence’, described further 
in Chapter 2) such that areas that take up contrast are highlighted by bright 
signal.  By imaging both breasts rapidly as contrast is injected, contrast uptake 
can be visualised dynamically, producing a representative impression of tumour 
vascularity and potentially angiogenesis [42]. 
 
As angiogenic vessels are formed rapidly in order to facilitate tumour growth, 
they tend to be permeable with large endothelial fenestrations.  The contrast is 
rapidly taken up in areas with an abundance of these vessels due to the 
increased microvascular density, which leads to an early and strong post 
contrast enhancement.  Subsequently, the contrast leaks into the extra-cellular 
space, giving rise to a ‘Type III’ wash-out signal intensity time curve as 
demonstrated in Figure 1.8 [48, 49].  As normal regions of fibroglandular tissue 
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will display a continuous steady uptake of contrast agent (‘Type I’- Figure 1.8), 
areas of strong early enhancement are readily identifiable.  It is this 
physiological process that makes Breast MRI a particularly sensitive imaging 
modality, with reported sensitivities of 100% [43, 46, 50]. 
 
Whilst there is lower neoangiogenesis associated with intraductal tumours, MRI 
has been able to reliably identify and diagnose DCIS, particularly high grades, 
due to the greater vessel density associated with such areas [16, 51]. 
 
1.4.3 Lesion Diagnosis on MRI 
The Breast Imaging Reporting and Data System (BI-RADS) reporting method has 
been widely used in mammography and breast ultrasound in order to 
standardise reporting of imaging examinations and provide categories that are 
widely recognised.  In 2003 this BI-RADS lexicon was extended to include 
standardised reporting of breast MRI examinations, as described by the 
Time
SI
Time
SI
Time
SI
Type I Type II Type III 
Type I- Monotonic uptake over 
scanning period. Benign lesion 
Type II- Peak Intensity reached 
within 3 minutes and plateau 
maintained. Suspicious lesion.  
 
Type III- Decrease in Signal 
Intensity immediately after 
peak. Malignant lesion.  
Figure 1.8- Uptake and washout patterns after administration of intravenous contrast 
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American College of Radiology [52].  In order to obtain a BI-RADS category, both 
morphological and kinetic data is described. 
 
Morphology is described in terms of shape, margin and the internal 
enhancement characteristics.  Spiculated margins and peripheral enhancement 
of masses is most commonly associated with malignant breast lesions [53].  The 
distribution and pattern of non-mass like enhancements are also dealt with as 
well as the assessment of the kinetic curves.   
 
Final assessment categories are defined from BI-RADS:1 (no lesion identified 
and return to routine follow-up) up to BI-RADS:6 (known malignancy requiring 
appropriate action) which allow standardised reporting methods across all 
imaging modalities used in diagnosis and staging of breast cancer. 
 
Breast MRI has demonstrated very high sensitivity in identification of 
malignancy within the breast (Table 1.4) and while the specificity has been 
reported as variable in the literature [27, 43-46], it is generally accepted to be 
around 90% for expert radiologist readers [45].  There are a range of factors 
that can affect the uptake of contrast within the breast and it has been reported 
that there is an increase in unnecessary biopsies and other investigations, based 
on the findings from MRI.  One report states MRI overestimates the size of 
identified malignant lesions [27], while another reports that the use of the 
examination has led to an increase in avoidable mastectomies, with no proven 
improvement in the future re-operation rate [45, 54]. 
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Due to the hormonal influences on breast tissue, the stage of the menstrual 
cycle can influence the contrast uptake within normal, healthy breast 
parenchyma.  During the luteal phase of the cycle (days 20-28), normal healthy 
fibroglandular tissue undergoes increased proliferation [55, 56], which can in 
turn lead to foci of enhancement that exhibit suspicious contrast uptake 
characteristics.  Generally, by imaging patients when the hormonal influences 
are minimal (usually on day 7-13 of the menstrual cycle), this effect can be 
minimised [57], although this is not always an option in patients with a known 
cancer. 
 
There are similarly a number of benign changes within the breast that can 
appear suspicious on MR imaging, particularly in the case of a fibroadenoma, 
formed from lumps of glandular tissue within the breast.  Despite the benign 
morphological appearance (usually rounded lesions with definite margins), 
contrast uptake can result in a highly suspicious appearance due to the high 
vascular density- often similar to that of invasive breast cancer [58].   
Other benign changes within the breast that cause neo-vascular changes also 
require careful classification- for example wound healing or inflammation can 
result in increased and suspicious uptake patterns within such regions [42]. 
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1.4.5 Advanced MRI Techniques 
A number of advanced imaging techniques are becoming more widely utilised 
within all aspects of MRI, and particularly within cancer imaging.  The 
techniques that are discussed briefly in this section are those that are becoming 
more clinically applicable.   
 
Assessment of tumour vasculature is assessed by rapidly acquiring the breast 
volume during contrast acquisition in order to model the washout parameters 
and use this to infer malignancy as outlined above.  However, there have been 
methods described that model the upslope of the contrast wash-in and use this 
to identify malignancy, in a technique known as pharmacokinetic modelling  [59, 
60].  By utilising acquisition times below 20s and fitting contrast parameters to a 
pre-defined compartmental model, parameters can be fitted to estimate blood 
and extracellular volumes as well as transfer rates between each compartment 
[60, 61].  Such techniques, however, often compromise the spatial resolution, 
which is critical for assessing morphology in order to fully characterise the 
lesion in terms of the BI-RADS lexicon.  Recent drives towards high 
spatiotemporal sequences have produced promising results [61], however the 
sophisticated computational analysis techniques have slowed the progression of 
this technique from the research arena into routine clinical practice.  
 
Diffusion imaging uses a special imaging sequence in order to characterise the 
mobility of water molecules [62, 63].  As malignant tumours consist of densely 
packed cells, the diffusion of water molecules is generally restricted within 
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these areas and therefore imaging sequences sensitised to this can provide 
information relating to the cellularity and therefore the tumour grade [64].  
Quantitative values of diffusion coefficients can be calculated and these have 
been reported to reliably differentiate between benign and malignant lesions 
[64-68] with malignant lesions generally exhibiting lower diffusion coefficients 
relative to surrounding tissues, however absolute cut-off values cannot be 
universally applied due to subtle differences in sequence acquisition parameters 
[67] and there can be overlap in diffusion characteristics between invasive and 
non-invasive cancers.  Despite this, however, diffusion has been reported to 
increase the specificity of breast MRI to around 81-88% [66, 68].  Benign lesions 
exhibiting high cellularity such as papillomas can appear malignant on diffusion 
imaging and therefore diffusion imaging cannot be used alone for the diagnosis 
of breast malignancy. 
 
Other, more specialist, techniques such as spectroscopy [69, 70] and 
magnetisation transfer imaging [71] have also been demonstrated to potentially 
increase the specificity of the examination and shown initial promise in 
identification and classification of malignancy.  However, these techniques are 
still very much research based and are not widely available and therefore have 
yet to demonstrate their full potential. 
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1.5 IMPROVING LESION DETECTION AND CLASSIFICATION 
1.5.1 Importance of Morphological Classification 
The majority of the BI-RADS reporting criteria focuses on morphology as this is 
recognised to be an important factor in identification of malignancy.  
Assessment of this technique, however, can be subjective and dependent on 
the reader experience.   
 
It has been reported that radiologists differ substantially in the interpretation of 
images using the BI-RADS classification.  One group report that when 14 
observers reported ultrasound images of known breast lesions using the BI-
RADS system, the agreement using the kappa statistic (κ) was 0.39 (kappa is a 
measure of agreement with categories less than 0.21, 0.21-0.4, 0.41-0.6, 0.61-
0.8 and 0.81-1.0 considered poor, fair, moderate, good and very good 
agreement respectively) [72].  Another group condensed the BI-RADS categories 
down into 3 categories rather than 5, and with this they estimated κ=0.48 for 
ultrasound and κ=0.58 for mammography [73].  This is in agreement with 
Redondo et al who reported κ=0.53 when the BI-RADS categories were 
categorised into further investigation required (BI-RADS 3-5) or not (BI-RADS 1 
and 2), however when all five categories were included, the reported 
agreement was significantly lower at κ=0.37.  This group also reported intra-
observer agreement and found moderate agreement when the full BI-RADS 
scoring system was used (κ=0.53) [74] 
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There are fewer reports on the agreement between readers for breast MRI, 
although one study found that between expert breast radiologists using a 
scoring system identifying whether a mass was deemed to be spiculated or not 
resulted in κ=0.38-0.56 on axial images, and the agreement was significantly 
lower on sagittal imaging (κ=0.27-0.51)  [75]. 
 
Due to the reported variability in morphological assessment of lesions on 
different imaging modalities, a standardised more objective measure is required 
in order to improve diagnostic accuracy and certainty.  There has been a drive 
over the past decade or so to develop Computer Aided Detection (CAD) systems 
that will have the capability of identification and classification of lesions on 
various imaging modalities.  
 
With the advent of digital technology such as digital mammography, 
development of CAD systems to analyse digital images has become simpler.  
Although the technique utilised for each imaging modality is slightly different, 
generally a thresholding step is used to remove false signals and then 
segmentation performed prior to classification.  These are then identified on 
the image to prompt an experienced user to the region.  Whilst some groups 
report an increase in the sensitivity [76] and specificity [77], one group report 
that the inclusion of CAD in a large scale study considering over 115,500  
mammograms had no statistically significant impact on breast cancer detection 
or recall rates [78]. Therefore it is unclear whether the inclusion of CAD in a 
screening environment would have a significant impact on overall breast cancer 
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detection rates, although it is possible it may be a useful tool for junior 
radiologists [79]. 
 
CAD systems for ultrasound have been less well described and are more 
complex, requiring descriptors of shape, margin and mass characteristics to be 
quantified.  However, Shen et al report a sensitivity and specificity of 90.6% and 
92.2% respectively for the CAD system they designed, which computerised the 
BI-RADS mass features [80].  They describe that the most useful features were 
the ‘angular characteristic’ feature which describes the margin and the 
abruptness of the lesion boundary, both of which provide a measure of how 
spiculate a lesion is on the image. 
 
CAD systems for MRI are mainly based around analysis of kinetic contrast 
uptake data [81-83] due to the volume of images generated, however there 
have been reports on morphological assessment of lesions using in-house and 
commercial software [84, 85].  These software packages utilised descriptors of 
shape in order to describe the shape and margins of the lesion, as well as 
‘texture’ features which were used to quantify the internal characteristics of the 
lesion on the image.  This resulted in reported diagnostic accuracies of 93.5% 
[84], with area under operator receiver characteristic curves (a method of 
describing accuracy of diagnostic tests, see Chapter 2.3.2) of 0.82 [85]. 
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1.5.2 Texture Analysis 
Texture is a difficult concept to define, however is generally described using 
words such as rough, smooth, dense, random etc. [86].  When applying this to 
images, the texture is characterised by the spatial distribution of the grey level 
pixel intensities and by quantifying these, patterns can be identified and 
classified. 
 
In medical diagnostics, it has been reported that radiologists visually assess 
texture in clinical images in order to diagnose pathology  [87] and therefore if 
computer software could be used to mimic the expert eye, it could prove useful 
in identification of abnormality within tissue.  This technique is known as 
‘texture analysis’ (TA). 
 
Texture analysis is computationally demanding as the assessment of the 
distribution of pixel intensity values requires calculation of higher-order 
statistics [88] as well as fitting to models [89] and rescaling the data in order to 
obtain maximum information from the images.  This technique allows 
differentiation of regions by considering the image on a pixel-by-pixel basis and 
therefore can detect changes that may not be visually apparent [90]. 
 
Texture analysis has been widely used in medical diagnostics.  It has been 
demonstrated to reliably characterise brain tissue and differentiate between 
tumour and oedema [87, 91] and has also been used to identify abnormalities 
that have not been visually identified in epilepsy sufferers [92, 93].  Currently 
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Alzheimer’s disease is only accurately diagnosed by a histological sample [94], 
however Nedelec et al. reported that TA may prove useful in the diagnosis and 
monitoring of therapies for this debilitating disease [92].  Brain gliomas are 
difficult to differentiate from metastases in the brain; however Zacharaki et al. 
have demonstrated that using TA, the two can be differentiated with 
concomitant sensitivity and specificity using MRI images [95].  
 
In other areas of the body, TA has been used for identifying cirrhotic lesions in 
the liver, and differentiating these from normal healthy liver [96].  It has also 
proved to be a useful tool in the classification of osteoporotic bone [97, 98].  
 
More recently, the technique has become more widely used in cancer imaging, 
not only in the identification and classification of disease [99-105], but also as a 
potential predictor of prognosis for the disease and treatment stratification 
[106-108]. 
 
1.5.3 Texture Analysis in Breast Imaging 
Texture analysis has been used extensively in breast imaging.  In 
mammographic images, texture analysis has been used to differentiate between 
malignant and normal breast masses [99, 101] as well as between cluster 
patterns of calcification in order to discriminate between invasive cancer and 
DCIS [109].  Similarly in ultrasound imaging of the breast [100, 102], Garra et al  
demonstrated that texture analysis could be used to reduce the number of 
biopsies carried out on benign lesions [102]. In both modalities, texture analysis 
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has been demonstrated to increase the specificity [99, 100, 102] and therefore 
it is likely it could potentially be used for the same purpose in Breast MRI. 
 
There are an increasing number of journal articles published investigating the 
use of texture analysis in breast MRI [103-105, 110].  The technique has been 
demonstrated to distinguish between benign and malignant lesions [103, 104] 
and a small, preliminary report suggests also between different histological 
breast cancer types [110]. 
  
The main limitation of TA is that reports in the literature suggest that the 
technique is not transferable between sites or scanners [111].  It has been 
suggested that data acquired in one centre will not necessarily correlate with 
that acquired elsewhere.  This could potentially be due to differences in 
sequence acquisitions, RF coil architecture and image processing, which may 
result in dissimilar levels and structures of noise and received signal across the 
final image.  
 
1.6 AIMS AND SCOPE OF THESIS 
A comprehensive literature review suggests that texture analysis in breast 
magnetic resonance imaging shows initial promise in being an exciting area for 
further development.  The aim of this thesis is to more thoroughly investigate 
the role of the technique in a clinical department utilising images from routinely 
referred patients, recently diagnosed with primary breast cancer.   
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In order to utilise the technique, an assessment of the robustness of the 
technique and influences of image acquisition conditions will have to be 
considered prior to application on routinely acquired images. 
 
The role of texture analysis in the identification, classification and staging of 
breast cancer in patients referred for breast MR will then be considered, and 
the research seeks to extend the preliminary work that has already been 
published by using the technique to classify breast cancers into their respective 
histological and molecular subtypes.  To fully assess the usefulness of the 
technique in diagnosis, a classification model will be built and tested and an 
assessment made of the classification accuracy and therefore clinical 
applicability. 
 
A preliminary investigation into TA as a tool in the neoadjuvant chemotherapy 
setting will be considered as this is a new, developing, area of MR in the 
monitoring of such treatment.   
 
This work will hopefully lead to a consideration as to whether a currently 
research-only tool could potentially be applied in a clinical setting and the role it 
may play in the management of patients referred to the MR unit through the 
breast clinic. 
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CHAPTER TWO: THEORY 
 
2.1 MAGNETIC RESONANCE IMAGING 
2.1.1 Hardware- Magnets, Gradients and Radiofrequency System 
In order to perform magnetic resonance imaging (MRI), a large magnetic field is 
required.  This magnetic field is typically on the order of 1.5 Tesla (T) for clinical 
applications to 3.0 T and higher for research applications.  In order to generate 
such large, stable 
magnetic fields, 
superconducting 
magnets are 
generally used in 
modern MRI scanner 
design (see Figure 
2.9 [112]). These 
magnets are 
manufactured from 
coils of superconducting wires (typically niobium-titanium) which are held in a 
copper matrix for mechanical stability.  Once cooled below a critical 
temperature (Tc=7.7K, -265.3°C) the wires exhibit no resistivity and therefore 
after sufficient current is in the windings to generate the required field, the 
power supply can be removed and persistent currents will flow with no 
degradation due to losses from electrical resistance.  Modern superconducting 
Figure 2.9- Schematic diagram of the inside of MRI scanner main bore 
housing [111].   
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magnets have coils of superconducting wire cooled in a bath of liquid helium 
(boiling point 4.2K, -268°C).   A refrigerated cold head is used to ensure 
minimum helium boil-off. 
 
Gradient coils are used for signal localisation in order to create the final image 
and are mounted just inside the bore of the magnet and are held at room 
temperature, with water cooling to remove excess heat.  These coils are built 
into the main scanner and produce smaller magnetic fields that either add or 
subtract from the main static field, resulting in a linearly varying magnetic fields. 
Electromagnets are used with amplifiers that control how rapidly gradients can 
be switched (have the polarity of the current reversed) and the maximum field 
strength they can produce.  Faster and stronger gradients allow for higher 
image resolution and faster image acquisition times.  
 
The final essential component for creation of MR images is the radiofrequency 
(RF) system.  This comprises of two parts- an RF transmitter and RF receiver.  
The RF transmit system 
creates an external oscillating 
magnetic field at a resonant 
frequency which is absorbed 
by the nuclei and disturbs 
them from their thermal 
equilibrium position.  Once 
the external RF source is switched off, the nuclei will then return to their 
Figure 2.10- InVivo 7-channel breast coil 
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equilibrium position, and in the process they create an external oscillating 
magnetic field which can be detected by a receiver coil, due to the induction of 
a small current.  As these currents are very small, receiver coils have to be 
placed as close to the region being imaged as possible.   In MRI, specific coils are 
manufactured for each imaging application- e.g. head coils, spine coils, breast 
coils etc. (see Figure 2.10) which are designed to fit closely around the imaged 
area to maximise the signal received. 
 
Modern MRI systems are controlled by highly sophisticated computer control 
systems which manage not only timing of gradients, RF transmit/ receive pulses 
and acquisition processes, but also control safety systems and ensure safe 
modes of operation.   
 
2.1.2 Basics of Nuclear Magnetic Resonance (NMR) Theory 
Nuclei of some atoms possess small magnetic fields which arise due to the 
nucleus possessing a charge and spinning.  The resulting moving net charge 
results in a magnetic moment.  For conventional, routine MRI, hydrogen is the 
most commonly imaged nucleus due to the plentiful abundance in the human 
body (more than 70% of the atoms in the body).  Due to the large number of 
randomly distributed individual moments, the net magnetisation is zero,  
however when placed in a strong external magnetic field, the individual 
moments can either align parallel to the field (low energy state) or anti-parallel 
(high energy state).  In these energy states, the moments precess around the 
external field axis at a given frequency- the Larmor frequency, ωL, which is 
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governed by the gyromagnetic ratio, γ, and the strength of the external field, B0 
(Equation 2.1). 
0L Bγ=ω  
Equation 2.1 
The gyromagnetic ratio is a constant for any given nucleus and is the ratio of the 
magnetic moment and the angular momentum.  For hydrogen, γ=42.58 MHz/T. 
At thermal equilibrium, there will be a small excess of spins in the low energy 
state relative to the high energy state- around 4 spins per million at 1.5T.  We 
can define a bulk magnetisation vector, M, that describes the combined effect 
of the sample rather than considering the motion of individual spins, which in 
equilibrium conditions is aligned along B0 (M0).  By viewing this bulk 
magnetisation vector, M, from a rotating frame of reference also rotating at ωL, 
and using classical mechanics, the description of complex excitation and 
relaxation processes is 
simplified.  
 
In order to infer information 
regarding the surroundings 
of the nuclei of interest, the 
system has to be perturbed 
from its equilibrium state.  
Energy is delivered into the 
system in the form of an 
B0, z 
x' 
y' 
α° 
Mo 
Mxy 
Mz 
RF 
Figure 2.11- Rotating frame depiction of the effect on bulk 
magnetisation vector, M, of an applied external RF pulse 
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external radiofrequency (RF) field applied perpendicularly to B0, with a 
frequency equal to ωL.  This external field is conventionally denoted as B1.  This 
RF field has the effect of ‘tipping’ M away from B0 in a spiral trajectory (a simple 
arc in the rotating frame), and the angle which it makes to the M0 position is 
called the flip angle, α, which is dependent on the strength and time that B1 is 
applied for (see Figure 2.11). 
 
The component of M perpendicular to the main static field (Mxy, see Figure 
2.11) generates a current that can be measured, and it has a maximum value 
when there is no longitudinal (Mz) component- i.e. in the transverse plane of 
the rotating frame of reference. 
Once the B1 field is removed, the 
signal rapidly decays to zero as the 
protons undergo relaxation 
processes in order to return to 
thermal equilibrium.  The resulting 
Free Induction Decay (FID) signal, Figure 2.12, contains information relating to 
the environment from which the signal was received and this is the NMR signal 
that is used for producing images in MRI. 
 
Figure 2.12- Free induction decay signal 
Time (ms) 
Signal 
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2.1.3 Relaxation 
Relaxation is the process by which M returns to the equilibrium condition, M0.  
There are two processes of relaxation in NMR: longitudinal and transverse 
relaxation. 
 
Longitudinal relaxation is also known as spin-lattice, or T1, relaxation.  It is 
progressive loss of thermal energy to surroundings to realign magnetic 
moments with B0.  The time for this process to occur is governed by the 
microenvironment and occurs with a time constant T1, which is the time for 63% 
of M to return to M0 (Equation 2.2).  
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Equation 2.2 
Transverse relaxation, also known as spin-spin, or T2, relaxation describes the 
loss of phase coherence between the nuclei. As each individual precessing 
moment produces its own local magnetic field, neighbouring spins experience a 
slight perturbation of the main field and precess at slightly different frequencies 
around ωL, therefore there is a loss of phase coherence and the transverse 
component of the magnetisation vector, Mxy. The time constant associated with 
this, T2, is the time for Mxy to be reduced by 63% (Equation 2.3). 
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Inhomogeneities in B0 also result in small changes in precessional frequencies 
that cause an additional dephasing component that result in an effective time 
constant T2
*
, which is shorter than T2 (Equation 2.4). 
 
0
2
*
2
B
T
1
T
1 ∆γ+=  
Equation 2.4 
These relaxation properties are directly related to the environment and 
associated movement of the molecule containing the excited spins.  The 
movement of the molecules causes slight fluctuations in the Larmor frequency 
due to changes in magnetic field, and the characteristic time of these 
interactions between molecules is described by the correlation time, τc. Free 
water has short correlation times, due to rapid, free movement of the water 
molecules, while bound water (for example water molecules bound to proteins) 
exhibits long correlation times. 
 
Due to the short correlation times of free water, the rapidly oscillating magnetic 
field tends to result in a resonance slightly higher than the Larmor frequency, 
while solids exhibit a slightly lower precessional frequency.   
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In order to have efficient T1 relaxation, the resonance condition of ω=ωL is 
required, and where 
this is not met, T1 
times are longer due 
to inefficient transfer 
of energy to 
surrounding 
molecules- see Figure 
2.13. 
T2 relaxation times 
are also affected by 
τc.  Where τc values 
are short, such as in free water, interaction times are short and therefore the 
rate of change of phase is lower than compared with bound water, resulting in 
long T2 relaxation times (Figure 2.13).  In the case of bound water, τc times are 
longer resulting in a more rapid loss of phase coherence between the molecules 
and shorter T2 relaxation times as protons experience both local fields from 
bound water and applied external fields.  As the T1 relaxation is relatively 
unaffected by low frequency fluctuations, longitudinal relaxation times are 
always longer than transverse relaxation times.  
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Figure 2.13- Relationship between correlation times, τc and T1 and T2 
relaxation times 
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2.1.4 NMR Signal Localisation 
In order to localise where the NMR signal has been received from, it is 
necessary to introduce a known relationship between precessional frequency, 
phase and spatial position.  This is achieved by using magnetic field gradients, 
which are additional, smaller, magnetic fields applied either during RF 
excitation, between excitation and signal detection, or during signal detection. 
 
The slice selection gradient is applied during excitation to ensure that only a 
thin section of the patient experiences the excitation RF pulse, thus ensuring 
that signal from only one slice of the patient is received.  The gradient is applied 
perpendicular to the required slice orientation, and results in the frequency of 
precession varying linearly along this axis.  Due to the resonant nature of NMR, 
energy will only be transferred to spins precessing at ωL and only these nuclei 
will produce an FID.  The slice width is determined by the RF bandwidth and the 
gradient strength. 
 
During signal detection, a gradient is applied in one direction across the slice to 
encode the received signal, such that the received frequency will be directly 
related to the position within the slice.  This is known as the frequency encode 
gradient and results in a complex signal relating to the position and strength of 
the signal received across the slice. 
 
Phase encoding is used for spatial encoding in the final orientation of the slice. A 
gradient is applied for a short time between RF excitation and detection.  The 
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gradient causes relative phase shifts across the plane of the slice due to small 
changes in precessional frequencies caused by the gradient.  These phase shifts 
are retained after the gradient is switched off, when spins return to precessing 
at the Larmor frequency.  The detected phase change can be directly linked to 
the spatial position via the gradient.  To fully encode the imaging slice, the 
phase encode step is repeated a number of times with different gradient 
strengths, requiring a number of excitations.  The number of phase encode 
steps required is defined by the imaging matrix (i.e. for a 256×256 matrix, there 
are 256 phase encoding steps and therefore 256 excitations).  
 
The NMR signal is composed of combinations of sine and cosine waves with 
different frequencies and phases.  These complex waveforms contain the 
information about the area being imaged and are digitised and stored in raw 
data space.   The digitisation of these received signals results in raw data space, 
which is conventionally known as ‘k-space’ as shown in Figure 2.14.  Each data 
(a) (b) 
Figure 2.14-  (a) k-space raw data from a T2 Spin Echo sequence of the breast 
 (b) Final image formed by fast Fourier transform of raw data in (a) 
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point represents a wave in the final image with the k-space numerical value 
encoding the final amplitude (brightness), and the position within k-space 
determining the wave frequency and angle.  Therefore every point in k-space is 
represented in every voxel in the final image.  As the values close to the centre 
of k-space represent waves with longer wavelengths, these primarily represent 
contrast detail in the final image.  Those points on the periphery of k-space have 
high frequencies and therefore contain the detail of the image. 
 
In order to form the final image from k-space, the constituent frequencies and 
amplitudes are calculated using the Fast Fourier Transform (FFT).  This extracts 
all frequency information from the encoded signal, and as the gradients 
imparted a known positional relationship between frequency, phase and spatial 
position, the NMR signal can be translated to a final image. 
 
2.1.5 Magnetic Resonance Imaging (MRI) - Pulse Sequences 
The nucleus of hydrogen contains only one proton and as they are naturally 
abundant atoms in fat and water, they are used in most MR imaging, although 
other atoms such as phosphorus (
31
P), carbon (
13
C) and sodium (
23
Na) can be 
used. 
 
By manipulating the timing, strength and duration of the B1 field, as well as 
timing of the signal detection, tissues can be differentiated due to different 
micro-environments of the hydrogen nuclei.  The timings can be described by 
pulse sequence diagrams.   
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There are three common sequence types, upon which all others are based.  
These are Inversion Recovery (IR) sequences, Spin Echo sequences (SE) and 
Gradient Echo sequences (GE).  This thesis will deal with only GE sequences. 
 
2.1.6 Gradient Echo Sequences 
Rather than sampling the FID produced immediately after the application of a B1 
excitation, it is more common in MRI to form echoes due to limits on the time 
to ramp-up gradients for signal readout.  In GE sequences, the echo is formed 
by using the frequency encoding gradient to dephase and rephase the protons 
to form an echo that can be fully sampled.  The rephasing is achieved by 
reversing the polarity of the dephasing gradient and at the point when the 
rephasing lobe equals the area of the dephasing lobe, the maximum echo signal 
is received.  The time between the excitation pulse and the maximum echo 
signal is known as the echo time, TE.  
 
As described earlier, the phase encode gradient has to be applied a number of 
times to fully spatially encode the imaging slice, and therefore a number of RF 
excitations are required.  The time between each excitation is called the 
repetition, TR.  To prevent saturation of protons, a TR greater than five times 
the maximum T1 of the tissue being imaged is required, to allow full longitudinal 
relaxation prior to the next excitation.  In gradient echo imaging, however, TR 
values are usually significantly shorter than this to speed up the acquisition 
process.  To reduce the effect of proton saturation, flip angles of less than 90° 
are used for excitation.  The contrast in the images is determined by the T1, T2, 
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T2
*
 and proton density (PD) of the imaged tissues, and is highlighted by 
manipulating the parameters associated with the imaging sequence- the flip 
angle (α), TR and TE. 
 
2.1.7 Fast Gradient Echo Sequences 
In order to acquire images faster, it is possible to shorten the TR to reduce the 
overall scan time.  When full T1 recovery is not possible within each TR, 
saturation can occur resulting in little or no signal from tissues with long T1 
relaxation times and therefore to reduce this effect, small flip angles are used.  
Whilst this results in an overall lower signal by not allowing full T1 recovery to 
the equilibrium position, a component of magnetisation is retained along the z-
axis for further excitations which prevents saturation.  For a tissue with a given 
T1 value, the maximum signal is obtained by using a flip angle known as ‘the 
Ernst Angle’, αE, as given in Equation 5.5. 
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Equation 5.5 
Image contrast in fast gradient echo sequences is mainly controlled by the flip 
angle and TE.  To produce T1 weighted images, it is necessary to ensure that full 
T1 recovery has not taken place when the FID is sampled and therefore large flip 
angles (typically more than 50°[113]) and short TE values (less than 15ms) are 
utilised.  In T1 weighted images, fluid is dark and fat very bright and such images 
are most commonly used for looking at anatomy. 
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To produce T2
*
 weighted images, full T1 recovery is required to remove T1 
weighting and low flip angles (less than 40°) and long TE (>30ms) values are 
used. T2
*
 images show bright fluid, while fat is darker than in a T1 image and are 
most commonly used for highlighting pathology. 
 
Proton Density (PD) weighted images provide a representation of the density of 
hydrogen nuclei in the tissues.  This is achieved by removing all T1 and T2 
weighting in the image (i.e. small flip angle and short TE).  These images have 
less contrast than either T1 or T2 as all tissues have similar water content. 
 
Fast GE sequences allow short TR values to be used, thus reducing the overall 
acquisition times.  When TR values are reduced sufficiently that full transverse 
relaxation cannot occur, remnant transverse magnetisation from previous 
excitations can cause artefacts on the final image due to the formation of 
stimulated echoes.  There are various methods of dealing with this remnant 
transverse magnetisation to prevent such imaging artefacts- by either using the 
echoes to form the final image, combining the echo with the FID signal or by 
using only the FID signal.  This thesis deals only with the final method, in which 
the remnant transverse magnetisation is destroyed to prevent interactions 
between successive repetitions.  Such sequences are known as spoiled gradient 
echo sequences, and the Siemens nomenclature for this is ‘Fast Low Angle 
SHot’, or FLASH, sequence.  FLASH sequences utilise strong ‘spoiler gradients’ 
which destroy phase coherence between successive TR intervals.  These 
sequences can provide T1 and T2
* 
weighting, although in the context of this 
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thesis, and Breast MRI, they are used for rapid three dimensional T1-weighted 
scanning. 
 
2.1.8 Additional Contrast 
As well as traditional T1, T2, T2
*
 and PD weighted images, further contrast can be 
introduced into images either by the use of saturation techniques or by the 
artificial addition of a contrast agent. 
 
Due to the different micro-environments of the hydrogen nuclei in fat and 
water, the Larmor frequency of each is slightly different- around 220Hz 
difference in precessional frequencies at 1.5T.  In a frequency spectrum there is 
therefore a slight difference in the fat and water peaks.  By applying a pre-
excitation saturation RF pulse at the frequency of the fat protons, then 
immediately applying the excitation B1 at the ωL of the water protons, there is 
no signal received from fat and therefore it appears dark in the final images.  
Such a technique is known as fat suppression and is commonly used in fatty 
tissues (such as the breast), as the high signal intensity can mask underlying 
pathologies. 
 
Contrast agents can also be used in MRI.  The most commonly used agents are 
based on chelated gadolinium-based compounds.  As gadolinium is highly 
paramagnetic, it disturbs the local magnetic field, thus reducing the T1 in the 
immediate vicinity.  Therefore on a T1-weighted image, areas of contrast uptake 
appear bright. 
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2.2 TEXTURE ANALYSIS 
2.2.1 What is Texture? 
Texture is a particularly difficult physical property to define, despite the fact it is 
a concept that is widely identified with.  The Oxford English Dictionary defines 
texture as ‘‘the constitution, structure or substance of anything with regard to 
its constituent or formative elements’ [114].   
 
The eye processes and identifies the texture of an object by the variance in the 
light reflected from a surface [115] and therefore it is a physical property 
relating to the composition of the object in question.  The texture is composed 
from the randomness, periodicity, directionality and orientation of the 
composite elements making up the structure of the object [115].  The eye can 
extract complex information from images in order to infer texture properties of 
the objects in question and therefore much work has been carried out to 
understand the human perception of texture using computer analysis 
techniques [88, 116].   
 
The concept of texture becomes more difficult when trying to describe images, 
but the generally accepted description of texture in an image is based on that 
which Haralick described in the 1970’s.  He described texture as comprising 
spatial distributions of tonal compositional elements  [86, 88, 115, 117]- i.e. the 
spatial distribution of grey-levels within an image. 
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There are two main areas of texture analysis in imaging- in the classification of 
different regions within an image and in segmentation of textures in order to 
establish boundaries between regions [118].  This thesis deals only with the 
former application. 
 
The visual system can distinguish between regions in an image by using cues 
such as changes in texture, colours, luminance etc, and in general classification 
accuracy is increased for more than one visual cue, rather than relying on one 
stimulus alone [119].  However, as more textures are introduced into an image, 
it becomes more difficult for the brain to readily classify the data quickly with 
minimal effort [116].  In such cases, computer methods for describing texture 
can prove useful in complex discriminatory tasks. There are many ways in which 
to perform texture analysis.  The three main methods for computationally 
describing texture features as used in this thesis- namely statistical methods, 
model-based methods and transform methods- are described in the following 
sections. 
 
Mathematical derivations of features associated with each model can be found 
in Appendix A.   
 
2.2.2 Statistical Methods for Texture Analysis 
Texture can be described using words such as uniform, rough, smooth, 
directional, random etc. which relate to the pixel values and distributions that 
comprise the image [86, 120].  This leads us to a statistical description of 
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texture.  Statistical methods are classified as first, second or higher-order 
methods.  Statistical methods use the grey level distribution of pixels in the 
image for texture analysis.  Generally statistical based methods will provide 
better discrimination between classes than structural or transform methods 
[121] and are the most widely used in medical applications. 
 
Histogram Methods 
First order techniques utilise the frequency of grey-levels contained in the 
image histogram to infer texture properties such as image mean, variance, 
skewness and kurtosis.  Such descriptors are simple, however they do not 
provide a high discriminative power as no consideration is made of correlation 
or co-occurrences of more than one pixel [118]. 
 
Max-Min Method 
The max-min method of texture analysis utilises the visual perception of texture 
being dependent on the frequency of extremes in grey level intensity.  By 
smoothing the data and determining the number of grey-level minimum and 
maximum values in a given direction, a texture feature can be defined [122].  
Smoothing is carried out on the original data-points (xk) with reference to a 
threshold value (T), such that a new smoothed curve is defined (yk) (Equation 
2.6, Figure 2.15). 
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Equation 2.6 
 
The number of maximum and minimum intensity extremes detected will 
therefore depend on the threshold value chosen- large T values result in a 
reduction in max-min values, small T values result in less of a reduction.  To fully 
characterise an image, therefore, a number of T values are used and each time 
the number of extreme values is calculated. The ratio of extremes at one 
threshold value to another are then calculated to reduce the dependency on 
the absolute number of extreme values.  These ratio values form the texture 
description.  
 
T
/2 
MAX 
MAX 
MAX 
MIN 
MIN 
MIN 
Original data 
Smoothed data 
Figure 2.15- Schematic diagram of max-min smoothing and identifications of extreme values 
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Co-Occurrence Matrix 
The co-occurrence matrix (COM) is commonly referred to as a ‘second-order 
histogram’ as it is concerned with pairs of pixels rather than individual pixels 
[86]. It represents the count of pixels in a given direction and at a specified 
distance with co-occurring pixel values of i and j [88, 121].  A matrix is produced 
in each direction, θ, for each interpixel distance, d, with the matrix dimensions 
being equal to the number of intensity levels.  This can, therefore, become 
computationally intense and the number of grey levels in an image would 
normally undergo a rescaling and re-binning procedure to reduce the range of 
pixel values contained within an image.  While this process increases the 
counting statistics of the COM, it leads to a potential reduction in the 
discriminatory power of the model. 
 
There are eleven texture features derived from the co-occurrence matrix that 
will be used in this work, calculated in four directions and for distances up to 
five pixels.  The full list of statistical texture features is listed in Table 2.5. 
 
Images with identical second order statistics are visually indistinguishable [123] 
and therefore computer-aided texture analysis is essential for assessing texture 
on a pixel-by-pixel basis, and for allowing potential discrimination. 
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Gradient Features 
The gradient model considers the relationship of variations in grey level 
intensities across neighbouring pixels.  High gradients are produced when pixels 
change intensity rapidly, while low gradients are produced for gradually varying 
pixel intensities [121]- see Figure 2.16 below. 
 
Texture features such as the mean gradient, kurtosis and variance can be 
calculated as shown in Table 2.5. 
 
Table 2.5- List of statistical texture features used in this thesis 
 
   Number of 
Features 
calculated 
Co-occurrence Matrix COM angular second moment, 
contrast, correlation, difference 
entropy, difference variance, 
entropy, inverse difference 
moment, sum average, sum 
entropy, sum of squares, sum 
variance 
(in four directions and up to 
interpixel distances of 5) 
220 
 
Absolute Gradient GRA gradient mean, kurtosis, 
nonzero, skewness, variance 
5 
Run Length Matrix RLM fraction of image in runs, grey-
level non-uniformity, run length 
non-uniformity, long run 
emphasis, short run emphasis 
(in four directions) 
20 
 
High gradient Low gradient 
 
Figure 2.16- Pictorial depiction of high and low gradient in an image when considering  
the three central pixel grey levels 
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Run-Length Matrix 
The run-length matrix is based on the number of consecutive pixels in a given 
direction having the same grey-level intensity 
value [89].  A matrix is composed using the 
number of intensity levels in the image and 
the number of pixel runs (i.e. how many 
consecutive pixels have the same pixel 
intensity- see Figure 2.17) [121].  This is highly 
dependent on the number of grey levels in 
the image and these will often be reduced to 
increase the counting statistics, at the expense of reduction in textural 
information in the image [86]. 
Run length matrices are usually calculated in four directions (horizontal, vertical 
and along the two diagonals) as shown in Figure 2.17 (see Table 2.5) [124]. 
 
2.2.3 Model Based Methods for Texture Analysis 
Auto-regressive Model 
Model based texture analysis methods assume that the image texture can be 
represented by a computational model to which parameters can be fitted [86, 
89].  The method employed in the MaZda texture analysis software program, as 
used in this thesis, is the auto-regressive model (ARM) [125, 126].  This 
calculates grey levels using weighted sums of neighbouring pixel intensities and 
the auto-regressive parameters are those weights.  These are used to establish 
1 
2 
3 
4 
Figure 2.17- Example image showing run 
length of 4 in 45° direction for light grey 
pixel intensity 
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a relationship and are therefore measures of the statistical similarities between 
a pixel and its neighbours, which can be related to texture [86, 89]. The weights 
are denoted by theta (θA), while the noise in the image is denoted by sigma, σA 
(see Table 2.6). 
Table 2.6- Auto-regressive model features used in this thesis 
 
2.2.4 Transform Methods for Texture Analysis 
Wavelet Transform 
Transform methods consider the data in a different space and the method 
implemented in MaZda, the wavelet transform, analyses the image in frequency 
space. 
 
In an image, fine detail is represented by high frequency signals while low 
frequency signals encode the contrast information.  How we perceive an image 
is also dependent on the size at which we view it- i.e. if we view an image at a 
large scale we notice gross features while smaller details are noted at small 
scales [117].  This accounts for the dependence of texture perception on image 
resolution as well as the overall size of the image.  The wavelet transform 
utilises the frequency information and viewing scale to analyse texture content 
of an image. 
 
   Number of 
Features 
calculated 
Auto Regressive 
Model 
ARM theta (θA) 1-4, sigma (σA) 5 
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Table 2.7- Wavelet parameters as calculated by MaZda, used in this thesis. 
 
The image is passed through low and high pass filters before being rescaled and 
again filtered.  This provides information on the frequency content of the image 
at various viewing scales (as shown in Table 2.7).  The wavelet energy is then 
calculated using the signal in each frequency channel, which is directly linked to 
the frequency content of the whole image and therefore the image texture [86]. 
The Haar wavelet is the most commonly implemented transform as it allows for 
the precise localisation of texture, whilst minimising the signal distortion.  
Wavelet energy is calculated for each scale. 
 
 
2.3 COMPUTER SOFTWARE USED IN THIS THESIS 
2.3.1 Computer Aided Texture analysis  
Texture analysis is a computationally demanding technique and there are a 
number of steps performed in order to obtain meaningful results from the 
technique (Figure 2.18).  Texture analysis within the scope of this thesis has 
been carried out using MaZda (Technical University of Lodz, Poland) [125-127], 
which is a well-known and established software program, which is freely 
available.  Additionally, in Chapter Five a custom, independently-written piece 
of software was used to compare a max-min texture analysis technique with 
   Number of 
Features 
calculated 
Wavelet Transform WAV sub-bands LL, LH, HL, HH at 
different energies 
(up to five energies calculated) 
20 
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results obtained from MaZda.  The computer coding for this can be found in 
Appendix B. 
 
Image Normalisation 
As there are typically 256 or more grey level intensities contained within an 
image, it is normal to compress the data into a smaller intensity range in order 
to simplify further computation of texture features.  Performing this step 
increases the statistical power; however some texture information may be lost 
within this step. The most common way of performing this step is to rescale the 
histogram to fit into ±3 standard deviations (σ) of the histogram mean (µ). 
Normalised Data 
(µ±3σ) 
Original Data 
-3σ 3σ µ 
 
Image with region of 
interest defined 
Norr maa lll iiiss aa tt iiion   
Fee aa tt urr ee    Computt aa tt iiion   
Fee aa tt urr ee    
Ree ducc tt iiion///See lllee cc tt iiion   
Clllaa ss ss iiiff iiicc aa tt iiion   
Figure 2.18- Graphical representation of the process required for texture analysis and feature classification 
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Feature Computation 
MaZda software calculates features based on the image histogram, co-
occurrence matrix, absolute gradient, run-length matrix, auto-regressive model 
and wavelet transform.   
 
Feature Selection 
Due to the large number of features generated by MaZda, all features or only a 
subset can be selected to export for further analysis.   
While it is also possible to perform feature reduction to decrease the 
dimensionality of the data [118] using various methods such as mutual 
information, probability of error and the Fisher combination, as these 
techniques were not used within this work, they have not been defined further.  
 
2.3.2 Data Classification 
As texture analysis results in a large number of features being generated to 
describe regions of interest within an image, classification regimes are 
employed to look for patterns within the data.  The software used in this thesis 
for classification of features were the packages B11 (Technical University of 
Lodz, Poland) [128, 129] and Weka (The University of Waikato; Hamilton, New 
Zealand) [130].   
 
Classification has been performed throughout using the k-nearest neighbour 
technique (k-NN) where distance functions are calculated to ascribe feature 
vectors to the class with a minimum distance in feature space.  The number of 
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neighbours required in order to ascertain whether a data vector should be 
assigned to the class (the ‘k’) can be selected according to requirements.  Using 
a higher number of nearest neighbours generally results in a slight reduction in 
the number of correctly classified vectors, but an increase in the classification 
certainty. 
 
Validation methods are employed in classification packages to minimise the 
possibility of classification due to chance, and can be categorised as either 
internal or external methods.  The internal method utilised in this thesis is the 
cross-validation regime using a ten fold regime.  The data is split into a number 
of ‘folds’, in this case ten.  The model is built on 
9
/10 of the data and tested on 
the remaining tenth and this procedure is repeated ten times.  This ensures that 
the best model is built to fit the data supplied.  External validation regimes test 
the model on ‘unseen’ data, and the method employed by Weka is the holdout 
method.  The percentage of data to be training data is selected (this was 66% of 
data except where explicitly stated to be different) and the model is formulated 
on this prior to testing on the remainder of the data.  This provides a more 
accurate representation of how well a model can be expected to perform on 
new data. 
 
Assessment of how well the classification has been performed can be made 
using the classification accuracy, which normally describes a percentage of the 
data that has been correctly classified and area under receiver operator curves 
(ROC).  ROC curves are particularly useful as they demonstrate the trade-off 
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between correct identification of positives vectors as a function of misclassifying 
negatives as positives.  They are commonly used in medical diagnostics to 
determine cut-off values in clinical tests. 
 
2.3.3 Statistical Analysis 
As well as considering the individual feature classification accuracies, 
assessment was also made of the raw feature values themselves.  All statistical 
assessment was performed using SPSS version 21.0 for Windows (IBM 
Corporation; Armonk, New York) [131]. 
As data could not be assumed to belong to a normal distribution, Mann 
Whitney U tests were used for all pair-wise comparisons, and Wilcoxon tests 
employed in Chapter 7 for paired comparisons.  Where comparisons were 
required between multiple groups, Kruskal Wallis tests were employed. 
In all cases, a significant level of p<0.05 was utilised, except where explicitly 
stated to be otherwise. 
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CHAPTER THREE: PHANTOM VALIDATION STUDY 
 
OUTLINE OF CHAPTER: This chapter deals with the stability of texture 
measurements by designing and making a standard ‘texture phantom’.  
Assessment is then made of the impact that different MRI scanners and 
different imaging parameters have on texture analysis outcome. 
  
3.1 INTRODUCTION 
One of the main concerns surrounding the use of texture analysis (TA) in routine 
clinical practice is reports in the published literature indicating that the 
technique is highly dependent on MRI hardware and acquisition conditions 
[111, 132-135].  This would suggest that while texture analysis can be used 
reliably in one centre for image analysis, setups in other centres may result in 
completely different results. 
 
The main reason cited within the literature for this inconsistency is due to signal 
to noise ratio (SNR) differences  [136, 137].  The aim of this study was therefore 
to identify first of all whether a routine clinical breast sequence could be used 
for accurate texture classification, using a custom-designed texture phantom, or 
whether sequence optimisation was required prior to further studies.  The 
robustness of texture analysis was also investigated by altering acquisition 
conditions and examining the effect on the accuracy of texture analysis. 
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3.2 MATERIALS AND METHODS 
3.2.1 Breast Phantom 
There have been a wide variety of texture phantoms described within the 
literature, including polystyrene spheres, fine glass tubes, reticulated foam and 
glass spheres embedded in agarose gel or doped water [111, 132, 133, 138, 
139].  On imaging such phantoms, however, macroscopic patterns are often 
visually apparent and therefore visual classification is possible without the need 
for a computer-based technique.  As the aim of this work was to develop TA as a 
clinical tool, a phantom was designed that would incorporate texture objects 
that appeared visually identical on imaging.  This would allow assessment of the 
successfulness of TA between different acquisition conditions, without any bias 
introduced according to the visual appearance of the images. 
 
Reticulated foam has been used successfully as texture objects in other studies 
[111, 134, 136] and does not result in any obvious visual differences on resulting 
images acquired at clinical MRI resolutions.  It was therefore felt to be the most 
appropriate material for composing a phantom for our validation studies. 
 
Foam with specific porosities of 30, 45, 75 and 90 pores per inch (ppi) was 
sourced to use in the test phantom (Foam Engineers Ltd.; Buckinghamshire, 
UK)- Figure 3.19 (a-d).  The foam samples were submerged in tubes filled with a 
2% agarose solution (Sigma Aldrich; St. Louis, MO) held at 70°C.  The agarose 
was doped with 0.2% Magnevist (Bayer Healthcare; Germany) to shorten T1 
relaxation times to values comparable with those measured in vivo [140].  As air 
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bubbles can adversely affect the TA outcome by artificially introducing further 
texture [133] and causing susceptibility artefacts, each piece of foam underwent 
repeated cycles of compression in the liquid agarose solution followed by a 
period of settling.  Once there was no visual evidence of the presence of air 
bubbles, the texture objects were cooled slowly in a water bath- Figure 3.19. 
Once the agarose had set, the phantoms were imaged on a 3.0T Siemens Trio 
(Siemens; Erlangen, Germany) MRI 
scanner using a high resolution T1 
FLASH sequence with an in-plane 
resolution of 0.4×0.4mm2 to ensure 
that there were no remaining air 
bubbles in the gel test objects.  
 
 The breast phantom was then 
made by forming a 5mm layer of 
Figure 3.19- Reticulated foam texture phantoms showing different grades of foam ((a)- 30ppi; (b)- 
45ppi; (c)- 75ppi; (d)- 90ppi) and then embedded in agarose gel (right hand image) 
 
(a) (b) 
(c) (d) 
Cod liver oil 
capsule 
Layer of 
lard 
Figure 3.20- Final phantom with four texture objects 
embedded in the agarose gel 
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cooking lard around a cylindrical container to simulate mammary fat.  Agarose 
gel with the same composition as in the test objects was used to fill the 
container to mimic fibroglandular tissue, and the test objects were embedded 
into it (see Figure 3.20).  A cod liver oil capsule was placed on the side of the 
container to ensure reproducible slice positioning when imaging the phantom. 
 
Both T1 and T2 values of the agarose and lard were measured on a 1.5 T Siemens 
Avanto MRI system using standard techniques and compared with clinically 
obtained values for fibroglandular tissue and mammary fat- shown in Table 3.8.   
Table 3.8- T1 and T2  measurements obtained from phantom, compared with those obtained in 
vivo 
 
Images acquired with the phantom in the 2-channel breast matrix coil and using 
a standard T2 TSE and T1 FLASH sequence from the routine breast protocol are 
shown Figure 3.21. 
  T1 (ms) T2 (ms) 
Agarose Gel 1370 65 
Phantom Measurements 
Lard 272 49 
Fibroglandular tissue 1266 57 Previously reported in vivo 
measurements [140] Mammary fat 296 53 
30ppi 90ppi 
45ppi 75ppi 
T2 TSE 
TR/TE: 4510/89 ms 
voxel size: 1.0×1.0×2.0 mm
3 
30ppi 90ppi 
45ppi 75ppi 
T1 FLASH 
TR/TE: 28/4.70 ms 
voxel size: 0.7×0.7×1.0 mm
3 
Figure 3.21- Phantom images acquired using typical clinical breast MRI sequences 
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3.2.2 MR Imaging 
All imaging was carried out using a 3D spoiled gradient echo sequence (FLASH), 
as described in Section 2.1.6. Clinically, this sequence is used as a dynamic 
acquisition, imaging both breasts axially prior to, during and for a period of time 
after the administration of a contrast agent to identify regions of increased 
vascularity, often associated with malignancy.  This sequence was chosen for all 
analysis to be performed on as it is often used to identify lesions in the breast, is 
incorporated into all breast MR clinical protocols and also because efforts have 
been made by the European Society of Breast Imaging to standardise its usage 
across equipment and sites [141]. 
 
The standard 3D FLASH dynamic acquisition run clinically acquires a number of 
volumes sequentially to provide a temporal representation of the contrast 
uptake.  The total scan time is determined by the number of these volumes that 
are acquired and therefore to minimise imaging time using the phantom, only 
one volume was acquired. 
 
The phantom was imaged as shown 
in Figure 3.22, using three different 
protocols on two different scanners, 
with acquisition conditions as shown 
in Table 3.9.  A standard quality 
assurance phantom was used on the 
contralateral side of the coil to the phantom, to ensure adequate coil loading. 
Figure 3.22- Phantom setup for sequence testing 
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  Protocol 1 Protocol 2 Protocol 3 
Scanner  
16-channel 
Siemens Avanto 
32-channel 
Siemens Trio 
32-channel 
Siemens Trio 
Field strength (T) 1.5 3.0 3.0 
Imaging coil  2-channel 7-channel 7-channel 
Repetition time (ms) 3.8 3.8 3.5 
Echo time (ms) 1.24 1.28 1.19 
Field of view (mm) 320×320 320×320 320×320 
Matrix  384×384 384×384 256×256 
Slice thickness (mm) 0.83 0.83 2.0 
Voxel size (mm
3
) 0.83×0.83×0.83 0.83×0.83×0.83 1.25×1.25×2.0 
Flip angle (°) 6 6 10 
Bandwidth (Hz/px) 650 650 560 
Grappa factor  ×2 ×2 ×2 
Number of slices  192 192 72 
Imaging Time (s) 61 60 24 
Table 3.9- Sequence parameters used for each of the three imaging protocols 
 
Protocol 1 was acquired on a 16-channel 1.5 T Siemens Avanto MRI scanner 
using a 2-channel breast matrix coil and Protocols 2 and 3 were acquired using a 
32-channel 3.0 T Siemens Trio MRI scanner with a 7-element open breast biopsy 
coil.  Both Protocol 1 (P1) and Protocol 2 (P2) were high spatial resolution 
techniques, with lower temporal resolution, which are used at our institution as 
routine clinical protocols allowing morphological assessment as well as semi-
quantitative enhancement analysis. Protocol 3 (P3) uses a higher temporal 
resolution with lower spatial resolution which could potentially be used for 
pharmacokinetic modelling [142-144]. 
 
The effect of sequence parameter changes on TA outcome was investigated by 
altering three of the acquisition parameters most likely to be altered in a clinical 
setting- the repetition time (TR), the bandwidth/echo time (BW) and the flip 
angle (α).  The echo time (TE) is set as the minimum value for a given bandwidth 
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to minimise acquisition times, as per the manufacturers recommended 
protocol. 
 
For each protocol the phantom was imaged using the baseline protocols as 
outlined in Table 3.9, and then four parameter changes were implemented to 
cover the range likely to be 
encountered clinically (see 
Table 3.10). Only one 
parameter was changed at 
any given time, while the 
other parameters remained 
at their respective baseline 
values (TR1, BW1, α1). 
All images were stored in 
Siemens DICOM format (.IMA) 
and were re-saved as true DICOM (.dcm) files for texture analysis by using a 
filename extension changer. 
 
3.2.3 Texture Analysis 
Texture analysis was performed using MaZda version 4.7 [126, 127, 145] and 
data classification performed using Weka, version 3.6.9 [130]. 
 
For texture analysis, circular regions of interest (ROI) were drawn manually with 
a fixed area of no less than 300 pixels (corresponding to a physical area of 
  P1 P2 P3 
TR1 3.80 3.80 3.50 
TR2 4.00 4.00 3.25 
TR3 4.25 4.25 3.75 
TR4 4.50 4.50 4.00 
(m
s)
 
TR5 4.75 4.75 4.25 
BW1/ TE 650/1.24 650/1.28 560/1.19 
BW2/ TE 590/1.26 590/1.33 650/1.11 
BW3/ TE 540/1.29 540/1.55 530/1.22 
BW4/ TE 500/1.31 500/1.57 510/1.23 
(H
z/
p
x/
m
s)
 
BW5/ TE 470/1.34 470/1.60 470/1.29 
α1 6 6 10 
α2 5 5 8 
α3 4 4 12 
α4 3 3 14 
(°
) 
α5 2 2 16 
Table 3.10- Sequence parameter changes for each of the 
considered acquisition parameters at each imaging 
protocol 
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approximately 216 mm
2
) for P1 and P2, and no less than 170 pixels 
(corresponding to a physical area of approximately 276 mm
2
) for P3.  Slight 
differences in ROI sizes were mainly due to the marginally larger Gibbs artefact 
(bright and dark lines next to the border of abrupt signal intensity changes) in 
the images acquired with P3- ascribed to the larger pixel size.  These ROIs were 
placed in the centre of each foam phantom across the ten central slices.  
 
Image data was re-binned according to the model in question using previous 
experience, reports in the literature [105] and recommendations from the 
software developers [146] (co-occurrence matrix: 6 bits/pixel, gradient features: 
8 bits/pixel, run-length matrix: 4 bits/pixel, wavelet transform: 12 bits/pixel).  
Grey level normalisation, which is known to minimise the effect of contrast and 
brightness variations on the outcome of TA [127, 137] was carried out within 
MaZda by rescaling the histogram to fit within µ±3σ (where µ- grey level mean, 
σ- grey level standard deviation). 
 
Texture features were calculated using five different techniques: the auto-
regressive model (ARM), co-occurrence matrix (COM), absolute gradient (GRA), 
run length matrix (RLM) and wavelet transform (WAV), as described in Chapter 
2.2.  The texture features associated with each category are shown in Table 
3.11. 
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   Number of features  
Auto-regressive model ARM theta (θ) 1-4, sigma (Σ) 5 
Co-occurrence matrix COM angular second moment, contrast, 
correlation, difference entropy, 
difference variance, entropy, 
inverse difference moment, sum 
average, sum entropy, sum of 
squares, sum variance 
11 
(in four directions 
and up to interpixel 
distances of 5) 
Absolute gradient GRA gradient mean, kurtosis, non-zero, 
skewness, variance 
5 
Run-length matrix RLM Fraction of image in runs, grey-level 
non-uniformity, run-length non-
uniformity, long run emphasis, 
short run emphasis 
5 
(in four directions) 
Wavelet transform WAV sub-bands LL, LH, HL, HH at five 
energies 
4 
(up to five energies) 
Table 3.11- Texture features derived from each of the categories used in this study 
 
As there are a total of 220 features that can be calculated using the COM model, 
these were standardised to limit the number of features calculated.  Only 
texture features for pixel pairs at an interpixel distance of n=1 and in arbitrarily 
chosen directions of 0° and 45° were calculated, which then gave an input of 22 
features from the COM model for classification (two entire datasets of eleven 
COM features).  The interpixel distance was selected as it was believed to be the 
best for representing fine texture due to the large number of pixel pairs it would 
produce. 
 
For classification using Weka, cross-validation was utilised in order to increase 
certainty in the classification outcome.  The classification itself was performed 
using the k-nearest neighbour technique, in which data vectors are classified 
based on the surrounding vectors in feature space.  For this investigation the 
k=3 nearest neighbour technique was used in order to increase the specificity of 
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the classification.  As the true class of the data vector in question was known, 
the percentage of misclassified vectors was calculated to provide an indication 
of the successfulness of texture analysis [147]. 
 
The aim of this work was two-fold- firstly to identify if four grades of foam 
within one image could be differentiated using TA for each of the protocols 
outlined in Table 3.9; and secondly, to determine if changes to baseline 
acquisition parameters resulted in a measurable difference in the image 
texture.  The rationale for the latter part was to assess whether routine, clinical 
sequences could be used for TA or whether optimisation was required.   
 
3.2.4 Signal to Noise  
 
To identify whether any differences in TA in response to changing acquisition 
parameters were real or due to changes in noise levels within the image, signal 
to noise (SNR) was measured for each sequence parameter change using each 
protocol. 
 
Measurements were made of the mean signal intensity in each foam sample 
and the standard deviation of the background noise using circular ROIs and SNR 
calculated using Equation 3.7. 
 
noisebackgrounddevstd
signalmean
655.0SNR ×=  
Equation 3.7 
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The 0.655 scaling factor is required to correct for the Rayleigh distribution of the 
noise in magnitude images. 
 
The SNR was plotted as a function of the percentage of misclassified vectors to 
determine if any relationship could be established.  
 
 
3.3 RESULTS 
Each dataset consisted of 40 datapoints (four different foam porosities over 10 
imaging slices) and a total of 13 datasets (baseline parameters plus four of each 
parameter change) were analysed for 
each of the five texture models and for 
each protocol. This led to a total 
analysis workload of 195 datasets. 
An example phantom image is shown in 
Figure 3.23, which was acquired using 
P1 with the standard baseline 
parameters. It is clear from this figure 
that each foam sample cannot be 
discriminated visually (Multi-Modality 
WorkPlace (MMWP) workstation 
resolution: 1280×1024). 
 
Figure 3.23- MR image acquired using the standard 
baseline sequence (P1) of the breast phantom 
composed of four different grades of reticulated foam, 
as shown 
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First order statistics were calculated and confirm that the foams could not be 
differentiated without the use of second order statistics (Mean: 143.63 [141.40-
147.16]; Variance: 35.53 [28.68-39.78], Skewness: 0.20 [0.15-0.34]; Kurtosis: 
0.28 [0.20-0.42]). 
 
3.3.1 Differentiation of Foam at Each Baseline Imaging Protocol 
The ability of TA to discriminate between the four different grades of foam was 
assessed by considering the percentage of misclassified vectors for each of the 
individual models.  Results are presented in Table 3.12 for the images acquired 
with baseline parameters for each protocol.  Figure 3.24 shows these results 
graphically in 3-D feature space.  It is clear from these results that the wavelet 
transform, WAV, and the co-occurrence matrix, COM, features performed the 
best for discriminating between the four foams across all protocols.  The run-
length matrix, RLM, gradient features, GRA, and auto-regressive model, ARM, 
resulted in the poorest overall classification. 
  ARM COM GRA RLM WAV 
P1 baseline 52.5 52.5 62.5 77.5 2.5 
P2 baseline 22.5 20.0 30.0 17.5 0.0 
P3 baseline 27.5 17.5 62.5 62.5 0.0 
Table 3.12- Percentage of misclassified vectors for baseline sequence parameters for each 
protocol and texture analysis model 
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ARM COM GRA 
 1- 90ppi, 2- 75ppi, 3- 30ppi, 4- 45ppi  
  
 RLM WAV  
Figure 3.24- Graphical representation in 3-D feature space of texture features from each model derived from 
the baseline images for P2 baseline parameters 
 
 
3.3.2 Effect of Sequence Parameter Changes 
The ability of TA to differentiate between the four foams when using the 
different sequence 
parameters outlined 
in Table 3.10 is 
presented in Table 
3.13.  The results are 
the average 
percentage rates of 
  ARM COM GRA RLM WAV 
 TR 57.00 67.50 69.00 68.50 2.50 
P1 BW 51.25 50.00 69.00 76.00 1.50 
 α 51.50 56.00 61.00 73.50 1.50 
 TR 21.00 15.00 37.50 28.50 0.00 
P2 BW 21.50 10.00 29.50 23.00 0.00 
 α 10.10 12.50 23.50 20.50 0.00 
 TR 43.95 21.00 64.50 68.50 1.00 
P3 BW 38.00 28.50 54.00 56.50 1.00 
 α 32.00 26.50 56.00 62.00 0.50 
Table 3.13- Average percentage of misclassified vectors across 
sequence acquisition parameters for each model at each protocol  
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misclassification across all parameter changes in each category (i.e. TR1-TR5, 
BW1-BW5 and α1-α5).  Again, WAV features resulted in excellent classification 
across all sequence parameter changes for each protocol.  The COM features 
also resulted in good classification, particularly for the 3.0 T protocols, and 
results are presented in Figure 3.25 for each individual sequence parameter 
change and every protocol for COM features only.  While the COM resulted in 
particularly good classification for P2, which was the 1.5 T parameter matched 
sequence acquired on the 3.0 T scanner, both the RLM and GRA models 
appeared to again perform poorly when compared with the other models 
across all sequence parameters and protocols.  
 
Figure 3.25- Percentage of misclassified vectors for each of the sequence parameters at each protocol for 
COM features 
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3.3.3 Comparison of Sequence Parameters 
Figure 3.26 shows the comparison of TA when discriminating between two 
images acquired with different sequence parameters, one of which was 
baseline.  Results are presented graphically only for the COM and WAV as these 
have been demonstrated in our study to be good at discriminating between the 
foam phantoms across a range of acquisition conditions. 
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Figure 3.26- Percentage of misclassified vectors calculated when images acquired with different sequence 
parameters were compared.  Data is presented graphically only for the COM and WAV 
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For variations in the repetition time, P1 resulted in relatively high rates of 
misclassification, and there was a reduction in the misclassification rates for 
both P1 and P3 as the TR was changed further from baseline value, suggesting 
there may be an influence of this parameter change on TA outcome.   
When varying the bandwidth/ echo time, P1 resulted in fairly consistent levels 
of misclassification, while P2 and P3 had a reduction in misclassification as 
BW/TE was changed further from baseline parameters.  
Flip angle changes resulted in a largely unchanged level of misclassification for 
both COM and WAV features across all changes.  
 
Interpretation of Figure 3.26 shows that the rate of misclassification was highest 
for both P1 and P3.  Protocol 2 consistently resulted in the lowest rates of 
misclassification and appeared to be most affected by changes to acquisition 
parameters, suggesting that TA was able to detect differences between two 
images acquired with different sequence parameters using this protocol.   
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3.3.4 Effect of SNR on Misclassification 
Measurements of SNR are given in Table 3.14 
There were significant differences in the 
measured SNR between protocols P1 vs P2 and 
P2 vs P3 (p<0.001), however there were no 
significant differences found between P1 and 
P3.  The measured signal to noise ratio was 
lowest for P2. 
Despite differences in the measured SNR, there 
was no obvious influence on the outcome of TA.  
For all protocols there was no correlation 
between the rate of misclassified vectors and 
the measured SNR (r
2
<0.042). 
 
 
3.4 DISCUSSION 
One of the main concerns surrounding the use of texture analysis in routine 
clinical practice is reports within the published literature highlighting the 
dependence of the technique on MRI hardware and acquisition conditions [111, 
132-135].   
 
In order to assess the effect of changing the sequence parameters and further 
investigate the relationship between SNR and texture analysis outcome, a stable 
breast-mimicking phantom with texture objects embedded was constructed.  
 P1 P2 P3 
TR1 49.41 30.85 45.88 
TR2 50.10 35.11 61.18 
TR3 52.01 41.15 69.94 
TR4 63.09 47.78 73.08 
TR5 56.16 44.22 84.67 
BW1 49.41 30.85 45.88 
BW2 53.84 44.67 49.88 
BW3 48.07 45.44 57.35 
BW4 50.26 51.01 55.83 
BW5 50.69 54.14 66.87 
α1 49.41 30.85 45.88 
α2 58.87 32.58 66.9 
α3 45.53 28.10 52.15 
α4 47.17 31.90 48.73 
α5 39.23 17.51 37.80 
Table 3.14- Measured SNR values 
for all protocols and all sequence 
parameter changes 
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Agarose gel and lard were used to represent the breast and four different 
grades of foam were used as texture objects. 
 
The aim of the first part of the experiment was to demonstrate whether routine 
imaging practices could be used to differentiate between the different grades of 
foam using texture analysis techniques.  The findings from the investigation 
show that TA is able to differentiate between the four grades of foam porosities 
using standard clinical imaging protocols and imaging techniques on two MRI 
systems of different field strengths, despite the foam phantoms appearing 
visually identical on the acquired MR images.  Whilst the WAV consistently 
resulted in accurate classification of the four foams, the COM also resulted in 
good classification, particularly when considering P2- the high spatial resolution 
sequence acquired on the 3.0 T scanner.  Both the RLM and the GRA features 
performed poorly for classification of this particular foam phantom within the 
imaging protocols tested. 
 
When acquisition parameters were changed for each of the imaging protocols in 
the second part of this investigation, TA was still able to differentiate between 
the four phantoms and WAV again performed best with very low 
misclassification for any of the protocols or sequence parameter changes. 
Wavelet transforms have proved to be a valuable tool for texture analysis as 
frequency components are analysed at different ‘scales’, and as texture is 
critically linked to the scale at which the data is viewed, this is likely to a 
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particularly relevant texture model- especially when no visual differences are 
observed. 
 
The COM model, which has been reported in the literature to be the most 
effective method for performing texture analysis on medical images [121], 
provides highest misclassification for P1, the 1.5 T high spatial resolution 
protocol.  For this case, the repetition time appeared to affect the classification 
accuracy the most (see Figure 3.26).  COM performed much better using the 
high field protocols (both P2 and P3) compared with the lower field strength 
protocol, and particularly so for P2, the 1.5T matched high spatial resolution 
protocol, which showed good classification across all sequence parameter 
changes.  For the high temporal resolution sequence acquired at 3.0 T (P3), the 
changes to the bandwidth/ echo time appeared to have a more dramatic impact 
on the classification success.  Our results show that the repetition time (TR) 
appears to have the biggest impact on texture analysis when TA is used to 
detect texture differences between images acquired with different imaging 
parameters.  This was consistent for both the COM and WAV features using P2.  
For BW/TE, there was again a similar trend between COM and WAV features for 
P2, with an increasing classification performance for decreasing BW values 
relative to the baseline suggesting TA was able to detect differences between 
the two images.  
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Protocol 1 (P1) appeared to be the least affected by changes in sequence 
parameters with the overall highest rates of misclassification across all 
sequence parameter changes for both COM and WAV texture analysis models. 
 
Measurements of SNR were carried out and no significant correlations were 
found between the percentages of misclassified vectors and the measured SNR.  
The lowest SNR was measured for P2, and this is attributed to the flip angle 
selected, which potentially may result in lower signal at 3.0 T compared with 1.5 
T. 
 
The limitations of this study include the use of only three different sequence 
parameters.  These acquisition parameters were chosen as those most likely to 
be changed clinically and only very small changes to the baseline values were 
used, as again this is most reflective of standard clinical practice.  Whilst 
bandwidth and echo time could have been changed independently, the 
manufacturer’s recommended protocol suggested that a minimum TE value 
should be used for a given BW.  
 
This study, whilst not exhaustive, demonstrated unambiguously that TA could 
be successfully used on a breast-mimicking phantom with a standard clinical 
setup and more extensive changes in acquisition conditions were therefore not 
deemed necessary.  It should be noted that while a 2° flip angle was considered 
in this study for completeness, it is unlikely to be of use clinically due to the low 
resulting SNR.  While the foam phantoms are unlikely to directly replicate 
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similar textures exhibited in the breast, this study was designed to look at 
comparability of texture outcomes acquired under different imaging conditions, 
rather than to truly mimic the underlying textural patterns likely to be 
encountered in a human breast.  There is, however, potential for future 
development of such a phantom, should this technique become more widely 
utilised and also to perform quality assurance measures for multi-centre 
studies. 
  
When considering TA using the COM, we limited the range of calculated 
features to just 22 by using an interpixel distance of one pixel in only two 
arbitrarily chosen directions of 0° and 45°.  MaZda has a built-in option for 
selecting the ‘best features’ to describe the data using methods such as the 
probability of error and Fisher coefficients [126].  However, in this study we 
wanted to consider a standard set of features to compare between all analyses, 
and therefore we did not use this option as it was likely to return different 
features for each individual analysis.  Accordingly, the results are likely to reflect 
a slightly higher rate of misclassification than could be achieved using a set of 
automatically selected best features to optimise any given dataset.  The 
directions of 0° and 45° were chosen at random and could have been any other 
combination of directions.  This method of utilising two full sets of COM 
features for standard comparison between analyses has been previously 
reported by Mayerhoefer et al [135] and was felt to be most appropriate for this 
study as well.   
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An additional limitation in the analysis phase is the use of slightly different ROI 
sizes between high spatial resolution and lower spatial resolution protocols.  
This may have an effect on the outcome of TA due to different counting 
statistics, but was unavoidable due to the presence of the ringing artefact, 
which could result in artificial texture properties if included within the ROI. 
 
Finally, we acquired data on both 1.5 T and 3.0 T systems; however both of 
these systems use different types of RF coil: a 2-element breast matrix on the 
1.5 T, and a 7-element on the 3.0 T. While this is not ideal to form a comparison 
of two dissimilar coils, it is frequently the case in clinical practice where two 
systems are equipped with different imaging setups.  As there was no 
opportunity for a direct comparison of both coils on the same MR imaging 
system, a potential drawback of this study is the inability to directly assess the 
effect of the field strength on the outcome of TA.  While there were measurable 
differences in the SNR of the final images from the two imaging setups, these 
appeared to have no correlation with the outcome of texture analysis 
classification accuracy.  It is possible, however, that there were subtle 
underlying differences in the images not possible to verify from this study due 
to different coil designs.  Further investigation would therefore be required to 
consider the precise impact of coil architecture on the outcome of texture 
analysis. 
 
The data presented supports previous studies that have also investigated the 
outcome of TA for various acquisition techniques, using spin echo sequences 
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[133, 135].  Our study was concerned with the use of a fast 3D gradient echo 
sequence with typical clinical imaging parameters and is in agreement with 
those of Jirak et al. that spatial resolution appears to be the main factor 
influencing the success of TA [133].  Field strength also appears to have an 
influence on TA, with protocols matched between a 1.5 T and a 3.0 T scanner 
suggesting that TA is more consistent on a 3.0 T scanner.  While we would 
expect the most likely explanation for this finding to be attributed to the higher 
SNR, our measurements were inconclusive when considering the measured SNR 
in relation to the rate of misclassified vectors, which makes it difficult to explain 
objectively why there may be an improvement of TA classification using P2 
when compared with P1.  However, as previously noted, the RF coil used with 
the 3.0 T system was a 7-element design, whereas for the 1.5 T system a two-
element coil was used.  Although there may be no correlation between 
measured SNR and texture data classification accuracy, it is possible that there 
are other factors to consider, such as the structure of noise across the final 
image, which could contribute to the improvement in TA.  Coil homogeneity 
could also have a role in the outcome of TA; however this was not investigated 
within the scope of this work.   
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CHAPTER SUMMARY: This chapter has demonstrated that texture analysis can 
reliably differentiate between four grades of foam, despite visually identical 
appearance on MR imaging.  Both co-occurrence matrix and wavelet features 
have performed best over a range of acquisition parameter changes, and these 
changes appear to have relatively little influence on the outcome of TA.  There 
appears to be no obvious correlation between outcome of texture analysis with 
signal-to-noise ratio. 
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CHAPTER FOUR: RETROSPECTIVE PATIENT STUDY 
 
OUTLINE OF CHAPTER:  The previous chapter dealt with the stability and robustness 
of texture analysis measurements using standard clinical protocols on different 
scanners by way of a phantom.  This chapter considers the use of texture 
analysis on patients, including the reproducibility of the technique and the 
usefulness in detection and classification of disease. 
 
4.1 INTRODUCTION 
The variable specificity of breast MRI has been widely reported in the literature 
[43, 46] due to contrast uptake in healthy, hormonal glandular tissue and the 
overlap in contrast kinetics between benign and malignant disease.  Breast 
cancer has distinctive growth patterns that are used in morphological and 
histological classification and with work based on 20 patients, Holli et al. 
suggested that texture analysis may be able to differentiate between lobular 
and ductal carcinomas of the breast [110]. 
 
Recently there has been a drive towards targeted patient treatments based on 
the molecular classifications of breast cancers [21] as clinically categorised by 
estogen (ER), progesterone (PR) and human epidermal growth factor 2 (HER2) 
receptor status and tumour grade.  The main subtypes (Luminal, HER2 
overexpressed (HER2) and triple negative (TNBC)) exhibit different growth 
patterns [22, 23] and require different therapeutic regimens. 
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As there is an increasing drive towards the use of MRI in multidisciplinary 
decision making for breast cancer, we sought to investigate the use of texture 
analysis in the detection and classification of breast cancer.  We have 
considered differentiation between normal and malignant tissue, considered 
malignant and benign lesions and then investigated the use of TA in 
classification of disease in various ways, including traditional histological 
subtyping, receptor status categorisation and finally in accordance with full 
molecular subtyping. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Subjects  
All women with a primary, operable breast cancer who were referred for a 
Breast MRI examination between August 2009 and June 2012 were included in 
this study.  All examinations were performed following diagnostic core biopsy 
10-21 days prior to MRI. Patients were referred as part of standard clinical care 
and not actively recruited and only images from patients who agreed for their 
examination to be used for research and developmental purposes were 
included.  As there was no additional imaging performed and the results of this 
research had no implications on individual patient care, ethics approval was not 
required, however Caldicott approval was sought at a local level and approved 
(Appendix C).  
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Only lesions greater than 8mm have been included in the following study to 
enable a standard region of interest for texture analysis to be performed across 
all datasets, and any examinations where patients moved were excluded from 
the dataset. 
   
MRI image analysis was performed blinded to histopathological core biopsy 
data.  Cancer subtypes, grading, receptor status and immunohistochemical (IHC) 
subtypes were obtained from the histopathological reports.  Molecular subtype 
was assessed based on oestrogen, progesterone and HER2 receptor status, with 
in situ hybridisation for equivocal HER2. 
 
4.2.2 MR Imaging 
MR imaging was performed 
post-biopsy, which was carried 
out using ultrasound-guided 14 
gauge needles as per routine 
clinical care. Either a 1.5T 
(Siemens Avanto) or 3.0T 
(Siemens Trio) MRI scanner 
with the set-up as described in 
Chapter 3.2.2 was used.  
Patients were imaged in a head-first and prone position (Figure 4.27).  After the 
acquisition of standard T1 and T2- weighted sequences, a 3D FLASH volumetric 
sequence was acquired axially through both breasts with an acquisition time of 
Figure 4.27- Patient positioning for breast MRI examination 
(setup shown is on 1.5T Siemens Avanto using a 2-channel 
breast matrix coil) 
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62s.  The complete dynamic acquisition consisted of 8 volumetric acquisitions 
(total imaging time of 8 minutes 16 seconds) with two volumes acquired prior to 
the administration of the contrast agent, which was injected using a power 
injector pump (MedRad; Pittsburgh, PA) (Figure 4.27).  All patients received a 
0.1mmol/kg dose of Dotarem (Guerbet Laboratories; Villepinte, France) injected 
at 2.0 ml/s, followed by a 20 ml flush of saline solution at the same injection 
rate. 
 
Subtracted volumes and maximum intensity projection (MIP) images were 
generated automatically by the scanner software and DICOM images from the 
post contrast subtraction acquisitions were exported for analysis. 
 
4.2.3 Texture Analysis and Classification 
Texture analysis was performed using MaZda 4.7, with image data re-binned 
and normalised as previously described (Chapter 3.2.3). 
 
Slices with maximum lesion diameter were selected and square regions of 
interest (ROI) of 100 pixels (10×10) were drawn manually on sequential slices 
according to the experiments described.  This ROI size was selected as the 
minimum reported number of pixels required for successful texture analysis 
[94] to maximise the number of lesions that could be included within this study.  
Identical ROIs were also drawn in the contralateral, un-enhancing breast. 
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For all patient work, only the co-occurrence matrix features (COM) were 
considered in accordance with other works reporting the use of texture analysis 
in MRI
 
[104, 105].  These were calculated in four directions (0°, 45°, 90° and 
135°) and using inter-pixel distances of n=1, 2, 3, 4 and 5, resulting in a total of 
220 calculated features.  Despite the previous success using wavelets for 
phantom work, they were found to provide particularly poor results for all 
patient work and therefore were not considered further. 
 
Classification was performed using Weka, with a k-NN technique (k=3) and a 10-
fold internal cross-validation routine.  Assessment of classification accuracy was 
reported in terms of correctly classified data and area under ROC curves. 
Statistical assessment of raw feature values was also assessed using either 
Mann-Whitney U tests or Kruskal Wallis tests in SPSS, with p<0.05 considered to 
be significant. 
 
4.2.4 Signal to Noise 
As the data included in this study was 
acquired using two different MRI 
scanners, SNR measurements were 
performed for all cases to ensure that no 
significant differences were measured 
between each classification of cancer type 
which may have influenced the Figure 4.28- ROI positioning for SNR 
measurements in  lesion for each patient. 
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classification of texture data.  In each case, ROIs were placed in the central slice 
of the lesion and three in background noise in lateral left and right regions as 
well as medially, between the breasts (Figure 4.28).  SNR was then calculated 
using Equation 3.7. 
 
4.2.5 Aims of Study 
Using this retrospective data set, a number of different considerations were 
carried out as detailed below. 
 
Patient Validation Study 
A validation study was first of all performed on 20 randomly selected patients to 
identify the most appropriate analysis technique.  In each case the 1, 2 and 3 
minute subtracted contrast volumes were used and ROIs placed in a lesion and 
normal tissue.  Comparisons were made between regular, square ROIs and 
irregular ROIs, conforming to the shape of the lesion as well as the number of 
slices used in the analysis- 3, 5 or 10 slices.  Mann Whitney U tests were carried 
out in SPSS to compare statistical differences between lesion and normal tissue, 
with p<0.001 considered significant. Paired t-tests were then used to compare 
each of the validation criteria to ascertain the optimal analysis criterion 
(p<0.05). 
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Reproducibility 
In order for a clinical tool to be useful and applicable, it must be reproducible 
for all readers.  To assess this, 50 lesions were randomly selected from the 
databank and analysed twice by one observer (Obs1; SAW) to assess intra-
observer reproducibility.  An expert MaZda software user, but a novice to breast 
imaging, was also asked to perform TA on the same 50 lesions to provide a 
measure of inter-observer reproducibility (Obs2; RAL). 
Correlation of the results was then carried out using Bland-Altman plots and 
also calculating intra-class correlation coefficients using SPSS. 
 
Malignant vs. Normal Tissue 
Using the entire dataset of lesions, and analysing in accordance with findings 
from the validation study, classification and statistical assessment was made as 
to whether TA could differentiate between normal and malignant tissue and 
therefore potentially be of use in the detection of breast cancer. 
 
Malignant vs. Benign Lesion 
Within the general population, it is estimated that 7-13% of women will have 
benign lesions such as fibroadenomas [148], which tend to enhance rapidly on 
breast MR and can mimic pathology hence accounting for up to 50% of breast 
biopsies performed [148].  Therefore it was expected that in our cohort of 
patients a number of benign lesions would be identified on MR imaging.  Again, 
classification and statistical assessment was used to identify if TA can 
differentiate between malignant and benign lesions, and therefore provide a 
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measure of how applicable TA could be in increasing specificity of breast MR for 
inexperienced readers. 
 
Classifications of Malignancy 
As breast cancer is such a heterogeneous group, there are a number of methods 
for classification of malignancy- either in terms of invasive or in situ, different 
histological subtypes, grading or full IHC classification.   
Pair-wise and global classification, using k-NN; and statistical assessment, using 
Mann-Whitney U and Kruskal Wallis tests respectively, were performed to assess 
how well TA could be used in the discrimination of cancer subtypes. 
Data was considered as: 
- Cancer subtype  (ductal; lobular; DCIS) 
- Cancer histological grade (grade 1, 2 or 3) 
- Immunohistochemical subtype (ER status; HER2 status, Triple Negative 
(TN) status) 
- Molecular subtype of invasive cancers (Luminal; HER2; TNBC) 
 
 
4.3 RESULTS 
4.3.1 Patient Cohort 
From our cohort of patients recruited over a 35 month period, there were a 
total of 148 lesions identified in 200 symptomatic patients (age range 30-81; 
mean age 55 years), that could be used in our study- i.e. were over 8mm, had full 
pathological data available obtained within a month of the MRI examination 
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and had consented for images to be used for research purposes.  A total of 93 
lesions had to be excluded as they did not meet inclusion criteria (i.e. were less 
than 8mm in size, had incomplete pathological data, did not consent for images 
to be used or there was gross patient movement on the MRI images).  A 
summary of the lesion characteristics is presented in Table 4.15. 
Of these lesions, 108 were identified on examinations that had taken place on 
the 1.5 T system and 40 were identified on 3.0 T examinations. 
 
  
Patient Age 30-51 (median 54 years) 
Maximum lesion diameter 12.6 mm (range: 8.0-25.2mm) 
Histological Subtype Ductal: 92; Lobular: 45; DCIS: 7 
Histological Grade 
Ductal- Gd1: 1; Gd2: 30; Gd3: 61 
Lobular- Gd2: 35; Gd3: 10 
Molecular Subtype Luminal: 97; HER2: 26; TNBC: 17 
Table 4.15-  Summary of population characteristics of lesions included in retrospective set. 
 
 
4.3.2 Patient Validation 
Of the 20 lesions randomly selected from the patient cohort, there were 18 
patients with invasive cancer and 2 with in situ cancer.   
 
The number of slices to be used for TA was first of all investigated by 
considering the number of significantly different features for the COM model 
between malignant and normal tissue using 3, 5 and 10 slices.  Statistical 
comparison using a student’s t-test showed that 10 slices appeared to provide 
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significantly better discrimination compared with only 3 slices (Table 4.16).  
However, as the analysis regime was required to be identical across all lesions, 
this indicated that all 
lesions less than 8.3 
mm (10  
slices, 0.83mm slice 
thickness) in the superior-inferior orientation would have to be discarded, 
further reducing our data set.  We therefore concluded that as there were no 
significant differences between the 3 and 5 slice datasets, that to allow a quick, 
easily applied regime, 3 slices would be used for texture analysis for this work. 
 
The optimum time after contrast administration was considered by analysing 1-, 
2- and 3-minute post contrast subtraction images and regular (square) and 
 3 vs. 5 slices 3 vs. 10 slices 5 vs. 10 slices 
p-value 0.107 <0.001 p=0.513 
Table 4.16- t-test results from comparisons of texture analysis 
carried out using 3, 5 and 10 slices.  Results show significant 
differences between number of significant COM parameters  
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Figure 4.29- Graphical summary showing percentage of significant features between malignant and 
normal tissue for different post-contrast subtraction images using both regular and irregular ROIs 
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irregular (conforming to lesion shape) ROIs were drawn on each of the three 
central slices of the lesions in the validation set.  The number of significantly 
different features between normal and malignant tissue were calculated 
(p<0.001; Mann Whitney U) and are displayed in Figure 4.29 as the percentage 
of total COM features overall. 
 
From these results, the 2-minute post contrast subtraction scan analysed using 
a regular ROI (of 10×10 pixels) results in the highest number of significantly 
different features.  There were no significant differences found between the 
analysis performed at each time-point (p>0.05, students t-test), however it 
should be noted that only 18 data-points were available for the 1-minute post-
contrast series due to 2 lesions not enhancing early.  There was also no 
significant difference found between using regular and irregular ROIs (p=0.053; 
students t-test). 
The conclusion was therefore that all analysis would be performed using square 
ROIs of 10×10 pixels on the 2-minute post contrast subtraction series, averaged 
across the three central slices of the lesion. 
 
4.3.3 Reproducibility 
Results show that the overall intra-observer reproducibility obtained by Obs1 
demonstrated an excellent intra-class correlation coefficient of 0.870.  The 
intra-class correlation coefficient for entropy features was 0.832 for intra-
observer measurements. 
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Coefficient of variation (CoV) and coefficient of repeatability (CoR) were 
calculated using Equation 4.8 and Equation 4.9 respectively and are presented 
for each COM texture feature in Table 4.17. 
 
average
deviationstandard
CoV =  
Equation 4.8 
  
)1n(
)measuremeasure(
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2
21
−
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×=  
Equation 4.9 
 
 
 
Bland-Altman plots were used in order to assess the agreement between the 
two measurements [149].  An example plot for all the entropy features is shown 
in Figure 4.30.  
 
 Average value Average difference CoV (%) CoR 
Angular 2
nd
 Moment 0.028 0.001 80.0 0.046 
Contrast 199.827 578.044 10.0 47.123 
Correlation 0.086 0.007 123.4 0.164 
Diff Entropy 1.125 0.049 18.8 0.436 
Diff Variance 65.259 178.406 12.9 26.179 
Entropy 1.751 0.120 24.0 0.678 
Inverse Diff Moment 0.081 0.0003 17.6 0.034 
Sum Average 62.399 42.005 6.8 12.703 
Sum Entropy 1.278 0.071 22.4 0.523 
Sum of Squares 99.464 157.180 8.9 24.573 
Sum Variance 198.028 1183.949 17.2 67.441 
Table 4.17- Repeatability parameters for each COM feature as calculated as intra-observer 
repeatability performed on 50 test cases 
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Inter-observer measurements also demonstrated an excellent intra-class 
correlation of 0.881.  For entropy features alone, the intra-class correlation 
coefficient was 0.834 for inter-observer repeatability measurements. Values for 
CoV and CoR were calculated according to Equation 4.8 and Equation 4.9 and  
are presented in Table 4.18. 
 
 
 
 
 
Figure 4.30- Bland Altman plot representing repeatability for intra-observer (Obs1) measurements of 
entropy features in 50 lesions.  Dashed lines indicate ±2 standard deviations of the average feature values 
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A Bland Altman plot for Obs1-Obs2 inter-observer repeatability for the entropy 
features is shown in Figure 4.31.  As the values do not appear to be centred 
around the x-axis, this suggests a small and systematic skew of measures 
between observers. 
 Average value Average difference CoV (%) CoR 
Angular 2
nd
 Moment 0.017 0.011 73.0 0.066 
Contrast 187.699 24.296 12.7 104.479 
Correlation 0.064 0.102 137.2 0.349 
Diff Entropy 1.221 0.101 10.9 0.581 
Diff Variance 62.644 6.203 15.7 35.157 
Entropy 1.960 0.264 15.3 1.035 
Inverse Diff Moment 0.092 0.017 17.7 0.080 
Sum Average 62.825 1.719 10.7 25.794 
Sum Entropy 1.422 0.170 13.2 0.767 
Sum of Squares 99.624 2.122 11.0 47.494 
Sum Variance 210.797 15.806 15.3 128.795 
Table 4.18- Repeatability parameters as calculated for comparing results from Obs1 and Obs2 to 
demonstrate inter-observer repeatability of TA parameters 
Figure 4.31- Bland Altman plot showing repeatability for inter-observer (Obs1-Obs2) measurements 
of entropy features. .  Dashed lines indicate ±2 standard deviations of the average feature values 
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4.3.4 Malignant vs. Normal 
Comparison was made between normal and malignant tissue.  For all COM 
features as calculated the difference was found to be significant (p<0.001; 
Mann Whitney U).  Classification results demonstrated a 97.9% accuracy with 
ROC= 0.998.  When only the entropy features were considered (entropy, sum 
entropy and difference entropy), the difference was still significant (p<0.001; 
Mann Whitney U) and classification was improved with 99.8% of data correctly 
classified with an ROC area of 0.998.   
 
These results are demonstrated graphically in Figure 4.32 in a box-whisker plot.  
The difference between normal and malignant tissue can readily be seen from 
this plot.  Malignant tissue demonstrates statistically, significantly higher values 
of entropy, sum entropy and difference entropy, suggesting greater 
heterogeneity in pixel intensity compared with normal tissue. 
 
-126- 
 
 
4.3.5 Malignant vs. Benign 
In our cohort of 200 patients recruited for this retrospective study, a total of 21 
enhancing lesions were identified that were subsequently confirmed to be 
benign. 
These were a mixture of fibroadenomas (16), myxoid fibroadenomas (3), 
papilloma (1) and one case where the lesion was not visible at follow-up 
examination. 
Figure 4.32- Box-Whisker plot showing entropy-based features for both malignant 
and normal tissue.  The differences are statistically significant (p<0.001) 
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Figure 4.33 shows two examples of benign lesions identified on MRI 
examinations.  Most of the enhancing benign lesions show similar enhancement 
patterns to regions of suspicion and particularly in cases where the patient 
already has a known malignancy (e.g. Figure 4.33(b)), it is imperative to follow 
these up to determine their nature. 
 
Normal and benign tissue data was added to the tissue from the malignant data 
obtained in 4.3.3 in order to compare the three types of tissue.  Classification 
results were excellent (see Table 4.19) with 100% classification accuracy in all 
comparisons and ROC areas of 1.000.  Statistical comparisons also resulted in 
significant differences for all COM features as shown in the last column of Table 
4.19. 
(a) (b) 
Figure 4.33- Benign lesions identified in the right breast as shown by purple arrows 
(a) myxoid fibroadenoma that enhanced and demonstrated washout 
(b)  patient presenting with extensive high-grade DCIS in the left breast (as shown by green 
arrow) who also had enhancement in the right breast.  This was later confirmed by ultrasound 
biopsy to be fibroadenomatoid change. 
 
DCIS 
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Entropy values are represented graphically in Figure 4.34.  Entropy features are 
demonstrated to be lowest for the benign lesions, suggesting a more 
homogeneous pixel distribution compared with both normal and malignant 
tissue.  
 
Classification  
Accuracy (%) 
ROC 
Statistical Testing 
Benign vs Normal 100% 1.000 p<0.001 
Benign vs Malignant 100% 1.000 p<0.001 
Benign vs Malignant vs Normal 100% 1.000 p<0.001* 
Table 4.19- Results of classification and statistical analysis for normal, malignant and benign tissue.  
Statistical testing was performed using a Mann Whitney U test except for (*) where more than two 
comparison groups required a Kruskal Wallis test to be employed 
Figure 4.34- Box-whisker plot demonstrating entropy features as measured in normal, benign 
and malignant tissue 
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4.3.6 Classifications of Histological Subtype and Grade 
Histological subtype 
was extracted from 
the pathological 
report obtained 
from the pre-MRI 
biopsy.  Histological 
subtyping 
information was available for all lesions and the data used is summarised in 
Figure 4.35.   
Classification of the data was performed both pair-wise and also across the 
entire dataset.  The results of the classification when using all COM features and 
only entropy features are presented in Table 4.20. Classification accuracy was 
good for the whole dataset with an overall accuracy of 74.7% and ROC area of 
0.816. 
   All COM features All Entropy features 
   Classification 
Accuracy 
ROC Classification 
Accuracy 
ROC 
Ductal  vs. Lobular 71.4 % 0.745 64.7 % 0.632 
Ductal  vs. DCIS 96.8 % 0.781 96.8 % 0.433 
Lobular  vs. DCIS 95.1 % 0.772 93.2 % 0.616 
       
All Histological Subtypes  74.7 % 0.816 64.3 % 0.637 
Table 4.20- Summary of histological classification accuracies and ROC areas for pair-wise and 
global classification using k-NN (k=3) and 10-fold cross validation 
 
 
 
Other, 4
DCIS, 7
Ductal, 92Lobular, 45
Figure 4.35- Split of lesion histopathology included in classification of 
histological subtype study 
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Data is displayed graphically in Figure 4.36 for the entropy features which 
demonstrate the relative spread of the lobular entropy measurements 
compared with either the ductal cancers or DCIS.   
 
Out of the 220 COM features calculated, there were found to be 114 
significantly different (p<0.05; Kruskal Wallis), and the summary of 
contributions from each individual feature category is presented in Figure 4.37. 
 
 
 
Figure 4.36- Summary of entropy-based features for histological subtypes of breast cancer 
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Average values for each individual COM feature were also considered, and 
statistical analysis performed between groups using a Kruskal-Wallis test to 
identify features significantly different between the histological subtypes.  
Results are presented in Table 4.21. 
 Ductal Lobular DCIS Kruskal-Wallis 
0.0120±0.002 0.013±0.002 0.012±0.002 
Angular 2nd Moment 
(0.010±0.01) (0.010±0.01) (0.0110±0.01) 
p=0.001 
185±20 187±20 205±10 
Contrast 
(184±100) (187±100) (206±50) 
p=0.005 
0.080±0.06 0.0800±0.07 0.030±0.04 
Correlation 
(0.080±0.3) (0.070±0.4) (0.210±0.1) 
p=0.021 
1.27±0.04 1.26±0.04 1.29±0.03 
Difference Entropy 
(1.27±0.2) (1.26±0.2) (1.30±0.09) 
p=0.001 
66.0±8 64±8 73.0±7 
Difference Variance 
(65.5±50) (64±50) (74.8±20) 
p=0.013 
1.99±0.05 1.96±0.07 1.99±0.05 
Entropy 
(2.00±0.3) (2.00±0.3) (2.01±0.1) 
p=0.002 
0.100±0.01 0.0990±0.02 0.0880±0.007 
Inverse Diff Moment 
(0.090±0.08) (0.09±0.1) (0.0890±0.02) 
p=0.124 
66.0±1 66±1 65.0±1 
Sum Average 
(65.7±5) (66.1±5) (64.7±3) 
p<0.001 
1.47±0.04 1.45±0.05 1.47±0.03 
Sum Entropy 
(1.48±0.20) (1.47±0.2) (1.48±0.1) 
p=0.001 
100±8 100±6 106±5 
Sum of Squares 
(102±40) (101±40) (106±10) 
p=0.070 
218±20 216±20 220±10 
Sum Variance 
(219±100) (215±100) (224±10) 
p=0.340 
Table 4.21- Summary of average ± standard deviation (median ± range) of each COM feature for 
each histological subtype and the results of Kruskal Wallis statistical testing, with significant 
differences highlighted in grey (p<0.05; Kruskal Wallis).  All mean/ median values are quoted to 
3 significant figures (3 sigfigs) and standard deviation/ ranges to 1 sigfig. 
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Figure 4.37- Number of significantly different features in each COM group between histological subtypes 
(p<0.05; Kruskal Wallis).  Entropy features are highlighted in dark blue.  There is a maximum of 20 features 
possible for each texture parameter. 
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From these it is clear that there 
are significant differences in most 
features between each 
histological subtype, with only inverse difference moment, sum of squares and 
sum variance exhibiting no significant differences.   
As there were only 7 DCIS cases, these were not considered for assessing 
histological grade.  The histological grade of the ductal and lobular cancers is 
summarised in Table 4.22.  Grade 1 ductal cancers were not considered further 
since only one lesion was identified - most likely due to the minimum size 
criteria.  A summary of classification results for ductal and lobular histological 
grade is provided in Table 4.23.  Classification accuracy was excellent using all 
features, with high values of ROC obtained when classifying between grades 
two and three.  For the lobular cancers, entropy features alone also resulted in 
excellent classification of the cancers, suggesting that these features may 
dominate in the textural description of lobular cancer grade. 
 
  All COM features All Entropy features 
  Classification 
Accuracy 
ROC Classification 
Accuracy 
ROC 
Ductal Gd2 vs. Gd3 71.8 % 0.811 60.4 % 0.631 
Lobular Gd2 vs. Gd3 82.6 % 0.886 78.8 % 0.738 
Table 4.23- Summary of classification results for histological grade of ductal and lobular cancers 
 
 
 
Table 4.22- Summary of histological grade for ductal 
and lobular cancers 
 Grade 1 Grade 2 Grade 3 
Ductal 1 30 61 
Lobular - 35 10 
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4.3.7 Classifications of Immunohistochemical Subtype 
The receptor status of the 148 lesions was identified using the final pathological 
biopsy report.  HER2 status was unavailable for one lesion therefore to 
distinguish between the HER2 and triple negative breast cancers (TNBC) there 
were only 147 lesions considered.  The split in each category is as shown in 
Table 4.24. 
 
 Lesion Population Classification Results 
 All COM features All Entropy features 
 Positive Negative Classification 
Accuracy 
ROC Classification 
Accuracy 
ROC 
ER Status 105 43 73.4 % 0.776 68.8 % 0.643 
HER2 Status 50 97 68.3 % 0.733 62.4 % 0.607 
TN Status 26 121 81.1 % 0.801 79.0 % 0.618 
Table 4.24- Number of lesions with each immunohistochemical subtype and classification 
results 
 
The TNBC are well differentiated from the rest of the cancers with a high 
classification accuracy of over 80% and excellent ROC area of 0.801.  This 
suggests underlying grey-level patterns that can be well differentiated between 
the two types of cancers.  The ER+/- cancers also have good classification 
accuracy with reasonable ROC areas.   HER2+/- cancers seem to be less well 
distinguished using texture analysis, with overall lower accuracies but 
maintaining good ROC areas. 
 
The number of significantly different features was calculated for each receptor 
status for each immunohistochemical subtype (i.e. ER+/-; HER2+/-; TN/Other) 
using a Mann Whitney U test.  There were 24 out of the total 220 COM features 
significantly different for both triple negative and HER2 categories.  For the ER 
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subtype, there were 71 significantly different features between ER+ and ER- 
cancers.  The breakdown of these features into COM categories is shown in 
Figure 4.38. 
 
 
When statistical comparisons were carried out using a Mann-Whitney U test on 
the absolute values for each COM category: 
o ER subtypes demonstrated significant differences in entropy (p<0.001), 
sum entropy (p<0.001) and sum variance (p=0.011) features. 
o HER2 subtypes demonstrated no significant differences between any of 
the COM feature absolute values. 
o TN demonstrated significantly different values from other cancers in 
the angular second moment (p=0.005), entropy (p=0.003), sum entropy 
(p=0.007) and sum variance (p=0.018) features. 
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Figure 4.38- Number of significantly different features between receptor statuses from each COM category, for 
each immunohistochemical status category (p<0.05; Mann Whitney U).  Entropy features are highlighted in 
darker shades.  There is a maximum of 20 features possible for each texture parameter. 
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4.3.8 Classifications by Molecular Subtype 
Only invasive 
cancers were 
considered for 
molecular subtype 
categorisation.  As 
HER2 status was 
unavailable for one lesion and there were 7 cases of DCIS, only 140 cases were 
included in this study as shown in Figure 4.40. 
 
TNBC, 17
HER2, 26
Luminal, 97
Figure 4.40- Breakdown of lesions into molecular subtypes 
(a) (b) 
Figure 4.39- Entropy box-plots for both ER (a) and TN (b) immunohistochemical subtypes of breast cancer 
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Classification was performed between the molecular subtypes which resulted in 
a classification accuracy of 74% and ROC of 0.780 (Table 4.25).  Classification 
using only entropy-based features also resulted in a reasonable classification 
accuracy of 65%, although ROC areas were lower at 0.624. 
 
  All COM features All Entropy features 
  Classification 
Accuracy 
ROC Classification 
Accuracy 
ROC 
Luminal vs. HER2 vs. TNBC 73.0 % 0.783 65.2 % 0.625 
Table 4.25- Classification results for molecular subtypes.  
 
 
Results for this are presented graphically in Figure 4.42.  From this plot, the 
slight increased value in entropy features for both the triple negative cancers 
and HER2 cancers can be seen relative to all other luminal cancers.  The spread 
of entropy features is greater for the luminal cancers compared with either the 
HER2 or TN-type cancers.   
 
Statistical evaluation of the raw texture feature values was also carried out and 
the number of significantly different features for each COM category is 
presented below in Figure 4.41.   Again, it is clear from this plot that entropy, 
sum entropy and angular second moment features appear to be most 
significant at characterising differences in texture between these molecular sub-
groups.  
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Figure 4.41- Number of significantly different features in each COM category when all molecular subtypes of 
breast cancer are considered (p<0.05; Kruskal Wallis test). Entropy features are highlighted in darker shades.  
There is a maximum of 20 features possible for each texture parameter. 
Figure 4.42- Graphical box-whisker plot showing entropy distributions for each molecular 
subtype of breast cancer. 
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Average feature values for each of the categories, and the findings from the 
Kruskal Wallis test between each molecular subtypes are presented in Table 
4.26. 
 Luminal HER2 TNBC Kruskal-Wallis 
0.0121±0.002 0.0111±0.001 0.0115±0.002 
Angular 2nd Moment 
(0.0110±0.01) (0.0109±0.01) (0.0108±0.01) 
p<0.001 
186±20 182±20 187±20 
Contrast 
(187±100) (182±80) (186±100) 
p=0.265 
0.0771±0.06 0.0968±0.06 0.0877±0.07 
Correlation 
(0.0725±0.3) (0.0863±0.3) (0.0771±0.3) 
p=0.197 
1.26±0.04 1.27±0.03 1.27±0.04 
Difference Entropy 
(1.27±0.2) (1.28±0.1) (1.274±0.2) 
p<0.001 
66.0±8 65.3±8 64.9±9 
Difference Variance 
(65.6±49) (65.7±35) (64.9±40) 
p=0.358 
1.97±0.06 2.00±0.03 1.99±0.05 
Entropy 
(2.00±0.30) (2.01±0.2) (2.01±0.2) 
p<0.001 
0.0975±0.02 0.0954±0.01 0.0945±0.02 
Inverse Diff Moment 
(0.0950±0.1) (0.0935±0.04) (0.0914±0.1) 
p=0.013 
65.8±1 65.8±1 65.8±1 
Sum Average 
(65.9±6) (65.7±5) (65.8±4) 
p=0.260 
1.46±0.04 1.48±0.03 1.47±0.04 
Sum Entropy 
(1.48±0.2) (1.48±0.2) (1.49±0.2) 
p<0.001 
101±8 100±9 102±9 
Sum of Squares 
(102±40) (102±40) (103±40) 
p<0.001 
216±19 220±20 221±20 
Sum Variance 
(215±100) (224±100) (2223±100) 
p=0.055 
Table 4.26- Summary of average ± standard deviation (median ± range) of each COM feature 
for luminal, HER2 and TNBC molecular subtypes and the results of Kruskal Wallis statistical 
testing, with significant differences highlighted in grey (p<0.05; Kruskal Wallis). All mean/ 
median values are quoted to 3 significant figures (3 sigfigs) and standard deviation/ ranges to 1 
sigfig.  
 
These results demonstrate the importance of the entropy, sum entropy and 
angular second moment features in discrimination between the molecular 
subtypes of breast cancer.  
 
Pair-wise classification of the molecular subtypes of cancer was then performed 
with results presented in Table 4.27.  Statistical evaluation of the entropy 
-139- 
features was also performed for the pair-wise classification with significantly 
different entropy features highlighted in the table (p<0.05; Mann Whitney U). 
 
 All COM features 
Cross Validation 
Entropy Features 
Cross Validation 
 Classification 
Accuracy 
ROC 
Area 
Classification 
Accuracy 
ROC 
Area 
Statistical 
comparison of 
entropy features 
Luminal vs. HER2 84.6 % 0.717 84.0 % 0.663 p=0.003 
Luminal vs. TNBC 78.3 % 0.797 74.9 % 0.623 p=0.001 
HER2 vs. TNBC 68.8 % 0.750 62.5 % 0.625 p=0.822 
Table 4.27- Pair-wise classification of molecular subtypes for all COM features and entropy 
features only.  Statistical evaluation of entropy features is also presented, with p<0.05 
considered significant (Mann Whitney U) 
 
The results presented highlight that significantly different entropy features are 
demonstrated for luminal cancers compared with the higher grade, more 
aggressive HER2 and TN cancers.  These trends were generally mirrored by the 
results from the classification with those comparisons resulting in good 
classification accuracies and ROC areas. 
 
There were, however, no significant differences between the TNBC and HER2 
entropy features. 
 
4.3.9 Signal to Noise 
Signal to noise measurements were calculated for all lesions included in this 
study and compared between the histological and molecular subtypes of 
cancers as presented below in Figure 4.43.  Error bars depict the standard 
deviation of the SNR measures in each subtype category.  The large standard 
deviations are likely to be attributable to the distribution of scans performed on 
1.5T and 3.0T resulting in contrast enhancement characteristics differing slightly 
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between the different field strengths.  While this should have minimal impact 
on texture analysis outcome (due to the same pixel size and image 
normalisation being performed), the absolute signal intensity values were used 
for calculation of SNR 
and therefore this is 
likely to increase the 
range of values 
encountered.  Statistical 
pair-wise comparisons 
were performed between 
each histological and 
molecular subtype using 
a students t-test, and one 
way ANOVA across all 
subtypes, and results of 
statistical analysis are 
presented in Table 4.28.  
There were found to be 
no significant differences in measured SNR values in each pair-comparison, 
suggesting that differences in texture analysis were unlikely to be attributable 
to this particular factor. 
 
 
 
Figure 4.43- Summary of signal to noise measurements for (a) 
histological subtype groups and (b) molecular subtype groups 
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Histological Subtype 
Comparison 
SNR comparison 
p-value 
Molecular Subtype 
Comparison 
SNR comparison 
p-value 
  
Ductal vs. Lobular Luminal vs. HER2 
 
p=0.951 
 
p=0.443 
  
Ductal vs. DCIS Luminal vs. TNBC 
 
p=0.601 
 
p=548 
  
Lobular vs. DCIS HER2 vs. TNBC 
 
p=0.396 
 
p=0.856 
    
    
Histological subtype p=0.736* Molecular subtype p=0.163* 
Table 4.28- Summary of statistics performed on SNR differences between different histological 
and molecular subtypes of cancer.  There were no significant differences (p<0.05; students t-
test; *p<0.05; ANOVA) 
 
 
4.4 DISCUSSION 
This work has demonstrated the potential clinical utility of texture analysis and 
outlined the uses of the techniques in various applications, including 
identification of malignancy, differentiation from benign disease and 
classification of breast cancer subtypes. 
 
All the results have been reported in terms of the percentage of correctly 
classified data-points as well as area under the ROC curve.  This provides an 
assessment of how well separated the classes are and is not dependent on any 
decision threshold that may be selected.  As well as classifying the data in 
feature space, statistical assessment of the raw feature values has been 
performed in order to quantify whether the values themselves can be used in 
differentiating between breast cancer subtypes.  
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Reproducibility assessment was performed and demonstrated to be quite 
variable across all the COM parameters; however, the majority of features 
demonstrated a CoV of less than 25% across both intra- and inter-
reproducibility measurements.  The entropy based features were also 
demonstrated to be consistent across both readers. 
 
Classification of malignant from normal tissue resulted in near perfect 
classification with an accuracy of 97.9% (ROC=0.998), and this classification 
result was slightly improved when only entropy features were used (99.8%; 
ROC=0.998), suggesting that these features differ significantly between normal 
and malignant tissue. 
 
With the addition of benign lesions, the classification was found to be perfect, 
with a classification accuracy of 100% (ROC=1.000), and significant differences 
between the three tissue types when considering only the entropy features 
(p<0.001; Kruskal Wallis).  The entropy features were found to be lowest for 
benign tissue and highest for malignant tissue. This would indicate a more 
heterogeneous nature of the malignant tissue compared with either of the 
other two tissue types, and suggests that benign lesions may actually 
demonstrate a relatively homogeneous pixel intensity profile, which 
corresponds with the BIRADS-2 MRI descriptor that these types of lesions 
generally have a particularly homogeneous appearance on MRI [53]. 
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The cancers were then split into various subtypes and histological grading 
where TA was found to perform well.  While accuracies over 90% were achieved 
for the DCIS comparisons with both ductal and lobular cancers, this could be 
attributable to the relatively low numbers of these cases compared with the 
number of ductal and lobular cancers included.  However, ductal and lobular 
classification was good with accuracy of over 70% and corresponding ROC areas 
of 0.745.  When only entropy features were used, these were found to provide 
a lower accuracy at 65% (ROC=0.632).  Significant differences were found 
between most of the COM features between these three cancer types (p<0.05; 
Kruskal Wallis).  Entropy features demonstrated higher values for the ductal 
cancers (both in situ and invasive) compared with the lobular lesions. 
 
When the histological grading of both lobular and ductal cancers was 
considered, the classification accuracy was found to be good, with accuracies of 
over 70% and ROC areas greater than 0.8.  When only entropy features were 
considered, the lobular grade 2 and 3 cancers were still well classified (78%; 
0.738), while the accuracy for ductal was lower (60%; 0.631).  This would tend 
to suggest that the histological grade of cancers is reasonably well represented 
by the entropy textural features, particularly for the lobular cancers.   
 
Classification of the lesions according to the immunohistochemical receptor 
status was then performed to identify if differences in whether these receptors 
genes were present had an influence on appearance in MR images.   
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Classification was found to be good for both ER status (73.4%; 0.776) and for 
triple negative cancers (81.1%; 0.807), however was found to be significantly 
poorer for classification between HER2  groups (68.3%; 0.733).  
 
Both ER and TN groups demonstrated significant differences in the raw feature 
values between positive and negative state in entropy features, although the 
classification accuracies were lower when only entropy features were 
considered (ER: 68.8%, 0.643; TN: 79.0%, 0.618).   
 
The triple negative and ER- cancers appeared to demonstrate overall higher 
values of entropy, difference entropy and sum entropy compared with the 
other and ER+ cancers, suggesting a more heterogeneous pixel profile. 
 
Full molecular descriptions of the cancers were then considered, by categorising 
into Luminal, HER2 and TNBC subtypes.  Classifications remained good with 
accuracies of 73.0 % and ROC areas of 0.783.  Results for the entropy features 
resulted in disappointing results (65.2%; 0.625). 
 
Statistical comparison of the categories demonstrated significant differences in 
the angular second moment, entropy and sum entropy parameters, and entropy 
was found to be higher in both the HER2 and TNBC lesions compared with the 
luminal categories (p<0.05; Kruskal Wallis).   
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Pair-wise classification and statistical evaluation of all molecular subtypes 
demonstrates that the luminal categories appear to be most distinct from HER2 
and TNBC subtypes, in keeping with their different biological behavious (such as 
the way they are treated and time-frames to recurrence etc.) 
 
Signal to noise parameters were also assessed to ensure that classification 
accuracies and statistical evaluations were not influenced by differences in SNR 
measures between each group.  No significant differences were found between 
any of the histological or molecular subtypes (p>0.05; ANOVA). 
 
We have demonstrated the entropy features appear to consistently be the most 
discriminating between different regimens of classifying breast cancer.  This is in 
agreement with findings from other groups that entropy can be used in the 
differentiation between malignant and benign lesions [103, 104] and different 
histological subtypes of cancers [110].  The entropy features reflect internal 
pixel distribution patterns, which could potentially link directly or indirectly with 
underlying growth patterns.  Therefore TA could provide a method of mapping 
intra-tumoural heterogeneity and provide a useful means of classifying between 
different subtypes of cancers. 
 
Most previous studies in which TA has been applied in the field of breast MRI 
have been in the identification of malignancy within healthy breast tissue and in 
the discrimination between malignant and benign lesions [103-105, 109]. 
Further characterisation of such lesions is required for clinically useful 
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treatment planning, monitoring and distinguishing therapeutic effects [21, 150]. 
Whilst identification of a lesion using TA methods requires differences to be 
detected between suspicious and surrounding areas of tissue, characterisation 
is a more complex and challenging area as the difference in texture between 
pathologies needs to be clarified [109]. The versatility and applicability of TA in 
the diagnosis, classification and grading of cancers in a clinical setting is an 
emerging field and recent studies have used TA  in differentiation between 
invasive cancer and DCIS on mammographic images [109], classification of 
different types of glioblastoma [150] and distinguishing between gliomas and 
metastases [95] on MR images.  We have taken this one step further by aiming 
to classify cancer types based on underlying molecular subtype descriptions to 
identify any differences in growth patterns that may not be visually apparent. 
 
It should be noted that there appear to be no other imaging modalities capable 
of discriminating between subtypes of cancer reliably.  In a study carried out by 
Berg et al., it was found that mammography plus ultrasound combined resulted 
in an ROC area of 0.9 when predicting the probability of malignancy, compared 
with mammography alone where the ROC area was significantly lower at 0.74-
0.78 [151, 152].  We have demonstrated that texture analysis can differentiate 
between malignancy, normal and benign tissue with an ROC area of 1.000 
(perfect classification) and therefore this technique appears to outperform 
traditional breast imaging assessment.   
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Our results demonstrate that luminal cancers appear to have lower entropy 
feature values compared with the triple negative and HER2 cancer groups, and 
that entropy features are the most significant features in differentiating 
between these categories.  The growth patterns of luminal cells generally 
exhibit tight cell-cell junctions with epithelial-differentiated monoloayers [23].  
Triple negative cancers, however, demonstrate a more scattered morphology 
compared with the luminal cancers and exhibit a solid architecture and necrosis 
which is morphological distinct compared with the luminal tumours [22].  There 
have also been reports in the literature that there is an overlap in the 
histological growth patterns of triple-negative and HER2 over expressing cancer 
subtypes [22], which appear to correlate with our findings.  It would be 
worthwhile to further investigate the correlation of texture features as 
calculated using MR images with the indicators of systemic spread, such as 
nodal status and vascular invasion, although this study is outwith the scope of 
this work. 
 
While it is recognised that texture analysis does not represent the underlying 
growth pattern directly, due to the different orders of magnitude in resolution, 
it is possible that there is an indirect link between the growth patterns and 
resulting pixel distributions on MR imaging, which may or may not be due to 
patterns of contrast uptake, or relative relaxation time values.  Such 
characterisation of high and low grade gliomas based on entropy features has 
been reported for computed tomography (CT) imaging [153] and imaging the 
heterogeneity of lesions is becoming more topical [85, 106-108]  in the drive to 
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fully characterise entire lesions rather than small sub-samples as obtained using 
biopsy. 
 
The main limitation in this study is in the subtyping of breast cancers with such 
a small sample size.  While this population represents a group larger than 
similar studies reported in the literature [103, 104, 110], the number of 
subgroups that data was categorised into requires a large number of data 
samples in order to increase classification accuracies and statistical certainty.  
We have demonstrated promising initial findings, however in order to fully 
characterise and classify lesions based only on the entropy features, which we 
believe should be possible, it is likely that a large-scale cohort of patients would 
be required- most probably associated with a multi-centre approach.   It should 
be noted, however, that the cohort of patients considered in this study is not 
representative of breast cancer patients as a whole, but rather the typical 
subgroup that are routinely referred for MRI examination and therefore this 
does not necessarily translate as a technique that can be widely applied to all 
breast cancer patients as a whole.  Such a study would require considerable 
escalation of patient numbers and referral criteria. 
 
In the histological classification of data few DCIS lesions were available for 
comparison with invasive cancers, reflecting the reality of utilisation of MRI in 
clinical practice for DCIS and invasive breast cancer. It is recognised that invasive 
cancer may coexist with DCIS [109] and therefore comparisons may be complex. 
However in each case the main tumour body was used for placement of the ROI 
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in accordance with the radiologist report and due consideration was given to 
final pathology.   
 
Data was utilised in this study that was acquired under two different imaging 
conditions, which may attribute another variable to the study.  The rationale for 
this was to provide adequate patient numbers for the research, however this 
does also potentially represent the clinical reality where more than one MRI 
system may be used for a clinical service.  This also increases weight to the 
findings from our study, as we have demonstrated that good results can still be 
obtained despite using different equipment across the entire patient cohort.  
There were no significant differences in the measured SNR associated with the 
lesions included in the study and therefore there were no attributable effects 
from this particular parameter.  We also demonstrated in Chapter 3 that robust 
texture analysis can be performed across different magnets, and clinical 
protocols, providing the spatial resolution remains constant, as it does in this 
study. 
 
We also utilised a highly specific analysis technique with only 3 slices included in 
the texture analysis and only lesions greater than a minimum size of 8mm.  
Texture classification results are known to depend on the number of data-
points included in the analysis and therefore to include the entire number of 
imaging slices for every lesion included in the study could have introduced an 
artificial dependence on the size of the lesion, with larger lesions contributing 
more data-points than smaller lesions.  Also, luminal cancers are generally 
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smaller than TNBC and therefore direct comparisons between the two groups 
would not have been possible without some correction.  We therefore chose a 
method that would provide the same number of datapoints from every lesion.  
Only lesions greater than 8mm were included in the analysis.  This was again to 
ensure consistency of analysis between lesions- a fixed size of the ROI was used 
of 10×10, which corresponded with the reported lesion size.  This provides a 
major limitation to our study as we are unable to assess as to whether a 
minimum lesion size limit may exist for texture analysis to be useful in the clinic: 
rather, we hypothesise that this is most likely to be pixel-size limited.  
 
The data presented provides a quantitative method for assessing breast lesions 
using MR imaging.  Such non-invasive methods have potential in patients where 
sampling (multiple) breast lesions is anatomically difficult or could lead to 
histological underestimation of the disease present [95, 109].  Therefore it is 
concluded that TA could offer a real option for lesion characterisation in routine 
clinical practice. 
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CHAPTER SUMMARY: This chapter has demonstrated that texture analysis can be 
used with excellent classification between normal, benign and malignant tissue.  
Classification accuracies are good between each method of subtyping the 
cancers, with the exception of HER2 status.  Entropy features appear to be 
significantly different between these categories, however do not result in high 
classification accuracies when used alone for subtype classification.  The 
entropy features, which represent heterogeneity of pixel distributions within a 
region of interest, appear to follow the expected trends associated with 
underlying growth patterns (e.g. more entropy in high grade triple negative 
cancers), so there may potentially be an indirect link between the pixel 
distributions and/or contrast uptake on MR images and the underlying 
histological growth pattern, although the mechanism for this is unclear. 
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CHAPTER FIVE: COMPARISON OF TEXTURE ANALYSIS TECHNIQUES 
 
 
OUTLINE OF CHAPTER:  The previous chapter outlined the use of texture analysis in 
a clinical cohort of patients, and the usefulness in identification and 
classification of breast cancers.  This chapter considers a different method of 
texture analysis, known as the max-min technique, to reanalyse the work 
performed in Chapter 4.  The aim of this chapter is to carry out a technical 
comparison of different TA techniques which will either reinforce the method or 
identify if the outcome is dependent on the technique used. 
 
 
5.1 INTRODUCTION 
The co-occurrence matrix has been widely reported as a useful model in texture 
analysis for differentiating between tissue types in MR images.  Whilst this 
technique utilises second order statistics [87, 91, 93, 95, 96, 103-105, 109, 110], 
first order statistics have also been demonstrated to provide a level of 
discrimination between different textures in medical imaging [154].  First order 
statistics, such as local extremes of signal intensity, are believed to most closely 
match what the eye perceives as ‘texture’ [86], and therefore the ‘max-min’ 
method for texture analysis was described in 1977 by Mitchell et al. as a 
method of texture analysis [122].  
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By using different degrees of smoothing, and calculating the number of 
extremes at each smoothing level, the ratios of these values can be used to 
provide a measure of image texture.  This technique has been readily applied 
successfully in ultrasound, particularly for differentiation between various liver 
diseases [155, 156] and has the advantage of being computationally simple. 
 
This study aimed to identify whether this simple first-order technique could be 
used in the differentiation of malignant and normal tissue, and in the 
classification of different cancer subtypes.  This was performed on the same 
patient cohort as described in the previous chapter to identify if results were 
consistent between the two methods or if they provided conflicting results. 
 
 
 
5.2 MATERIALS AND METHODS 
5.2.1 Patient Population 
The patient population that this study was carried out on is the same as 
described in Chapter 4.2.1 and 4.2.2. 
 
5.2.2 Texture Analysis  
All regions of interest (ROI) were generated using MATLAB (v. 2012a, The 
Mathworks Inc.; Natick, MA) using the computer coding presented in Appendix 
B.  The 10×10 square ROIs were placed in the same region and same slices as 
those described in the previous chapter (see Figure 5.44). 
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Regions of interest of the same size were also placed in regions of non-
enhancing contralateral tissue.  Grey-level pixel values were stored in a matrix 
and exported as a text file.  FORTRAN (Intel Corp.; Santa Clara, CA) code, 
developed in house using Xcode (Apple Inc.; Cupertino, CA) and run on the Mac 
OSX operating system, was then used for calculation of Max-Min texture 
parameters. 
 
The grey-levels were represented by 9 bits/pixel (0-511) and the logarithm of 
grey level values was used to minimise the effect of brightness variations.  Data 
was smoothed using the regime described by Mitchell [122] and in Chapter 
2.2.2 (see Figure 2.7).  A logarithmic threshold value of 0.1 was used and 
performed a total of five times, with an incremental value of 0.01.  The number 
of extreme values detected for each smoothing process was expressed as a ratio 
Figure 5.44- Diagram showing placement of ROI using MaZda (a) and a screenshot using the max-
min method via MATLAB (b).  Figure (a) also shows the contralateral ROI in normal tissue, this had 
to be placed separately using the max-min method.  
(a) (b) 
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to the first count of extreme values to ensure independence from the size of the 
ROI. 
For each ROI, a total of four texture parameters were calculated, corresponding 
to the five smoothing values. 
 
5.2.3 Statistical Analysis 
The raw texture parameters calculated from the max-min algorithm were 
exported for statistical analysis using SPSS.  A p-value less than 0.05 was 
considered to be significant.  All comparisons as described in Chapter 4.2.5 were 
performed using this method- i.e. malignant vs. normal tissue and classifications 
of malignancy.   
 
 
5.3 RESULTS 
This study considered the same patient population as described in Chapter 4.3.1 
and therefore 148 lesions were identified and included in this comparative 
study, with 147 lesions included in receptor and molecular subtype comparisons 
due to one HER2 status being unavailable. 
 
5.3.1 Malignant vs. Normal 
Statistical assessment of max-min texture parameters showed there was a 
significant difference between malignant and normal tissue (p<0.001, Mann 
Whitney U) and this is displayed graphically in Figure 5.45, with the malignant 
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tissue demonstrating lower values of the measured tissue parameters 
compared with the normal tissue. 
 
 
 
 
 
 
 
 
Figure 5.45- Box-Whisker plot showing distribution of average max-min texture parameters for 
malignant and normal tissue 
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5.3.2 Classification of Cancer Subtype 
Data was then split according to the histological cancer subtype as described 
previously.  Again, the difference between the calculated texture parameters 
was found to be significant (p<0.001; Kruskal Wallis) for comparisons of cancer 
subtype as demonstrated in Figure 5.46.  Values of the max-min features are 
presented in Table 5.29.  In pair-wise comparisons, statistically significant 
differences were found between DCIS and both lobular and ductal cancers 
(p<0.05; Mann-Whitney U), although no significant difference was 
demonstrated between ductal and lobular cancers (p=0.533).   
 
 
 
 
 
 
 
 
 
 
 
 
 Ductal Lobular DCIS 
Mean ± std dev 0.22 ± 0.01 0.21 ± 0.01 0.39 ± 0.05 
Median (min-max) 0.11 (0.00-0.18) 0.06 (0.00-1.43) 0.33 (0.00-1.47) 
Table 5.29- Summary of mean, median and range of max-min values for each of the histological 
subtypes considered. 
 
Figure 5.46- Distribution of average max-min texture parameters for each histological cancer 
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5.3.3 Classification of Receptor Status of Cancer 
Comparisons of receptor status types demonstrated significant results for both 
the HER2 and triple negative types of 
breast cancer (p<0.05; Mann Whitney U).  
Results did not reach significance for 
comparison of ER+ and ER- types of breast 
cancer.  Results of statistical comparisons are presented in Table 5.30. 
 
5.3.4 Classification of Molecular Subtypes 
Average, median and range texture parameter values for each molecular 
subtype of cancer are presented in Table 5.31.  Statistical comparison of texture 
features for molecular subtypes demonstrated significant differences (p<0.001, 
Kruskal Wallis) when all subtypes were considered together.     
 
Pair-wise comparisons are 
presented in Table 5.32.  
Results are significant 
(p<0.05; Mann Whitney U) for 
comparisons of luminal and TNBC.  Results are shown graphically in Figure 5.47 
 
Table 5.30- Statistical results from 
comparisons of receptor statuses using 
max-min texture parameters 
 Mann Whitney U 
ER Status p=0.064 
HER2 Status p=0.041 
TN Status p<0.001 
Table 5.31- Summary of mean, median and range of max-min values for each of the molecular 
subtypes considered. 
 Luminal HER2 TNBC 
Mean ± std dev 0.21 ± 0.01 0.24 ± 0.03 0.30 ± 0.02 
Median (min-max) 0.12 (0.00-1.43) 0.04 (0.00-1.47) 0.25 (0.00-1.18) 
   Mann Whitney U 
Luminal vs. HER2 p=0.203 
Luminal vs. TNBC p<0.001 
HER2 vs. TNBC p=0.083 
Table 5.32- Statistical findings from pairwise comparison of 
texture parameters for each molecular subtype 
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5.4 DISCUSSION 
The max-min method of TA has demonstrated that it can provide good 
distinction between normal and malignant tissue and in the differentiation 
between cancer types. 
 
In comparison between normal and malignant, there was a significant 
difference in the texture parameters calculated using the max-min method, 
with malignant tissue demonstrating lower parameter values compared with 
normal tissue.  This would tend to suggest that malignant tissue has a greater 
number of extreme values that are not smoothed at higher threshold values 
Figure 5.47- Distribution of average texture parameter calculated using the max-min technique 
for each molecular subtype of breast cancer 
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and therefore resulted in overall lower values of the calculated texture 
parameters. 
When considering histological subtypes of breast cancer, the calculated texture 
parameters were found to be significantly different (p<0.05; Kruskal Wallis), 
which is in agreement with the findings from the work presented in Chapter 4.   
 
For molecular subtypes of cancer, significant differences were calculated 
between pair-wise comparisons of luminal and HER2 cancers with the average 
texture parameter largest for the TN cancers.  This suggests a more 
heterogeneous texture within the lesion as characterised by a larger number of 
extreme values, resulting in lower calculated parameters using the max-min 
method.  These results compare well with those demonstrated using the COM 
model and the entropy features, where both TNBC and HER2 were found to 
have the largest entropy values. 
 
The results from this study confirm with those demonstrated in Chapter 4, 
suggesting that there are measurable texture differences on our MRI images of 
breast cancer that can be used to differentiate between normal and malignant 
tissue and also between different histological and molecular subtypes.   
 
The texture parameters, as calculated using the max-min technique, appear to 
correlate most closely with the entropy features calculated using the COM 
model.  While the entropy features provide a measure of disorder in the ROI, 
with larger values representing more heterogeneous lesions, the max-min 
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technique is concerned with the number of minima and maxima detected in the 
ROI.  As the texture parameters are calculated as a ratio after smoothing, those 
regions with more heterogeneous appearance (greater number of maximum 
and minimum extremes in grey level pixel value) will result in a lower value of 
the calculated texture parameter.  
 
We therefore propose that the max-min technique also provides a measure of 
heterogeneity, with higher values of the calculated parameters representing 
more homogeneous lesions. 
 
Whilst common first-order statistics such as mean, variance, skewness and 
kurtosis of pixel grey-level values are generally unable to differentiate between 
different textures in medical images, calculation of texture using the first-order 
statistical method implemented by the max-min algorithm has demonstrated an 
ability to differentiate between not only malignant and normal tissue but also 
cancer subtypes.   
 
The advantage of the technique is that resulting features are essentially 
independent of the size of the ROI [157] and does not require the same 
computational power as more complicated methods.  However, the method is 
only able to calculate one parameter, rather than the range provided by the 
COM model and therefore is unlikely to be able to model more complex image 
textures and is unlikely to be of use for prospective prediction of cancer 
subtype. 
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The main limitation of this study is the low number of DCIS cases included in the 
histological subtyping section, as in the previous chapter, however this was due 
to the selection criteria for patients referred for MRI examinations at our 
institution.  We also did not consider the optimum threshold to use in 
differentiation between breast cancer subtypes but simply sought to replicate 
the work performed on the patient sub-group reported in Chapter 4.   
 
The results using the max-min technique have therefore validated those that 
were obtained using the COM model, lending weight to the hypothesis that 
textural differences within the image that may not be visually apparent, contain 
the information within the pixel grey-level distribution to allow distinction 
between different subtypes of cancer.  We hypothesise that the texture 
parameters as calculated using the max-min method provide a measure of the 
heterogeneity of the region of interest and therefore may provide similar 
outcomes to those obtained using entropy features from the COM. 
 
CHAPTER SUMMARY:  This chapter considered the use of an alternative technique 
for calculating texture within an MR image, using the max-min technique.  The 
results validate those from the previous chapter, using the COM model, 
indicating that the grey-level pixel distribution within the MR images contains 
information that can be used for differentiating between cancer subtypes.   
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CHAPTER SIX: PROSPECTIVE PATIENT STUDY 
 
OUTLINE OF CHAPTER: The previous chapters have demonstrated the usefulness of 
texture analysis in differentiation of malignant, benign and normal tissue.  It has 
also demonstrated initial capability in categorising malignant tissue into 
histological and molecular subtypes with reasonable classification accuracies.   
This chapter considers the use of these classifiers on a ‘blind’ test set in order to 
truly assess the usefulness of the technique in a clinical environment. 
 
6.1 INTRODUCTION 
It was demonstrated in Chapter Four that classification of lesions according to 
various categories of subtype using texture analysis alone could provide good 
classification accuracies and ROC areas.  It was also demonstrated that there 
were significant differences in the raw feature values between a number of the 
different breast cancer subtypes.   
 
Prior to concluding whether texture analysis can potentially be utilised as a 
clinical tool, it is essential to prospectively assess its ability to accurately classify 
data using the previously generated predictor model from the training set.  By 
using data that the model has never ‘seen’ before, it is then possible to assess 
the likelihood of the technique becoming useful in a clinical setting. 
This chapter considers a prospectively recruited patient lesion dataset in order 
to assess the utility of the model in predicting lesion subtype. 
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6.2 MATERIALS AND METHODS 
6.2.1 Subjects  
Women with the same inclusion criteria as outlined in Chapter 4.2.1, and 
scanned between June 2012 and August 2013 were prospectively recruited into 
this study. Again, only lesions greater than 8mm were included. 
Histopathological core biopsy data was obtained after MRI data had been 
obtained, analysed and classified. 
 
6.2.2 MR Imaging 
All MR imaging was performed in an identical manner to that described in 
Chapter 4.2.2. 
 
6.2.3 Texture Analysis and Classification 
All texture analysis was performed as previously described in Chapter 4.2.3.  All 
co-occurrence matrix features were considered, as well as entropy only 
features.  Classification models created in Chapter 4 using Weka were applied to 
the new data and the classification of the data recorded.  Pathology data was 
then compared to the predicted cancer subtype and an accuracy of the model 
calculated.  ROC curves were then generated using Weka. 
 
6.2.4 Classification of Entire Dataset 
Due to the larger number of categories for the molecular subtypes, it was 
unclear whether poorer classifications could be attributed to inadequate 
models or due to an insufficiency of data in the training set to build an accurate 
-165- 
predictive model. Therefore, once the pathology findings for the test data set 
were un-blinded, both the training and test datasets were combined in order to 
provide one single, large dataset.  Classification of this data was then performed 
using Weka and an external validation method in which a percentage of the 
data is withheld in order to test the model, thus producing a training and test 
set within the data.  The percentage split of this data was altered in order to 
assess whether classification accuracies could be further improved with larger 
training data sets. 
 
6.2.5 Signal to Noise  
 
Measures of signal to noise were also carried out in accordance with the 
method in Chapter 4.2.4. 
 
 
6.3 RESULTS 
6.3.1 Patient Cohort 
Within our patient cohort that was prospectively recruited over a 15-month 
time period, there were a total of 75 lesions identified in 57 symptomatic 
women (age range: 27-85; mean age 56 years) that could be used in our study 
(over 8mm with pathology data obtained within one month of MR examination 
and consenting to images being used for research purposes).  A summary of 
lesion characteristics is summarised in Table 6.33. 
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Of these lesions, 56 were identified on images that were acquired on the 1.5 T 
system and 19 were identified on 3.0 T examinations. 
 
  
Patient Age 27-85 (median 55.5 years) 
Maximum lesion diameter 12.5 mm (range: 8.2-24.5mm) 
Histological Subtype Ductal: 48; Lobular: 22; DCIS: 3 
Histological Grade 
Ductal- Gd2: 12; Gd3: 36 
Lobular- Gd2: 18; Gd3: 4 
Molecular Subtype Luminal: 46; HER2: 11; TNBC: 15 
Table 6.33-  Summary of population characteristics of lesions included in prospective set. 
 
 
6.3.2 Classification of Histological Subtype and Grade 
Full histological data was only available for 73 of the 75 lesions included in the 
test set.  The predicted histological subtype of these lesions is presented in 
Table 6.34. 
 
There was excellent classification accuracy using the created model and all 
features with an accuracy of 72.5% and ROC area of 0.823.   The classification 
results using the model created on the entropy features alone resulted in a poor 
classification accuracy with low ROC area, which is largely to be expected based 
on the poorer classification accuracy associated with the training set using these 
features alone.  
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Predicted   
Ductal Lobular DCIS 
Classification Accuracy 
and 
ROC Area 
Ductal 40 (35) 8 (13) 0 (1) 
Lobular 10 (17) 12 (5) 0 (0) 
A
ct
u
a
l 
DCIS 1 (2) 1 (0) 1 (0) 
All: 72.5%; 0.823 
Ent: 55.0%; 0.543 
Table 6.34- Predicted histological subtype for lesions identified, as well as actual subtype as 
obtained from pathology reports and the classification accuracy and ROC areas for the created 
model. Figures in brackets are those predicted using entropy features only 
 
 
The ROC curves generated for the histological classification of the data using the 
predictor model using all features, and entropy features alone are presented in 
Figure 6.48 (a) and (b) respectively. 
 
 
After histological grade predictive classification had been carried out, the 
histology of lesions was identified in order to classify data into ductal and 
lobular subtypes prior to classification of histological grade.  This step was 
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False positive rate 
(a) (b) 
Figure 6.48- ROC curves for classification in terms of histological subtype using (a) all features and (b) entropy 
only features 
ROC-0.823 ROC-0.543 
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performed in order to produce a simpler model and assess the performance on 
grade alone, rather than adding in another variable. 
The histological grade predictions for both ductal and lobular cancers are 
provided below in Table 6.35 and the ROC curve obtained for classification of 
lobular cancer grade represented graphically in Figure 6.49. 
 Predicted (all features) 
 
 
Grade 2 Grade 3 
Classification Accuracy 
and 
ROC Area 
Ductal     
Grade 2 7 7 All: 66.0%; 0.746 
Grade 3 8 26 Ent: 59.0%; 0.494 
     
Lobular     
Grade 2 16 1 All: 87.9%; 0.944 
A
ct
u
a
l 
Grade 3 2 3 Ent: 78.8%; 0.699 
Table 6.35- Predicted histological grade for ductal and lobular lesions identified, as well as true 
histological grading and calculated classification accuracies and ROC areas for the created 
model. 
 
 
The classification accuracy for ductal cancers is good when all features are taken 
into consideration in the predictive model, however is poor for only entropy 
features.  For lobular cancers, we had excellent classification accuracy, 
particularly when all features were incorporated in the predictive model, with 
almost 90% classification accuracy and ROC of 0.944.  However it should be 
noted that there were only 4 lesions that were classified as Grade 3 lobular 
cancer and only around 20% of the lesions used in the training set on which the 
model was based were Grade 3 and therefore there remains the possibility that 
this model may not be optimal. 
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6.3.3 Classification of Immunohistochemical Subtype  
Immunohistochemical information was available for all 75 lesions in the cohort.  
All predictive receptor status data is presented in Table 6.36.  Again the models 
based on the entire set of texture features perform much better that those 
models produced only on the entropy features.  The triple negative vs. all other 
classifications results in the best data classification with over three quarters of 
the data correctly classified with a reasonable ROC area.  For both the ER and 
HER2 status cancers, around two-thirds of data is classified correctly, although 
there are still high values of ROC area achieved. 
False positive rate 
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ROC-0.944 
Figure 6.49- ROC curve for grade classification of lobular cancer using all 
features 
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 Predicted 
 
 
Positive Negative 
Classification 
Accuracy 
and 
ROC Area 
ER Status     
Postive 42 (42) 8 (8) All: 66.7%; 0.732 
Negative 17 (21) 8 (4) Ent: 61.3%; 0.441 
     
HER2 Status     
Positive 11 (13) 16 (14) All: 68.8%; 0.762 
Negative 8 (15) 40 (33) Ent: 61.6%; 0.598 
     
TN Status     
TNBC 3 (1) 12 (14) All: 76.8%; 0.726 
A
ct
u
a
l 
Other 5 (3) 55 (57) Ent: 77.2%; 0.440 
Table 6.36- Predicted immuniohistochemical subtype for ER, HER2 and Triple Negative receptor 
status. True subtype and calculated classification accuracies and ROC areas for the created 
model are also presented. Figures in brackets are those predicted using entropy features only. 
 
6.3.4 Classification of Molecular Subtype  
Molecular subtype information was again available for 72 lesions which were 
identified as invasive cancers and the actual subtype and predicted subtype 
values are as presented in Table 6.37.  The molecular subtypes were classified 
into luminal, HER2 and triple negative cancers (TNBC).  From this data, there is 
reasonable classification accuracy when all features are considered, but when 
only entropy features are considered, the classification results are 
disappointing. 
Predicted  
Luminal HER2 TNBC 
Classification Accuracy 
and 
ROC Area 
Luminal 42 (41) 1 (2) 4 (3) 
HER2 8 (9) 2 (1) 1 (1) 
A
ct
u
a
l 
TNBC 10 (13) 0 (1) 4 (1) 
All: 65.5%; 0.755 
Ent: 58.6%; 0.437 
Table 6.37- Predicted molecular subtype.  True molecular subtyping as identified using 
pathology, as well as calculated classification accuracies and ROC areas for the created model 
are presented. Figures in brackets are those predicted using entropy features only. 
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ROC curves generated from these predictive classifications are shown in Figure 
6.50, where it is evident that the classifications based on all features result in 
significantly improved results. 
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False positive rates 
Figure 6.50- ROC curves for molecular subtypes classifying using all COM feature (top) and only 
entropy-based features (bottom) 
ROC- 0.755 
ROC- 0.437 
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6.3.5 Classification of Entire Dataset 
Combining the training and test datasets resulted in a total of 212 lesions with 
full molecular subtyping information available.  These were classified by setting 
different percentages of data to be used as training data with the remainder 
used to test predictive models.  Data splits chosen for training data were 66% 
(as most representative of current numbers in each dataset), 70%, 75% and 
80%.  Classification accuracies and obtained ROC areas are shown in Table 6.38.  
The effect of changing this data split on classification into the three molecular 
subtype categories is summarised in the ROC plots in Figure 6.51. 
Classification accuracy; ROC area 
Data Split 
Training 
Cases 
Test 
Cases All features Entropy features 
66%-34% 140 72 73.9%; 0.793 60.8%; 0.535 
70%-30% 148 64 73.5%; 0.776 60.7%; 0.549 
75%-25% 159 53 73.0%; 0.776 59.5%; 0.526 
80%-20% 170 42 71.0%; 0.803 53%; 0.521 
Table 6.38- Summary of classification results when training and test data considered together 
and a percentage of data withheld as test data. Classification results are presented as: [% 
accuracy; ROC area] 
 
For the 66% data split, which results in numbers in the generated training and 
test set approximately equal to the numbers from the true training and test 
sets, classification accuracies are slightly improved (65.5% vs. 73.9%) although 
on a similar order of magnitude.   
 
By increasing the number of cases that are included in the generated training 
dataset, the classification accuracies are relatively unchanged, however the ROC 
areas are improved, as is demonstrated in Figure 6.51, where there is a shift to 
the left of the plot, indicating improved classifier performance.   
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When 80% of the data is used as a generated training, the classification 
accuracy of the generated test data is good, with 70% of the data accurately 
classified and an ROC area of 0.803.  There is less of an improvement to the 
models generated using only entropy features.  
 
It should be noted that for the cases where a larger percentage of the data is 
used to generate a training set, this ultimately results in a lower number of 
cases in the test set, which could potentially influence the classification 
accuracies due to a smaller number of cases on which to test the model.  For 
this reason, splits greater than 80%/20% were not considered.  It seems 
possible, however, that an increase in lesion numbers could significantly 
improve classification accuracies. 
False positive rate 
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Figure 6.51- ROC curves for classification of molecular subtypes for various different splits of entire training 
and test data set 
0 0.5 1.0 
0 
0.5 
1.0 
66% split; ROC-0.793 
70% split; ROC-0.776 
75% split; ROC-0.776 
80% split; ROC-0.803 
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6.3.6 Signal to Noise 
Signal to noise measurements were calculated and compared as described 
previously and are 
presented in Figure 6.52.  
Error bars depict the 
standard deviation of the 
SNR measures in each 
subtype category.  Again, 
large standard deviations 
are likely to be 
attributable to the 
distribution of scans 
performed on 1.5T and 
3.0T. 
 
 Statistical pair-wise 
comparisons were 
performed between each 
histological and 
molecular subtype using a students t-test, and one way ANOVA across all 
subtypes, and results of statistical analysis are presented in Table 4.28.  There 
were found to be no significant differences in measured SNR values in each pair-
comparison, suggesting that differences in texture analysis were unlikely to be 
attributable to this particular factor. 
Figure 6.52- Summary of signal to noise measurements for (a) 
histological subtype groups and (b) molecular subtype groups 
(a) 
(b) 
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Histological Subtype 
Comparison 
SNR comparison 
p-value 
Molecular Subtype 
Comparison 
SNR comparison 
p-value 
  
Ductal vs. Lobular Luminal vs. HER2 
 
p=0.206 
 
p=0.443 
  
Ductal vs. DCIS Luminal vs. TNBC 
 
p=0.315 
 
p=0.548 
  
Lobular vs. DCIS HER2 vs. TNBC 
 
p=0.130 
 
p=0.856 
    
    
Histological subtype p=0.204
* 
Molecular subtype p=0.614
* 
Table 6.39- Summary of statistics performed on SNR differences between different histological 
and molecular subtypes of cancer.  There were no significant differences (p<0.05; students t-
test; *p<0.05; ANOVA) 
 
 
 
6.4 DISCUSSION 
Results presented in this chapter extend the work carried out in Chapter 4 to 
apply the classification models created on the previous training set to a blind 
test set which had not been used in the model creation.  Using this technique, a 
true representation of how the models are likely to perform in a routine clinical 
environment is obtained and can therefore provide a measure of the usefulness 
of the technique as a clinical tool. 
 
Classification of the test data set into ductal, lobular and DCIS histological 
subtype resulted in good classifications overall when all the COM features were 
used for model creation.  Accuracy was over 70% with an ROC area of 0.823. 
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Histological grade also resulted in good classification accuracies across ductal 
and lobular cancers, although it should be noted that there were only a small 
number of Grade 3 lobular lesions.    
 
When data was considered according to molecular subtype, classification 
accuracies were lower than anticipated with two thirds of the data well-
classified, with only fair ROC values (0.755).  
 
Once pathology data was available for all lesions, the training and test data sets 
were combined to provide one larger data set comprising 212 lesions with full 
molecular subtype information available.  Training and test datasets were then 
generated from this data randomly using a percentage split method.  For these, 
the classification accuracy was slightly improved compared with the true test 
data set predictions, however there is no control over the generation of the 
datasets and therefore it is unclear how many of each lesion type there is in 
each set, and also no method of knowing how many lesions were identified on 
1.5T scans compared with 3.0T scans.  This means that there could potentially 
be differences in SNR that we cannot quantify.  While Weka can stratify the data 
when creating the training and test data sets to try and ensure a similar 
underlying population of data points in each group, it can do this only on one 
variable (e.g. lesion category) and there is then no control over further 
categorisations (such as scanner field strength).  Unfortunately this provides a 
limitation to using this means of training/test set creation. 
-177- 
 
In Chapter 4, it was demonstrated that entropy features appeared to be 
statistically different between the HER2 and luminal cancers, suggesting that 
these features would result in a good classification accuracy, however in all 
predictive classifications performed, the entropy features result in disappointing 
classification accuracies, with meaningless ROC values around 0.5. 
 
However, as we obtained good training classification accuracies, and statistically 
significant differences in feature values between a number of the molecular and 
histological subtypes, it is possible that the existing study is underpowered to 
create a robust training model, particularly when this model is created using 
only a few of the calculated features as in the case of the entropy features.  
However, there are promising results when all COM features are used, and 
when the data is combined and a training and test set generated using a larger 
number of data points and therefore this technique warrants further 
investigation by increasing the number of cases significantly. 
 
The major limitation in this study was the number of patients, and hence 
cancers, that were included.  However, this was due to the inclusion criteria and 
matching as closely as possible the lesions that were included in the training 
data set to ensure there was no influence of lesion or ROI size on the outcome 
of the study.  A basic, retrospective power calculation (G*Power, v3.1.5; Kiel 
University, Germany) [158] performed using the mean values for the training 
dataset in Chapter 4 suggests that in order to classify differences between 
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luminal, HER2 and TNBC lesions with a 95% power, using entropy features 
alone, a dataset of 250 lesions would be required (split with approximately 60% 
of the data being luminal cancers).  This suggests that our study must be 
extended considerably in order to fulfil this criterion. 
 
Again, we had a low number of DCIS cases, which reflects the referral criteria for 
breast MRI examinations and was a factor that was out with our control. 
 
Predicted grade was performed after pathology results were available to allow 
us to split the data into ductal and lobular cancers prior to classifications into 
grade.  Whilst a full model could have been created in order to differentiate 
simultaneously between ductal and lobular cancers as well as grade, this step 
was not performed as this would also have required DCIS data to be included, 
and we were also trying to identify the usefulness of TA in each individual 
classification of cancer- for which we separated histological sub typing and 
grade classification.  
 
Classification of lesions into their respective molecular subtypes is still an 
evolving technique and in a recent study performed by Mackay et al. it was 
found that even in cases where expert microarray profilers were asked to 
classify lesions, the inter-observer agreement is reproducible (kappa>0.81) only 
in the classification of basal like and HER2 lesions [159].  For classification 
between luminal cancers the kappa value was less than 0.61 [159]. 
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Therefore, an image based system that can reliably differentiate between 
luminal, HER2 and TNBC with an ROC area of 0.733 and classification accuracy 
of 64.3% could potentially provide added value for decision making in a clinical 
environment, prior to biopsy information being available. 
The data provided in this chapter demonstrates that while we have insufficient 
data points to demonstrate with certainty that texture analysis can be used 
prospectively in classification of lesion subtype in a clinical environment, there 
is initial promise. Further patient recruitment and larger data sets are required 
in order to increase the training and test data sets in order to conclusively 
demonstrate whether the technique can produce accurate subtype predictions, 
but initial results suggest that this is a real possibility and one that warrants 
further investigation. 
 
CHAPTER SUMMARY: This chapter considered the usefulness of texture analysis 
predictive models as created previously applied to a blind test set.  Initial results 
suggest that using all features, classifications of histological subtype and grade 
can be performed with excellent results.  
 
The results from the molecular subtype classifications are inconclusive- which is 
most likely to be due to insufficient cases in order to build a robust model.  
However, there is initial promise shown and a brief investigation on the 
influence of training dataset size suggests that increasing the numbers could 
result in improved data classification. 
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CHAPTER SEVEN: TEXTURE ANALYSIS IN TREATMENT RESPONSE 
 
OUTLINE OF CHAPTER:  Previous chapters have outlined the usefulness of TA in the 
diagnostic setting for classification of malignant and benign lesions as well as 
histological and molecular subtypes. This chapter considers the use of texture 
analysis in early response to neoadjuvant chemoteherapeutic treatment and 
whether ultimate outcomes can be predicted based on texture analysis 
measures. 
 
7.1 INTRODUCTION 
Neoadjuvant chemotherapy (NAC) is drug treatment that is delivered prior to 
breast surgery with the aim of reducing the size of a locally advanced breast 
cancer into an operable tumour that may previously have been inoperable, or 
to reduce the extent of surgery required [160].  However, such treatment 
regimes are not effective in all patients and some women will undergo intensive 
therapy with potentially distressing side effects, and the disease will remain 
resistant or in some cases will have continued to grow throughout the 
treatment.  Magnetic resonance imaging is becoming more commonly used in 
the monitoring of treatment due to the lack of ionising radiation, allowing 
repeated examinations and dynamic contrast enhanced imaging provides a 
measure of tumour vascularity.  However, it has been reported that MR can 
under- or over- estimate residual tumour in around 30% of cases [161] and 
therefore more quantitative measures and earlier response markers are 
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required in order to increase the accuracy of such response measures and allow 
them to be implemented in routine practice.   
 
This chapter considers the use of texture analysis in a cohort of patients 
undergoing neoadjuvant chemotherapy at our institution and correlates this 
with traditional response evaluation criteria- using radiological assessment and 
final resectional pathology data. 
 
 
7.2 MATERIALS AND METHODS 
7.2.1 Subjects  
All women with biopsy-proven cancer who were scheduled for neoadjuvant 
chemotherapy (NAC) between January and August 2013 were included in this 
study.  Women were scanned after diagnosis but prior to commencement of 
chemotherapeutic treatment.  Only patients who had consented for their 
examination to be used for research and developmental purposes were 
included, and no active recruitment process took place.  Findings from this 
study bore no impact on the ultimate course of the patient treatment or 
management. 
 
As was previously described in earlier chapters, only lesions greater than 8mm 
were included in the study.  As NAC is rarely offered for cancers less than 2cm in 
size all patients who consented were included, and image analysis was 
performed blinded to the treatment outcome for each patient- this information 
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was obtained after texture analysis had been performed and prior to statistical 
evaluation of the data. 
 
7.2.2 MR Imaging 
All MR examinations were performed on the 3.0 T MRI Scanner (Trio; Siemens, 
Erlangen).  As per the standard NAC protocol, patients were scanned prior to 
starting their chemotherapeutic treatment, at interim (either post cycle 2 or 
cycle 3) to assess early response and at the end of their treatment in order to 
assess final response. 
 
All acquisition conditions were as described previously for the 3.0T protocol 
(Section 4.2.2) and texture analysis was performed on the baseline and interim 
examinations in order to identify if TA could identify or characterise early 
response. 
 
7.2.3 Texture Analysis  
Images from baseline and interim examinations were considered side-by-side in 
order to match slices depicting lesions from each examination to best match the 
region of analysis between the two separate examinations. 
 
Texture analysis was then performed as previously described, by placing 10×10 
pixel ROIs on the three slices with largest lesion dimensions.  There was also a 
10×10 ROI placed in healthy, normal contralateral breast tissue (see Figure 
7.53).  In order to ensure that changes measured were real and not due to 
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changes related to scan-scan conditions, average standard deviation of the 
background noise was measured by placing ROIs as shown in Figure 4.28 for all 
cases.  Comparisons of baseline and interim examinations were then made 
using paired t-tests, with p<0.05 considered significant.  SNR was not felt to be a 
valid measure in this instance as this would reflect contrast uptake kinetics 
within the lesion, adding a confounding factor to interpretation due to the link 
with response. 
 
Comparison of texture features in respect to response was considered in a 
number of ways: 
1. Comparing the number of significantly different features between 
baseline and interim examinations for each of the response categories, 
for normal tissue and lesion regions. 
Figure 7.53- Analysis protocol for comparing texture analysis at baseline and interim MRI examinations. 
Regions of interest were placed in normal and lesion tissue  
Normal  
Lesion 
Baseline (slice 110) Interim (slice 118) 
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2. Comparing baseline and interim absolute features using a Wilcoxon 
test for each response category. 
3. Subtracting baseline and interim features for each response category. 
4. Considering baseline values alone with respect to response categories 
to identify any features that may indicate whether lesions will respond 
or not. 
 
7.2.4 Assessment of Response 
The final response to chemotherapy was assessed by an expert breast MRI 
radiologist using RECIST criteria (Response Evaluation Criteria in Solid Tumours) 
[162].  This method defines response into four categories as outlined in Table 
7.40.  All size changes are measured relative to pre-treatment baseline values 
and are assessed at interim and final examinations.  All RECIST classifications 
were obtained from the NHS radiology report from the MRI examinations.  
Progressive and stable diseases were considered as one category, as were 
complete response and minimal residual disease based on evidence from 
survival studies. 
 
Response Category  Criteria 
Complete Response CR disappearance of lesions 
Minimal Residual Disease* MRD* Minimal enhancement, almost complete 
disappearance of lesions* 
Partial Response PR >30% decrease in longest diameter sum 
Progressive Disease PD >20% increase in longest diameter sum 
Stable Disease SD small changes that do not meet other criteria 
Table 7.40- RECIST criteria for response classification to treatment [162] (*note: MRD is not an 
official RECIST criteria but is used routinely at this institution) 
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As well as classification of disease using an image-based technique alone, the 
residual cancer burden (RCB) score was also calculated from final pathology 
[163].  This measure provides an assessment of tumour dimensions, cellularity 
and axillary node burden in the tumour after therapy and has been linked with 
disease-free survival [163] and therefore could potentially be a more useful 
prognostic marker with which to correlate texture results.  RCB scores were 
retrospectively calculated as requested by an expert specialist breast 
pathologist (Dr Colin A. Purdie) and reported in terms of the RCB index as shown 
in Table 7.41 [163]. 
 
RCB Category % population with relapse at 5 years 
pCR Pathological complete response 0.0 % 
RCB-I Minimal residual disease 21.6 % 
RCB-II Moderate residual disease 36.2 % 
RCB-III Extensive residual disease 52.2 % 
Table 7.41- Residual cancer burden categories and appropriate survival statistics at 5 years post 
treatment 
 
 
7.3 RESULTS 
7.3.1 Patient Cohort 
 A total of 61 patients were identified for this study, however due to scheduling 
problems, 7 received their first cycle of treatment prior to MRI examination, 3 
received their interim examination after four cycles of treatment and 2 patients 
had their treatment stopped after 4 cycles and therefore there was no true end 
of treatment assessment of response possible. 
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In the remaining 49 patients (age range: 30-79; mean age 50 years) included in 
the study, there were a total of 57 lesions identified over 8mm.  All patients 
were scanned at baseline and then after cycle 2 (22 patients) or cycle 3 (27 
patients) of their treatment, depending on scanner availability. 
 
All patients received 6 cycles of treatment as shown in Table 7.42.  FEC 
(fluorouracil, epirubicin 
and cyclophosphamide) is 
the most commonly used 
treatment regimen used 
at our institution for breast 
cancer patients and may be used alone or in combination with Docetaxyl (DOC) 
and/ or trastuzumab Herceptin (TRA).  There were also four patients in this 
study who received a docetaxyl in combination with TDM1 (trastuzumab 
emtansine) for treatment of aggressive HER2 positive cancer.  Trastuzumab and 
TDM1 treatments were only used where the breast cancer was HER2 positive. 
 
7.3.2 RECIST Response Criteria 
Of the patients that underwent treatment, 11 were considered to have had a 
complete MR response or have minimal residual disease (MRD), 27 were 
categorised as having a partial response (PR) and 11 were classified as stable or 
progressive disease (SD). 
 
 
First 3 cycles Second 3 cycles No of patients 
FEC FEC 26 
FEC DOC 8 
FEC DOC+TRA 11 
TDM1+DOC TDM1+DOC 4 
Table 7.42- Treatment regimes for patients included in this 
study (see text for regimen descriptors) 
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The number of significantly different features between baseline and interim 
examinations for each of the response categories was calculated using a 
Wilcoxon test with p<0.05 considered significant.  The statistics were calculated 
for normal tissue and within the lesion and results are presented in Figure 7.54. 
 
Statistical comparison of features was then performed between baseline and 
interim examinations for normal and lesion ROIs in each clinical response 
category as presented below in Table 7.43.  Unfortunately, it appears that there 
are significant differences between the baseline and interim values for normal 
tissue in most of these categories and therefore it is unlikely that differences in 
lesion features between MRI examinations can be conclusively linked with the 
ultimate outcome of treatment. 
94
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Figure 7.54- Number of significantly different features between baseline and interim examination for 
normal and lesion regions of interest, out of 220 calculated features (Mann Whitney U, p<0.05) 
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 Normal Lesion 
 MRD PR SD MRD PR SD 
AngScMom <0.001 <0.001 <0.001 <0.001 0.013 0.117 
Contrast 0.009 0.015 0.424 0.119 0.345 0.117 
Correlat 0.785 0.763 0.976 0.097 0.566 0.757 
DifEnt <0.001 0.219 <0.001 <0.001 0.009 0.642 
DifVarnc 0.018 <0.001 0.023 0.391 0.357 0.001 
Entropy <0.001 <0.001 <0.001 <0.001 0.067 0.221 
InvDfMom <0.001 <0.001 <0.001 <0.001 0.229 0.919 
SumAverg <0.001 <0.001 0.845 0.921 0.001 0.004 
SumEnt <0.001 0.009 <0.001 <0.001 0.252 0.547 
SumofSqs <0.001 <0.001 0.037 0.940 <0.001 <0.001 
SumVarnc 0.010 0.079 0.335 0.078 0.054 0.325 
Table 7.43- Statistical comparison between baseline and interim examinations for each texture 
feature for normal and lesion regions of interest in each clinical response category. Statistically 
different p-values are highlighted in grey (Wilcoxon test; p<0.05) 
 
Considering the background values, there was no significant differences found 
in the background standard deviation value between baseline and interim 
examinations for any of the response categories (p>0.281, students paired t-
test) suggesting measured differences were not attributable to scan-scan 
conditions. 
 
The difference between baseline and interim features were calculated as shown 
in Figure 7.55 for the entropy features for normal and lesion regions of interest.   
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(a) 
(b) 
Figure 7.55- Difference in entropy features between baseline and interim examinations for normal 
and lesion regions of interest (a) and lesion only (b) in each clinical response category 
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The normal tissue shows a wide range of values, and therefore lesion entropy 
values only, which show a tighter range of values, are also presented separately 
in Figure 7.55(b).  While statistically significant differences were obtained for a 
number of features (entropy, difference entropy, sum entropy and second 
angular momentum) between each response category, significant differences 
were also found in normal tissue (Mann-Whitney U; p<0.05) and therefore it 
was concluded that there was no real correlation between changes in texture 
values and ultimate clinical response to chemotherapy treatment as measured 
using RECIST criteria in these patients.  
 
Finally, assessment of whether absolute texture features at baseline correlated 
with ultimate clinical response assessed using RECIST was performed. Statistical 
comparison of each texture feature between each clinical response category 
was carried out using a Mann-Whitney U test with a significance level of 0.05.  
Results are presented in Table 7.44 for the four features which produce the 
most significant results.  It is clear that there appears to be no correlation of 
baseline feature value with differentiation between response categories.  
  MRD v PR MRD v SD PR v SD 
AngScMom 0.567 0.015 0.036 
DifEnt 0.378 0.142 0.386 
Entropy 0.437 0.002 0.003 
N
o
rm
a
l 
SumEnt 0.473 0.014 0.022 
AngScMom 0.173 0.111 0.659 
DifEnt 0.683 0.811 0.502 
Entropy 0.199 0.156 0.719 
Le
si
o
n
 
SumEnt 0.046 0.182 0.781 
Table 7.44- Statistical comparison of baseline features between each clinical response category, 
significant values are highlighted in grey (Mann-Whitney U; p<0.05) 
 
-191- 
Graphical representation of these results is presented in Figure 7.56 for entropy 
and difference entropy features. 
 
7.3.3 RCB Response Criteria 
RCB scores were available for only 40 of the 49 patients included in the study 
and were categorised 
as shown in Figure 
7.57. 
The number of 
significantly different 
features between 
baseline and interim examinations for each of the response categories was 
calculated using a Wilcoxon test with p<0.05 considered significant.  The 
statistics were calculated for normal tissue and within the lesion and results are 
presented in Figure 7.58. 
RCB-I, 7
RCB-II, 21
pCR, 6RCB-III, 6
Figure 7.57- Breakdown of patients in each residual burden category 
(a) (b) 
Figure 7.56- Baseline only values for each clinical response category for lesion regions of interest. Box-whisker plots are 
displayed for both entropy (a) and difference entropy (b) features 
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The texture features calculated at baseline and interim examinations for normal 
and lesion ROIs were then compared using a Wilcoxon test.  This data is 
presented in Table 7.45 for each RCB category. 
 
 pCR RCB-I RCB-II RCB-III 
 N L N L N L N L 
AngScMom 0.791 <0.001 0.389 0.044 0.038 0.060 0.606 0.192 
Contrast 0.171 0.161 0.293 0.017 0.920 0.691 0.226 0.888 
Correlat 0.203 0.064 0.791 0.005 0.694 0.836 0.462 0.521 
DifEnt 0.542 0.323 0.214 <0.001 0.046 0.809 0.406 0.542 
DifVarnc 0.239 0.001 0.406 0.019 0.079 0.772 0.040 0.406 
Entropy 0.767 0.001 0.355 0.047 0.046 0.029 0.673 0.085 
InvDfMom 0.767 0.013 0.389 0.059 0.050 0.316 0.673 0.521 
SumAverg 0.226 0.004 0.521 0.815 0.972 0.225 0.355 0.839 
SumEnt 0.815 0.001 0.542 0.864 0.026 0.059 0.265 0.135 
SumofSqs 0.406 0.913 0.040 0.563 0.940 0.727 0.767 0.339 
SumVarnc 0.767 0.323 0.013 0.111 0.698 0.509 0.719 0.389 
Table 7.45- Statistical results from comparisons of each texture feature between baseline and 
interim examinations in each residual cancer burden category. Significant p-values are 
highlighted in grey [N-normal, L-lesion] (Wilcoxon test; p<0.05) 
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Figure 7.58- Number of significantly different features between baseline and interim examination for normal 
and lesion regions of interest in each residual cancer burden index, out of 220 calculated features (Wilcoxon 
test, p<0.05) 
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From this data, the difference in lesion texture features between baseline and 
interim examination in the pathological complete response category (pCR) and 
minimal residual disease category (RCB-I) shows significant differences for 
angular second moment, entropy and difference variance features.  For 
difference variance, angular second moment and entropy, this is coupled with 
no measured differences in normal tissue for these texture features.  For the 
RCB-II category (moderate residual disease) there is also a statistically 
significant difference between baseline and interim measures of entropy 
features, although significant differences are also measured in normal tissue 
and therefore the meaning of this result is unclear. 
Figure 7.59- Absolute entropy values at baseline and interim for each residual cancer burden 
index category 
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The values for this entropy feature as measured in the lesion in each RCB 
category are shown in the box-whisker plot (Figure 7.59).  All lesions show a 
general trend towards a reduction in the entropy parameter at the interim 
examination compared with baseline suggesting a reduction in heterogeneity 
within the lesion.  The complete response category demonstrated a very wide 
range in the entropy values measured at the interim examination compared 
with all others. 
 
Measures of the standard deviation of background noise between baseline and 
interim examinations were not significant for any of the categories: pCR: 
p=0.330; RCB-I: p=0.662; RCB-II: p=0.553; RCB-III: p=0.589 (paired student’s t-
test) therefore there were no differences attributed to scan-to-scan variations 
between categories. 
 
The difference in feature values between baseline and interim examinations 
was calculated for each feature and each response category, considering the 
normal and lesion regions of interest.  These are represented graphically in 
Figure 7.60 for the entropy features which resulted in most discriminatory 
parameters, and the lesion only regions of interest subtractions are also shown 
alone in Figure 7.60(b). 
 
Statistical comparisons between the differences in texture features using Mann-
Whitney U tests are presented in Table 7.46 for the four features demonstrating 
the most significance. 
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(a) 
(b) 
Figure 7.60- Difference in entropy features between baseline and interim examinations for normal, 
background and lesion regions of interest (a) and lesion only (b) in each residual cancer burden index 
category 
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From these results, the difference in texture features between baseline and 
interim examination as measured in normal tissue is not statistically significant.  
However, for pCR compared with both RCB-II & III and for RCB-I compared with 
RCB-II angular second moment, entropy and sum entropy appeared to 
consistently result in a significant difference when the change in texture 
features were compared between response categories (Table 7.46). 
 
Table 7.46- Statistical comparisons for each region of interest in each residual cancer burden 
category. Significant differences are highlighted in grey  (Mann-Whitney U; p<0.05) 
 
From Figure 7.60 we can see that the difference in the entropy feature is higher 
for pCR than that of the other response categories, with a wider range of values 
compared with the other categories.  
 
The differences measured in other response categories fell within a much 
tighter range of entropy values as shown in Figure 7.60, even for the RCB-II 
category which contained the most patients and therefore this is unlikely to be 
a population effect. 
 
 
  pCR v RCB-I pCR v RCB-II pCR v RCB-III RCB-I v RCB-II RCB-I v RCB-III RCB-II v RCB-III 
AngScMom 0.213 0.561 0.300 0.084 0.444 0.381 
DifEnt 0.189 0.530 0.279 0.081 0.432 0.381 
Entropy 0.244 0.859 0.612 0.056 0.318 0.521 
N
o
rm
a
l 
SumEnt 0.259 0.791 0.526 0.076 0.394 0.464 
AngScMom 0.945 <0.001 0.006 0.003 0.083 0.435 
DifEnt 0.044 0.069 0.256 <0.001 0.008 0.864 
Entropy 0.708 <0.001 0.002 0.003 0.091 0.781 
Le
si
o
n
 
SumEnt 0.485 <0.001 0.023 0.037 0.336 0.532 
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Finally, an assessment was made as to whether absolute texture features as 
measured on baseline examinations could be correlated with the final residual 
cancer burden as categorised in Table 7.41.  Comparisons between response 
categories were made using a Mann-Whitney U test, and results are 
summarised in Table 7.47 for the four features which appear to provide most 
significant differences.  
Table 7.47- Statistical comparison of baseline features between each residual cancer burden 
category, significant values are highlighted in grey (Mann-Whitney U; p<0.05) 
 
Absolute values for these features in each response category are presented in 
Table 7.48 and are presented graphically for the entropy and difference entropy 
features in Figure 7.61. 
 
 
 
 
 
 
 
 
  pCR v RCB-I pCR v RCB-II pCR v RCB-III RCB-I v RCB-II RCB-I v RCB-III RCB-II v RCB-III 
AngScMom 0.155 0.439 0.331 0.079 0.084 0.117 
DifEnt 0.026 0.595 0.416 0.003 0.010 0.198 
Entropy 0.203 0.435 0.140 0.215 0.035 0.015 
N
o
rm
a
l 
SumEnt 0.114 0.541 0.189 0.066 0.026 0.047 
AngScMom 0.262 0.038 0.023 0.099 0.181 0.359 
DifEnt 0.105 0.050 0.013 <0.001 <0.001 0.235 
Entropy 0.443 0.045 0.046 0.085 0.179 0.319 
Le
si
o
n
 
SumEnt 0.005 0.026 0.073 0.468 0.763 0.698 
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Figure 7.61- Baseline only values for each residual cancer burden index category for lesion regions 
of interest. Box-whisker plots are displayed for both entropy (upper) and difference entropy 
(lower) features 
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From Figure 7.61, it is clear that there is a significant difference in the entropy 
and difference entropy features between the pathological complete response 
cases (pCR) and the moderate and extensive residual disease categories (RCB-II 
and RCB-III, respectively).  Considering the absolute values of the features in 
Figure 7.61, the pCR category lesions have a higher entropy and difference 
entropy value as measured on the baseline examination, suggesting that these 
lesions are more heterogenous than the lesions which respond poorly to 
therapy. 
 
The difference entropy parameter appears to perform well, also demonstrating 
a significant difference between RCB-I compared with RCB-II and RCB-III 
categories on the baseline images (Figure 7.60). 
 
 
Table 7.48- Absolute texture feature values in each response category for each region of interest 
(3sigfigs). Figures provided in brackets are median values. 
  pCR RCB-I RCB-II RCB-III 
AngScMom 0.0256 (0.0192) 0.0478 (0.0274) 0.0304 (0.0235) 0.0206 (0.0141) 
DifEnt 1.29 (1.29) 1.30 (1.26) 1.28 (1.29) 1.30 (1.31) 
Entropy 1.84 (1.86) 1.76 (1.81) 1.82 (1.84) 1.91 (1.95) 
N
o
rm
a
l 
SumEnt 1.42 (1.43) 1.36 (1.39) 1.41 (1.42) 1.45 (1.48) 
AngScMom 0.0107 (0.0107) 0.0108 (0.0108) 0.0111 (0.0109) 0.0109 (0.0108) 
DifEnt 1.29 (1.30) 1.31 (1.31) 1.28 (1.29) 1.27 (1.29) 
Entropy 2.01 (2.01) 2.01 (2.01) 2.00 (2.01) 2.01 (2.01) 
Le
si
o
n
 
SumEnt 1.50 (1.50) 1.49 (1.49) 1.48 (1.49) 1.49 (1.49) 
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7.4 DISCUSSION 
This work has demonstrated initial promise in the use of texture analysis in 
detecting early response to chemotherapy, albeit within a small cohort of 
patients. 
 
All texture analysis was performed by matching slices between baseline and 
interim examinations and comparing texture feature values between the 
examinations and correlating with final response to treatment, as measured 
using both traditional RECIST criteria and the state-of-the-art RCB scoring 
method [163]. 
 
Texture feature changes did not correlate well with RECIST criteria, as measured 
on final imaging examinations.  RECIST is a relatively crude measure of tumour 
response to therapy derived from World Health Organisation guidelines 
developed in the 1980’s.  The RECIST criterion was scored by a breast MR expert 
by assessing the change in dimensions of tumour between baseline and final 
MR examination.  While some significant differences were obtained in the 
lesion, these were also accompanied by significant changes in the texture 
features as measured in normal regions of interest and therefore the results 
were not felt to be a true reflection of changes within the lesion.  It is possible 
that some changes may occur within normal tissue in response to 
chemotherapeutic treatment, and as no significant differences were measured 
within background noise between baseline and interim examinations it is 
unlikely that such changes are merely due to scan-scan differences.  As the 
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change in contralateral breast density can be a biomarker for recurrence and 
cancer prevention in hormone therapy, it is possible that the textural changes 
occurring within normal tissue are real and could potentially link with outcome 
measures.  However these changes could not be linked within the scope of this 
study and further investigation would be required to identify such trends.  An 
attempt was also made to link the absolute feature values as measured on the 
baseline examination with the ultimate response to treatment.  There were no 
links between these data found. 
 
The same analysis process was then followed, but using a difference measure of 
response- the RCB score.  This technique is a pathological technique which 
assesses a number of factors, including lesion cellularity, dimensions and axillary 
burden in order to provide a quantitative histopathological assessment.  This 
measure showed statistically significant differences in feature values between 
the baseline and interim examinations, with significant differences in lesion 
texture features angular second moment, entropy and sum entropy between 
the pCR and RCB-II and RCB-III categories and also between the RCB-I and RCB-II 
category. There was also statistical significance measured in the difference in 
entropy feature between the RCB-I and RCB-III categories.  The difference in 
entropy feature value between baseline and interim was largest for the pCR 
category, suggesting there was a large change in this feature relative to the 
other response categories, which is perhaps intuitive in the cohort who will 
continue to have a complete response to treatment.   
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When absolute feature value on the baseline image only was considered, it was 
demonstrated that there appeared to be significant differences in the initial 
value of angular second moment, entropy and difference entropy between the 
pCR v RCB-II and RCB-III categories, as well significant differences in the 
difference entropy features between the RCB-I v RCB-II and RCB-III categories.  
Considering the absolute feature values of these categories, the entropy and 
difference entropy features of the pCR category are actually highest compared 
with the other groups, suggesting that the lesions that will progress to have a 
complete response to chemotherapy are more heterogenous than those who 
will have minimal response, where lesions are relatively more homogeneous.  
This is in agreement with findings that higher tumour grade (and therefore 
increased heterogeneity within the tumour) is associated with a better response 
to neoadjuvant chemotherapy, although a poorer overall disease-free prognosis 
[164, 165].  This provides an exciting preliminary result that potentially one 
initial examination can indicate whether the patient will go on to have a good or 
poor response to chemotherapy and potentially be used in management of 
patients in terms of therapeutic or surgical planning. 
 
These results demonstrate confounding results when comparing results with 
RECIST and RCB.  RECIST provides a radiological assessment of lesion response 
to treatment which is limited by technical specifications, reader experience and 
image quality.  Despite still being used routinely in many centres, it was not 
designed for looking at neoadjuvant therapy for breast lesions but was rather a 
general technique designed to assess response to drugs.  The RCB method is a 
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more quantitative breast and neoadjuvant specific approach based on true 
pathological tumour characteristics, rather than the appearance of a tumour on 
the imaging modality that can be confounded by other factors such as 
inflammatory response, fibrosis [161] as well as factors relating directly to the 
acquisition process such as patient compliance and technical failure.  The RCB 
method also provides real measures of patient prognosis and therefore is a very 
useful metric in patient management.  Previous studies have demonstrated that 
while MRI will agree with final pathological size assessment around 70% of the 
time [166], it can over- or under- estimate the residual tumour in around a third 
of patients [161, 166].  Such errors in size estimates will therefore have a 
significant impact on the final response assessment as defined by RECIST [162] 
which is based entirely on lesion dimension measurements.  In a study 
performed in 2013, it was reported that RECIST criteria agreed with the RCB 
score of response in less than 20% of cases (Cohens Kappa= 0.38) [167].   
This is in agreement with our findings where we found that 4 patients were 
classified as having minimal residual disease using the RECIST criteria, when the 
ultimate RCB score was RCB-II, suggesting moderate residual disease.  Similarly, 
one patient with RCB-I score (minimal residual disease on pathology) was 
classified as having stable disease using RECIST. 
 
This study is the first we are aware of using texture analysis to correlate with 
ultimate response as assessed using the RCB score system.  Ahmed et al. used 
texture analysis in the prediction of response to chemotherapy for breast 
cancer patients based on MRI images using a similar technique to this work 
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[168].  However, response was dichotomised into only two categories- either 
responders or non-responders using a cut-off threshold of volume changes 
greater than or less than 50% compared to pre-treatment, respectively.  This is 
again returning to a RECIST- type classification of response and therefore is not 
designed for, nor does it represent the underlying pathology.  Interestingly, this 
group report increased lesion heterogeneity to be linked with a reduced 
chemotherapeutic response, whereas our results suggest the opposite.  The 
underlying rationale for this is unclear and warrants further investigation.  
 
Our study considered not only the lesion itself but background and normal 
regions of interest in order to ensure that any measures and conclusions made 
on the basis of changes in lesion feature values could be concluded to be real 
and not due to scan-scan variations.  We have therefore reported throughout 
the comparisons in lesion, normal and background regions to provide a measure 
of how certain the results are. 
 
The main limitation within this study was the relatively small patient cohort.  
While there were only 49 patients included in this study, RCB information was 
available for only 40 of them.  This was attributable to a number of patients that 
had to be excluded for a variety of reasons in order to maintain integrity of the 
data, however the study provides a foundation for using texture analysis to 
correlate with RCB scores that warrants further investigation.  There was a wide 
variety of treatment regimes used, which further complicates analysis and could 
provide another avenue for further investigation with increased patient 
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numbers to assess different treatment regimens as well as ultimate response 
categories.  Due to the small number of patients, no further sub-categorisation 
of data was possible and these results provide only a preliminary investigation 
into this technique in patients.  It should be noted, however, that HER2 positive 
and TNBC are the two key indicators for neoadjuvant chemotherapy. 
 
The use of the RCB scoring system is still relatively new, and not widely used in 
clinical applications, however it has demonstrated a superior correlation with 
survival compared to other measures [163] and therefore is likely to become 
more widely utilised in the future.  Correlation of these findings with those 
obtained on imaging is a very novel area and one with many potential 
applications. It is a more useful measure than traditional comparisons with 
RECIST criteria and therefore the correlation of texture measures with this 
parameter is one that provides an exciting and important avenue for further 
investigation. 
 
CHAPTER SUMMARY: This chapter presents results correlating texture analysis with 
various measures of response to chemotherapy.  There were no correlations 
found between RECIST response criteria and texture analysis findings, however 
the RCB score categories appeared to have significantly different entropy and 
difference entropy features.  There is also preliminary findings indicating that 
absolute baseline texture feature values may be useful in prediction of ultimate 
treatment response outcome, however this requires further investigation.  
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CHAPTER EIGHT: CONCLUSIONS AND FUTURE WORK 
 
The aim of this thesis was to investigate how useful the image processing tool, 
texture analysis, could be in breast MRI examinations.  This has been addressed 
from a number of angles and results presented in previous chapters.  This, final, 
chapter considers the overall outcome from the work and looks to the future 
and where the findings could lead.  
 
8.1 PROJECT SUMMARY  
By constructing a breast-mimicking phantom, incorporating texture phantoms 
in the form of 4 different grades of reticulated foam, an assessment was made 
of the ability of texture analysis to differentiate between test objects that were 
visually undistinguishable on resulting MR images, and also to compare the 
effect of acquisition parameter changes and different acquisition conditions.  
Scanning was performed across two different scanner platforms with different 
field strengths and receiver RF breast coils.  We were able to demonstrate that 
in all cases, texture analysis could reliably differentiate between different 
grades of foam, despite there being no difference visually obvious in the images 
acquired, thus showing promise for the technique of texture analysis.  The 
results were consistent across both scanner platforms and acquisition protocols, 
with the most critical factor in the outcome of texture analysis being in the 
spatial resolution of the acquired images.  This is to be expected as TA is a 
statistically based technique and therefore is reliant on pixel size.  There were 
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no correlations found in the outcome of texture analysis and the measured 
signal to noise ratio and therefore texture analysis was considered to be 
attractive for further work considering patient data, without any changes to the 
existing imaging protocols, and the benefits of thus using currently clinically 
acquired MRI data. 
 
A retrospective patient data set was then considered by using data from 
patients gathered over a number of months.  Pathology data was also acquired 
in order to link findings with the classifications of the lesions.  Firstly, 
comparison was made of malignant lesions with those that were found to be 
benign (despite a malignant appearance on MR dynamic imaging) and normal 
tissue.  Texture analysis demonstrated with a 100% accuracy the ability to 
differentiate between the three tissue types (malignant, benign, normal) and 
therefore showed initial promise for clinical utility.   Consideration was then 
made of classification of the malignant lesions into their respective subtypes.  
Different methods of lesion classification were used- their histological subtype, 
receptor status as well as the full molecular subtype classification.  Good 
classification accuracies were obtained for all of these, with the exception of 
using the lesion’s HER2 status, which resulted in very poor classification 
accuracies.  Entropy features appeared to demonstrate significant differences in 
feature value, however gave low classification accuracies- potentially due to the 
lower number of sample points.  As has been evident from publications cited in 
earlier chapters, entropy has been reported to be of significant interest in 
texture analysis of cancer imaging as it provides a marker of internal tumoural 
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heterogeneity.  Within our research, this provided expected measures of lesion 
morphological characteristics, such as demonstrating high entropy within triple-
negative cancers, and therefore it is hypothesised that there may be an indirect 
link between underlying growth patterns and the pattern of contrast uptake 
within lesions, although the mechanism is unclear.  
 
This work was then extended in order to provide an assessment of how the 
technique would perform clinically by recruiting an independent test set.  The 
results from this study were less convincing (as is sometimes the case with such 
test sets in general), with molecular subtyping resulting in lower classification 
accuracies, although histological subtype and grading results showed promise.  
The number of patients recruited was relatively small, however, and this 
ultimately was due to the inclusion criteria and limited timeframes for the study 
over which we had little control.  By combining the entire dataset and utilising 
an external validation method, we demonstrated that increasing the sample 
numbers in the training set could, potentially, result in an increase in the 
classification accuracies and therefore these results hold initial preliminary 
promise for further investigative work to be carried out.  
 
Entropy was demonstrated to be a critical feature in describing lesions, and this 
was reinforced when the work carried out on the retrospective patient set was 
repeated using the Max-Min texture analysis method.  This Max-Min technique 
was developed in order to address computational issues, which are largely 
irrelevant now.  However, by considering the number of extremes in the pixel 
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intensity distribution (i.e. a measure of heterogeneity), a similar trend to the 
previous work on the same patient cohort was found, and the measure of 
heterogeneity appeared to link in with the results from the entropy feature 
using the COM model.  As subtypes of cancer were largely well differentiated 
using this technique also, this corroborates the hypothesis that entropy is one 
of the main classifying features in the categorisation of breast cancer subtypes.  
 
In the drive for patient-tailored treatments, and monitoring of therapy, texture 
analysis was finally applied to this theme, with a specific focus on early response 
to neoadjuvant chemotherapy for breast cancer.  Texture analysis was 
performed on both baseline and interim examinations to identify if early 
changes could be detected that would ultimately predict the outcome of 
therapy.  These results were found not to correlate at all with the traditional 
RECIST criteria of response, yet, reassuringly, correlated very well with the 
pathological outcome measure of residual cancer burden (RCB score).  As this is 
a measure of pathological assessment of the actual tumour response, rather 
than the appearance on a scan, the link between the TA results and this 
definitive pathology (with its implications for outcome) is very exciting in the 
drive towards assessment of early response to chemotherapy. TA appeared to 
be able to categorise between those patients who would have a complete or 
good response and those who would not.  While our cohort was relatively small, 
there were also preliminary findings that suggested that absolute baseline 
texture features may also prove to be a link with the final outcome of 
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treatment, although this warrants more exploration both in prospective clinical 
series and in the setting of randomised controlled trials of neoadjuvant therapy. 
 
 
8.2 FINAL CONCLUSIONS 
The results of the work carried out in this thesis confirm that texture analysis, as 
initially reported within the literature, is an exciting image processing tool with 
extensive potential.  Within the area of cancer, and specifically breast cancer, 
the advantages of an image-based technique that can differentiate between 
molecular subtypes and particularly can provide an early indication as to 
eventual response to chemotherapy given prior to surgery could have powerful 
implications for diagnosis, individualisation of treatment and the management 
of women with breast cancer more generally.  However, as has been 
demonstrated by this work, there is still a significant effort required in order to 
develop the techniques into a robust clinical tool.   
 
Preliminary indications suggest that there could be potential for classifications 
between different types of breast cancer as well as an indicator of early 
response to treatment, however in order to make any definitive conclusions, it 
is essential to significantly increase patient numbers in order to make reliable, 
robust conclusions.  
 
The research within this thesis has demonstrated that texture analysis is a 
useful research tool within the area of breast MRI.  While it is not ready for 
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clinical use at present until further development is carried out, it has provided 
great preliminary promise which certainly warrants further investment in this 
area. 
 
 
8.3 FUTURE WORK 
As was perhaps to be expected, this thesis has reported on findings that have 
ultimately led to a desire to extend this work beyond the scope of the initial 
research proposed. 
 
As has been alluded to earlier, it is essential that the numbers included within 
the patient cohort are significantly increased.  While initial results prove 
promising, in order to create a robust classification model, further data is 
required to develop this.  It would also be useful to assess the effect of lesion 
size and region of interest size in order to ascertain the limit(s) in the technique.  
It is hypothesised that this will be limited by pixel size, rather than absolute 
lesion size, however this, as yet, remains untested. 
 
Also extending the work of this thesis further, an increase in the NAC population 
is imperative in order to further investigate the link between the residual cancer 
burden scores and the textural changes between baseline and interim 
examination.  The work carried out within the scope of this research indicates 
preliminary findings that texture could provide a measure of response that 
appears to link with the pathological outcome of the treatment and therefore 
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this could potentially prove to be an exciting and essential area of research in 
improving patient management. 
 
There has been much work reported within the literature that the influence of 
peri-tumoural stroma has influence on the long term prognosis of patient 
outcome.  Therefore, extending this work to consider not only the tumour itself, 
but also tumour periphery and into the surrounding stroma would prove a 
useful further investigation to carry out.  Due to the excellent depiction of soft 
tissue on MR, this may be the most suitable modality to perform such research. 
 
Finally, it has been well established that patients with BRCA1 and BRCA2 gene 
mutations are at a higher risk of developing breast cancer, particularly at a 
young age.  Using a large scale study, most likely across multiple institutions, it 
would be fascinating to consider the fibroglandular tissue of patients within this 
group compared to women with standard population risk of breast cancer 
development.  Using texture analysis, could it be possible to identify 
fundamental textural differences between the fibroglandular tissues of these 
two groups?  While such research would require, most likely, UK wide 
collaboration to obtain sufficient patient numbers, a study investigating this 
issue would truly be exciting.  
 
Texture analysis of MR images in primary breast cancer is clearly at an early 
stage at what may prove to be a very exciting and clinically relevant tool to 
improve the management of women with breast cancer.
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APPENDIX A: MATHEMATICAL DESCRIPTION OF TEXTURE FEATURES 
 
STATISTICAL BASED METHODS 
Histogram-Based Features 
For an image histogram, with intensity levels defined from i=1…Ng, a normalised 
histogram vector, p(i), is defined and the following histogram-based features 
derived. 
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Co-Occurrence Matrix Features 
The co-occurrence matrix is defined as the estimated joint probability pdθ(i,j) of 
two pixels a distance d (d=1,2,3,4,5) apart in given direction θ 
(θ=0°,45°,90°,135°) having co-occurring values of i and j, in an image (f(x,y)) 
with intensity levels defined from i=1…Ng.  The co-occurrence matrix is defined 
with the (i,j) entry given by the number of times that  
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Co-occurrence matrix parameters are then derived as below. 
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Absolute Gradient Features 
MaZda considers the 3×3 pixel neighbourhood of an image pixel x(i,j), such that 
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For the matrix of M elements containing the gradient values for pixels in the 
region of interest (ROI), gradient features are defined as below. 
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Run-Length Matrix Features 
For an image with intensity levels defined from i=1…Ng, the run-length matrix 
p(i,j) is defined as the number of times there is a run of length j having grey-
level i, with Nr being the number of runs. 
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MODEL BASED METHODS 
Auto-Regressive Model Features 
The autoregressive model assumes that pixel intensity at a given site (s) is a 
weighted sum (fs) of neighbouring pixel intensities and independent distributed 
noise (es) as described by  
∑
∈
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The model parameters are described by vectors (θ) and MaZda implements an 
autoregressive model utilising four parameter vectors 
(θ1, θ2, θ3, θ4) and the standard deviation of the noise, σ, 
to describe the texture in the immediately surrounding 
area of the pixel s. 
The parameters are then estimated by minimising the sum of the squared error 
to give the following linear equations, which are solved for each ROI of interest. 
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TRANSFORM BASED METHODS 
Wavelet Transform Features 
The wavelet transform is a method of separating data into high (H) and low (L) 
frequency components and considering these components with resolutions 
matched to their scale.  MaZda utilises a Haar wavelet transform and considers 
only the energy feature at each sub-band (there are four image sub-bands at 
each scale- dHH, dHL, dLH, dLL).  
Energy can be calculated for any ROI with a 
number of pixels given by n, at any scale by: 
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APPENDIX B: PROGRAM CODING USED FOR MAX-MIN ANALYSIS 
ROI GENERATION 
This code was written using Matlab 2012(a) (MathWorks; Massachusetts, USA).  
The program loads in a selected DICOM image and generates a 10×10 square 
ROI in an area selected by the user.  A 10×10 text file of pixel values is 
generated and then resized to be 100×1 for calculation of Max-Min texture 
values. 
 
---------------------------------------------------------------------------------------------------------- 
 
% clear all memory to initialise program 
clc 
clear 
close all 
imtool close all 
cd('C:\Documents and Settings\swaugh\Desktop\MATLAB 
info\Images'); 
  
% read in image, display and display copy of image for ROI to be 
drawn on 
importfile=uigetfile('*.*'); 
image= dicomread(importfile); 
imshow(image,[]); 
image2=imresize(image,2); 
imshow(image2,[]); 
title('Original with ROI'); 
set(gcf, 'Position', get(0, 'ScreenSize'));  
set(gcf,'name','testing, testing','numbertitle','off'); 
  
% create ROI and display pixel values 
roi=impoint(gca); 
wait(roi); 
position=ans; 
xpos=position(1); 
ypos=position(2); 
roi=imrect(gca,[xpos ypos 10 10]); 
mask=roi.createMask(); 
pixelvalues=image2(mask); 
matrix=reshape(pixelvalues,10,10); 
display(matrix); 
  
% writes pixel value matrix to txt file 
m=double(matrix); 
n= reshape(m,100,1) 
fid=fopen('matrix.txt','wt'); 
fprintf(fid, [repmat('%g\t', 1, size(n,2)-1) '%g\n'], n.'); 
fclose(fid) 
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CALCULATION OF MAX-MIN TEXTURE FEATURES 
This code was written using Intel Fortran (Intel Corp., California, USA) and X-
Code 3.2.5 (Apple Inc.; California, USA) for Mac OSX.  The program prompts the 
user for a threshold value and an increment value in order to calculate number 
of maximum and minimum extreme values at a number of threshold values.  
Ratios are then calculated in order to determine the textural description 
features.   
 
---------------------------------------------------------------------------------------------------------- 
 
        PROGRAM maxmin 
cDEC$ FIXEDFORMLINESIZE:132 
c       A program to attempt the implementation of the 
c       Max-Min texture method of Mitchell et al (IEEE trans Comp 
1977) 
c       on clinical image files. 
c 
C       The Texture Analysis is performed firstly on horizontal 
lines with 
C       10x10 ROIs. The matrix is then flipped through 90 degrees 
so that the 
C       the procedure can be repeated thus doing vertical lines. 
c 
        Character*64 fname 
        Character*3 rdata(100),rd 
        real irdata(100),sdata(100),ird,T,Tinc,Nrat,krdata(100) 
        integer ncount(5),IJ(100) 
c         
        DATA IJ(1),IJ(2),IJ(3),IJ(4),IJ(5)/1,11,21,31,41/ 
        DATA IJ(6),IJ(7),IJ(8),IJ(9),IJ(10)/51,61,71,81,91/ 
        DATA IJ(11),IJ(12),IJ(13),IJ(14),IJ(15)/2,12,22,32,42/ 
        DATA IJ(16),IJ(17),IJ(18),IJ(19),IJ(20)/52,62,72,82,92/ 
        DATA IJ(21),IJ(22),IJ(23),IJ(24),IJ(25)/3,13,23,33,43/ 
        DATA IJ(26),IJ(27),IJ(28),IJ(29),IJ(30)/53,63,73,83,93/ 
        DATA IJ(31),IJ(32),IJ(33),IJ(34),IJ(35)/4,14,24,34,44/ 
        DATA IJ(36),IJ(37),IJ(38),IJ(39),IJ(40)/54,64,74,84,94/ 
        DATA IJ(41),IJ(42),IJ(43),IJ(44),IJ(45)/5,15,25,35,45/ 
        DATA IJ(46),IJ(47),IJ(48),IJ(49),IJ(50)/55,65,75,85,95/ 
        DATA IJ(51),IJ(52),IJ(53),IJ(54),IJ(55)/6,16,26,36,46/ 
        DATA IJ(56),IJ(57),IJ(58),IJ(59),IJ(60)/56,66,76,86,96/ 
        DATA IJ(61),IJ(62),IJ(63),IJ(64),IJ(65)/7,17,27,37,47/ 
        DATA IJ(66),IJ(67),IJ(68),IJ(69),IJ(70)/57,67,77,87,97/ 
        DATA IJ(71),IJ(72),IJ(73),IJ(74),IJ(75)/8,18,28,38,48/ 
        DATA IJ(76),IJ(77),IJ(78),IJ(79),IJ(80)/58,68,78,88,98/ 
        DATA IJ(81),IJ(82),IJ(83),IJ(84),IJ(85)/9,19,29,39,49/ 
        DATA IJ(86),IJ(87),IJ(88),IJ(89),IJ(90)/59,69,79,89,99/ 
        DATA IJ(91),IJ(92),IJ(93),IJ(94),IJ(95)/10,20,30,40,50/ 
        DATA IJ(96),IJ(97),IJ(98),IJ(99),IJ(100)/60,70,80,90,100/ 
c 
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        write(*,'(A\)') 'enter filename:  ' 
        read(*,'(A\)') fname 
c 
        open(3,file=fname) 
        Do 1 I=1,100 
1       read(3,'(A3)') rdata(I) 
        pause 'read data' 
        print *, rdata 
c 
c       convert to real log data 
        DO 10 I=1,100 
        rd=rdata(I) 
        read (rd, '(g6.0)') irdata(I) 
        irdata(I)=alog(irdata(I)+1.0) 
10      continue 
        print *, irdata 
c 
c       Count initial peaks (before smoothing) 
400     ncount(1)=0 
        DO 30 ILINE=0,9 
        DO 20 I=1,8 
        IF 
(irdata(ILINE+I)<irdata(ILINE+I+1).AND.irdata(ILINE+I+1)>irdata(I
LINE+I+2)) THEN 
        ncount(1)=ncount(1)+1 
        endif 
20      continue 
30      continue 
c 
        print *, ncount 
c 
        write(*,'(A\)') 'enter starting T value:  ' 
        read(*,*) Tstart 
        write(*,'(A\)') 'enter T increment value:  ' 
        read(*,*) Tinc 
c 
c       Smooth some data 
        sdata(1)=irdata(1) 
        T=Tstart 
        DO 31 ILINE=0,9 
        DO 21 I=1,8 
        IF (sdata(ILINE+I)<(irdata(ILINE+I+1)-T/2)) THEN 
        sdata(ILINE+I+1)=(irdata(ILINE+I+1)-T/2) 
        ELSE IF ((irdata(ILINE+I+1)-
T/2)<sdata(ILINE+I).AND.sdata(ILINE+I)<irdata(ILINE+I+1)+T/2) 
THEN 
        sdata(ILINE+I+1)=sdata(ILINE+I) 
        ELSE IF ((irdata(ILINE+I+1)+T/2)<sdata(ILINE+I)) THEN 
        sdata(ILINE+I+1)=irdata(ILINE+I+1)+T/2 
        endif 
21      continue 
31      continue 
c 
c       Count peaks (after first smoothing) 
        ncount(2)=0 
        DO 32 ILINE=0,9 
        DO 22 I=1,8 
        IF 
(sdata(ILINE+I)<sdata(ILINE+I+1).AND.sdata(ILINE+I+1)>sdata(ILINE
+I+2)) THEN 
        ncount(2)=ncount(2)+1 
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        endif 
22      continue 
32      continue 
c         
c       Perform second smooth and count 
        T=Tstart+Tinc 
        sdata(1)=irdata(1) 
        DO 33 ILINE=0,9 
        DO 23 I=1,8 
        IF (sdata(ILINE+I)<(irdata(ILINE+I+1)-T/2)) THEN 
        sdata(ILINE+I+1)=(irdata(ILINE+I+1)-T/2) 
        ELSE IF ((irdata(ILINE+I+1)-
T/2)<sdata(ILINE+I).AND.sdata(ILINE+I)<irdata(ILINE+I+1)+T/2) 
THEN 
        sdata(ILINE+I+1)=sdata(ILINE+I) 
        ELSE IF ((irdata(ILINE+I+1)+T/2)<sdata(ILINE+I)) THEN 
        sdata(ILINE+I+1)=irdata(ILINE+I+1)+T/2 
        endif 
23      continue 
33      continue 
c 
c       Count peaks (after second smoothing) 
        ncount(3)=0 
        DO 34 ILINE=0,9 
        DO 24 I=1,8 
        IF 
(sdata(ILINE+I)<sdata(ILINE+I+1).AND.sdata(ILINE+I+1)>sdata(ILINE
+I+2)) THEN 
        ncount(3)=ncount(3)+1 
        endif 
24      continue 
34      continue 
c 
c       Perform third smooth and count 
        T=Tstart+2*Tinc 
        sdata(1)=irdata(1) 
        DO 35 ILINE=0,9 
        DO 25 I=1,8 
        IF (sdata(ILINE+I)<(irdata(ILINE+I+1)-T/2)) THEN 
        sdata(ILINE+I+1)=(irdata(ILINE+I+1)-T/2) 
        ELSE IF ((irdata(ILINE+I+1)-
T/2)<sdata(ILINE+I).AND.sdata(ILINE+I)<irdata(ILINE+I+1)+T/2) 
THEN 
        sdata(ILINE+I+1)=sdata(ILINE+I) 
        ELSE IF ((irdata(ILINE+I+1)+T/2)<sdata(ILINE+I)) THEN 
        sdata(ILINE+I+1)=irdata(ILINE+I+1)+T/2 
        endif 
25      continue 
35      continue 
c 
c       Count peaks (after third smoothing) 
        ncount(4)=0 
        DO 36 ILINE=0,9 
        DO 26 I=1,8 
        IF 
(sdata(ILINE+I)<sdata(ILINE+I+1).AND.sdata(ILINE+I+1)>sdata(ILINE
+I+2)) THEN 
        ncount(4)=ncount(4)+1 
        endif 
26      continue 
36      continue 
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c 
c       Perform fourth smooth and count 
        T=Tstart+3*Tinc 
        sdata(1)=irdata(1) 
        DO 37 ILINE=0,9 
        DO 27 I=1,8 
        IF (sdata(ILINE+I)<(irdata(ILINE+I+1)-T/2)) THEN 
        sdata(ILINE+I+1)=(irdata(ILINE+I+1)-T/2) 
        ELSE IF ((irdata(ILINE+I+1)-
T/2)<sdata(ILINE+I).AND.sdata(ILINE+I)<irdata(ILINE+I+1)+T/2) 
THEN 
        sdata(ILINE+I+1)=sdata(ILINE+I) 
        ELSE IF ((irdata(ILINE+I+1)+T/2)<sdata(ILINE+I)) THEN 
        sdata(ILINE+I+1)=irdata(ILINE+I+1)+T/2 
        endif 
27      continue 
37      continue 
c 
c       Count peaks (after fourth smoothing) 
        ncount(5)=0 
        DO 38 ILINE=0,9 
        DO 28 I=1,8 
        IF 
(sdata(ILINE+I)<sdata(ILINE+I+1).AND.sdata(ILINE+I+1)>sdata(ILINE
+I+2)) THEN 
        ncount(5)=ncount(5)+1 
        endif 
28      continue 
38      continue 
C 
C       Flip ROI through 90 degrees to count vertical lines 
        do 100 I=1,100 
        J=ij(I) 
100     krdata(I)=irdata(J) 
c       repeat all smoothing and counting in vertical direction 
c 
c       Count initial peaks (before smoothing) adding to 
horizontal peaks 
        DO 130 ILINE=0,9 
        DO 120 I=1,8 
        IF 
(krdata(ILINE+I)<krdata(ILINE+I+1).AND.krdata(ILINE+I+1)>krdata(I
LINE+I+2)) THEN 
        ncount(1)=ncount(1)+1 
        endif 
120     continue 
130     continue 
c        
        print *, ncount 
c 
c       Smooth some data 
        sdata(1)=krdata(1) 
        T=Tstart 
        DO 131 ILINE=0,9 
        DO 121 I=1,8 
        IF (sdata(ILINE+I)<(krdata(ILINE+I+1)-T/2)) THEN 
        sdata(ILINE+I+1)=(krdata(ILINE+I+1)-T/2) 
        ELSE IF ((krdata(ILINE+I+1)-
T/2)<sdata(ILINE+I).AND.sdata(ILINE+I)<krdata(ILINE+I+1)+T/2) 
THEN 
        sdata(ILINE+I+1)=sdata(ILINE+I) 
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        ELSE IF ((krdata(ILINE+I+1)+T/2)<sdata(ILINE+I)) THEN 
        sdata(ILINE+I+1)=krdata(ILINE+I+1)+T/2 
        endif 
121     continue 
131     continue 
c 
c       Count peaks (after first smoothing) 
        DO 132 ILINE=0,9 
        DO 122 I=1,8 
        IF 
(sdata(ILINE+I)<sdata(ILINE+I+1).AND.sdata(ILINE+I+1)>sdata(ILINE
+I+2)) THEN 
        ncount(2)=ncount(2)+1 
        endif 
122     continue 
132     continue 
c         
c       Perform second smooth and count 
        T=Tstart+Tinc 
        sdata(1)=krdata(1) 
        DO 133 ILINE=0,9 
        DO 123 I=1,8 
        IF (sdata(ILINE+I)<(krdata(ILINE+I+1)-T/2)) THEN 
        sdata(ILINE+I+1)=(krdata(ILINE+I+1)-T/2) 
        ELSE IF ((krdata(ILINE+I+1)-
T/2)<sdata(ILINE+I).AND.sdata(ILINE+I)<krdata(ILINE+I+1)+T/2) 
THEN 
        sdata(ILINE+I+1)=sdata(ILINE+I) 
        ELSE IF ((krdata(ILINE+I+1)+T/2)<sdata(ILINE+I)) THEN 
        sdata(ILINE+I+1)=krdata(ILINE+I+1)+T/2 
        endif 
123      continue 
133      continue 
c 
c       Count peaks (after second smoothing) 
        DO 134 ILINE=0,9 
        DO 124 I=1,8 
        IF 
(sdata(ILINE+I)<sdata(ILINE+I+1).AND.sdata(ILINE+I+1)>sdata(ILINE
+I+2)) THEN 
        ncount(3)=ncount(3)+1 
        endif 
124      continue 
134      continue 
c 
c       Perform third smooth and count 
        T=Tstart+2*Tinc 
        sdata(1)=krdata(1) 
        DO 135 ILINE=0,9 
        DO 125 I=1,8 
        IF (sdata(ILINE+I)<(krdata(ILINE+I+1)-T/2)) THEN 
        sdata(ILINE+I+1)=(krdata(ILINE+I+1)-T/2) 
        ELSE IF ((krdata(ILINE+I+1)-
T/2)<sdata(ILINE+I).AND.sdata(ILINE+I)<krdata(ILINE+I+1)+T/2) 
THEN 
        sdata(ILINE+I+1)=sdata(ILINE+I) 
        ELSE IF ((krdata(ILINE+I+1)+T/2)<sdata(ILINE+I)) THEN 
        sdata(ILINE+I+1)=krdata(ILINE+I+1)+T/2 
        endif 
125     continue 
135     continue 
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c 
c       Count peaks (after third smoothing) 
        DO 136 ILINE=0,9 
        DO 126 I=1,8 
        IF 
(sdata(ILINE+I)<sdata(ILINE+I+1).AND.sdata(ILINE+I+1)>sdata(ILINE
+I+2)) THEN 
        ncount(4)=ncount(4)+1 
        endif 
126     continue 
136     continue 
c 
c       Perform fourth smooth and count 
        T=Tstart+3*Tinc 
        sdata(1)=krdata(1) 
        DO 137 ILINE=0,9 
        DO 127 I=1,8 
        IF (sdata(ILINE+I)<(krdata(ILINE+I+1)-T/2)) THEN 
        sdata(ILINE+I+1)=(krdata(ILINE+I+1)-T/2) 
        ELSE IF ((krdata(ILINE+I+1)-
T/2)<sdata(ILINE+I).AND.sdata(ILINE+I)<krdata(ILINE+I+1)+T/2) 
THEN 
        sdata(ILINE+I+1)=sdata(ILINE+I) 
        ELSE IF ((krdata(ILINE+I+1)+T/2)<sdata(ILINE+I)) THEN 
        sdata(ILINE+I+1)=krdata(ILINE+I+1)+T/2 
        endif 
127     continue 
137     continue 
c 
c       Count peaks (after fourth smoothing) 
        DO 138 ILINE=0,9 
        DO 128 I=1,8 
        IF 
(sdata(ILINE+I)<sdata(ILINE+I+1).AND.sdata(ILINE+I+1)>sdata(ILINE
+I+2)) THEN 
        ncount(5)=ncount(5)+1 
        endif 
128     continue 
138     continue 
 
        print *, ncount 
c 
c       calculate count ratios 
        DO 39 I=2,5 
        Nrat=FLOAT(ncount(I))/FLOAT(ncount(1)) 
        write(*,*) Nrat 
39      continue 
c 
        write(*,'(A\)') 'again (1) or stop (0)?  ' 
        read(*,*) iagain 
        IF (iagain.EQ.1) THEN 
        DO 200 I=1,5 
200     Ncount(I)=0 
        GOTO 400 
        endif 
        end 
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APPENDIX C: CALDICOTT APPROVAL 
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